US20040157893A1 - Pyrazole compounds useful as protein kinase inhibitors - Google Patents
Pyrazole compounds useful as protein kinase inhibitors Download PDFInfo
- Publication number
- US20040157893A1 US20040157893A1 US10/722,374 US72237403A US2004157893A1 US 20040157893 A1 US20040157893 A1 US 20040157893A1 US 72237403 A US72237403 A US 72237403A US 2004157893 A1 US2004157893 A1 US 2004157893A1
- Authority
- US
- United States
- Prior art keywords
- ring
- con
- aliphatic
- pyrazol
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C1=C([2*])NN=C1NC1=CC(*[1*])=CN=C1 Chemical compound *C1=C([2*])NN=C1NC1=CC(*[1*])=CN=C1 0.000 description 24
- JKJSHAXNXSLAEX-UHFFFAOYSA-N CC(=O)NC1=CC=C(SC2=NC(OC3CCN(C)CC3)=NC(NC3=NNC(C4CC4)=C3)=N2)C=C1 Chemical compound CC(=O)NC1=CC=C(SC2=NC(OC3CCN(C)CC3)=NC(NC3=NNC(C4CC4)=C3)=N2)C=C1 JKJSHAXNXSLAEX-UHFFFAOYSA-N 0.000 description 2
- KENZRPOCISVXDR-UHFFFAOYSA-N CC1=NC(NC2=NNC(C3CC3)=C2)=NC(CC2=CC=CC=C2)=N1 Chemical compound CC1=NC(NC2=NNC(C3CC3)=C2)=NC(CC2=CC=CC=C2)=N1 KENZRPOCISVXDR-UHFFFAOYSA-N 0.000 description 2
- UBONMTHOKJYGRV-UHFFFAOYSA-N COC1=CC=CC(CC2=CC(SC3=CC=CC=C3)=NC(NC3=NNC4=C3C=CC=C4)=N2)=C1 Chemical compound COC1=CC=CC(CC2=CC(SC3=CC=CC=C3)=NC(NC3=NNC4=C3C=CC=C4)=N2)=C1 UBONMTHOKJYGRV-UHFFFAOYSA-N 0.000 description 2
- KRPZLGMPISQQGY-UHFFFAOYSA-N C(C1)C1c1cc(Nc2cc(Nc3ccc(cn[nH]4)c4c3)nnc2)n[nH]1 Chemical compound C(C1)C1c1cc(Nc2cc(Nc3ccc(cn[nH]4)c4c3)nnc2)n[nH]1 KRPZLGMPISQQGY-UHFFFAOYSA-N 0.000 description 1
- VMVHZJLREQZWNX-UHFFFAOYSA-N C(c1ccc[s]1)Sc1cnnc(Nc2n[nH]c3ccccc23)c1 Chemical compound C(c1ccc[s]1)Sc1cnnc(Nc2n[nH]c3ccccc23)c1 VMVHZJLREQZWNX-UHFFFAOYSA-N 0.000 description 1
- JPDFQLQRDWMKJB-UHFFFAOYSA-N C.N#CCC1=CC=C(OC2=C3C=CC=CC3=NC(NC3=NNC(C4CC4)=C3)=N2)C=C1 Chemical compound C.N#CCC1=CC=C(OC2=C3C=CC=CC3=NC(NC3=NNC(C4CC4)=C3)=N2)C=C1 JPDFQLQRDWMKJB-UHFFFAOYSA-N 0.000 description 1
- DAOYZCXAJGBEJL-UHFFFAOYSA-N C1=CC2=C(C=C1)C(NC1=CC(NC3=CC4=C(C=C3)C=NN4)=NN=C1)=NN2.I[IH][I-29] Chemical compound C1=CC2=C(C=C1)C(NC1=CC(NC3=CC4=C(C=C3)C=NN4)=NN=C1)=NN2.I[IH][I-29] DAOYZCXAJGBEJL-UHFFFAOYSA-N 0.000 description 1
- COMPATSMEUGJCH-UHFFFAOYSA-N C1=CC2=C(C=C1)C(NC1=NC(NC3=CC4=C(C=C3)C=NN4)=NN=C1)=NN2.I[IH][I-14] Chemical compound C1=CC2=C(C=C1)C(NC1=NC(NC3=CC4=C(C=C3)C=NN4)=NN=C1)=NN2.I[IH][I-14] COMPATSMEUGJCH-UHFFFAOYSA-N 0.000 description 1
- BWRWGXULOPAYFQ-UHFFFAOYSA-N C1=CC2=C(C=C1NC1=NN=CC(NC3=NNC(C4CC4)=C3)=C1)NN=C2.I[IH][I-27] Chemical compound C1=CC2=C(C=C1NC1=NN=CC(NC3=NNC(C4CC4)=C3)=C1)NN=C2.I[IH][I-27] BWRWGXULOPAYFQ-UHFFFAOYSA-N 0.000 description 1
- VSQYEXJNRYTENW-UHFFFAOYSA-N C1=CC2=C(C=C1NC1=NN=CC(NC3=NNC(C4CC4)=C3)=N1)NN=C2.I[IH][I-12] Chemical compound C1=CC2=C(C=C1NC1=NN=CC(NC3=NNC(C4CC4)=C3)=N1)NN=C2.I[IH][I-12] VSQYEXJNRYTENW-UHFFFAOYSA-N 0.000 description 1
- BEFNPFXDOYJLCW-UHFFFAOYSA-N C1=CC2=C(C=C1SC1=CN=NC(NC3=NNC(C4CC4)=C3)=C1)SC=N2.I[IH][I-20] Chemical compound C1=CC2=C(C=C1SC1=CN=NC(NC3=NNC(C4CC4)=C3)=C1)SC=N2.I[IH][I-20] BEFNPFXDOYJLCW-UHFFFAOYSA-N 0.000 description 1
- JOZXJIWFESVRAL-UHFFFAOYSA-N C1=CC2=C(C=C1SC1=CN=NC(NC3=NNC(C4CC4)=C3)=N1)SC=N2.I[IH][I-5] Chemical compound C1=CC2=C(C=C1SC1=CN=NC(NC3=NNC(C4CC4)=C3)=N1)SC=N2.I[IH][I-5] JOZXJIWFESVRAL-UHFFFAOYSA-N 0.000 description 1
- LZLYDKGIGFJPCZ-UHFFFAOYSA-N C1=CC=C(COC2=C3C=CC=CC3=NC(NC3=NNC4=C3C=CC=C4)=N2)C=C1 Chemical compound C1=CC=C(COC2=C3C=CC=CC3=NC(NC3=NNC4=C3C=CC=C4)=N2)C=C1 LZLYDKGIGFJPCZ-UHFFFAOYSA-N 0.000 description 1
- XUXVJMMITUOVJP-UHFFFAOYSA-N C1=CN=CC(CNC2=C3C=CC=CC3=NC(NC3=NNC4=C3C=CC=C4)=N2)=C1 Chemical compound C1=CN=CC(CNC2=C3C=CC=CC3=NC(NC3=NNC4=C3C=CC=C4)=N2)=C1 XUXVJMMITUOVJP-UHFFFAOYSA-N 0.000 description 1
- ZHVNJCNWWLEZRJ-UHFFFAOYSA-N C1=CN=CC(CNC2=CN=NC(NC3=NNC(C4CC4)=C3)=C2)=C1.I[IH][I-19] Chemical compound C1=CN=CC(CNC2=CN=NC(NC3=NNC(C4CC4)=C3)=C2)=C1.I[IH][I-19] ZHVNJCNWWLEZRJ-UHFFFAOYSA-N 0.000 description 1
- MJGBKFHMEUUPHP-UHFFFAOYSA-N C1=CN=CC(CNC2=CN=NC(NC3=NNC(C4CC4)=C3)=N2)=C1.I[IH][I-4] Chemical compound C1=CN=CC(CNC2=CN=NC(NC3=NNC(C4CC4)=C3)=N2)=C1.I[IH][I-4] MJGBKFHMEUUPHP-UHFFFAOYSA-N 0.000 description 1
- NJEXHCKWQBCIEN-UHFFFAOYSA-N C1=CSC(CSC2=CN=NC(NC3=NNC4=C3C=CC=C4)=C2)=C1.I[IH][I-23] Chemical compound C1=CSC(CSC2=CN=NC(NC3=NNC4=C3C=CC=C4)=C2)=C1.I[IH][I-23] NJEXHCKWQBCIEN-UHFFFAOYSA-N 0.000 description 1
- ZCBRMMYICCNUJC-UHFFFAOYSA-N C1=CSC(CSC2=CN=NC(NC3=NNC4=C3C=CC=C4)=N2)=C1.I[IH][I-8] Chemical compound C1=CSC(CSC2=CN=NC(NC3=NNC4=C3C=CC=C4)=N2)=C1.I[IH][I-8] ZCBRMMYICCNUJC-UHFFFAOYSA-N 0.000 description 1
- KCWQIIAOLNJMGX-UHFFFAOYSA-N CC(=O)NC1=CC=C(SC2=C3C=CC=CC3=NC(NC3=NNC(C)=C3)=N2)C=C1 Chemical compound CC(=O)NC1=CC=C(SC2=C3C=CC=CC3=NC(NC3=NNC(C)=C3)=N2)C=C1 KCWQIIAOLNJMGX-UHFFFAOYSA-N 0.000 description 1
- SIOGAOYYCWVQMV-UHFFFAOYSA-N CC(=O)NC1=CC=C(SC2=CN=NC(NC3=NNC(C)=C3)=C2)C=C1.I[IH][I-17] Chemical compound CC(=O)NC1=CC=C(SC2=CN=NC(NC3=NNC(C)=C3)=C2)C=C1.I[IH][I-17] SIOGAOYYCWVQMV-UHFFFAOYSA-N 0.000 description 1
- CIWWSUYDMDPCOM-UHFFFAOYSA-N CC(=O)NC1=CC=C(SC2=CN=NC(NC3=NNC(C)=C3)=N2)C=C1.I[IH][I-2] Chemical compound CC(=O)NC1=CC=C(SC2=CN=NC(NC3=NNC(C)=C3)=N2)C=C1.I[IH][I-2] CIWWSUYDMDPCOM-UHFFFAOYSA-N 0.000 description 1
- VZCZAMMVYXMRNE-UHFFFAOYSA-N CC(=O)NC1=CC=C(SC2=NN=CC(NC3=NNC(C4CC4)=C3)=C2)C=C1.I[IH][I-28] Chemical compound CC(=O)NC1=CC=C(SC2=NN=CC(NC3=NNC(C4CC4)=C3)=C2)C=C1.I[IH][I-28] VZCZAMMVYXMRNE-UHFFFAOYSA-N 0.000 description 1
- MELOQLARCSBWQE-UHFFFAOYSA-N CC(=O)NC1=CC=C(SC2=NN=CC(NC3=NNC(C4CC4)=C3)=N2)C=C1.I[IH][I-13] Chemical compound CC(=O)NC1=CC=C(SC2=NN=CC(NC3=NNC(C4CC4)=C3)=N2)C=C1.I[IH][I-13] MELOQLARCSBWQE-UHFFFAOYSA-N 0.000 description 1
- HZNNAXWNKACLCL-UHFFFAOYSA-N CC(C)c1n[nH]c2c1cccn2 Chemical compound CC(C)c1n[nH]c2c1cccn2 HZNNAXWNKACLCL-UHFFFAOYSA-N 0.000 description 1
- FNPVXZFHPBEHAZ-UHFFFAOYSA-N CC(C)c1n[nH]c2c1cncc2 Chemical compound CC(C)c1n[nH]c2c1cncc2 FNPVXZFHPBEHAZ-UHFFFAOYSA-N 0.000 description 1
- XAGAJQVFWYDCLK-UHFFFAOYSA-N CC(Nc(cc1)ccc1Sc1nncc(Nc2n[nH]c(C3CC3)c2)c1)=O Chemical compound CC(Nc(cc1)ccc1Sc1nncc(Nc2n[nH]c(C3CC3)c2)c1)=O XAGAJQVFWYDCLK-UHFFFAOYSA-N 0.000 description 1
- AAKUWRXEOGTCIX-UHFFFAOYSA-N CC(Nc(cc1)ccc1Sc1nncc(Nc2n[nH]c(C3CC3)c2)n1)=O Chemical compound CC(Nc(cc1)ccc1Sc1nncc(Nc2n[nH]c(C3CC3)c2)n1)=O AAKUWRXEOGTCIX-UHFFFAOYSA-N 0.000 description 1
- XFQHDUOATASYGN-UHFFFAOYSA-N CC1=CC(NC2=CC(NC3=CC4=C(C=C3)C=NN4)=CN=N2)=NN1.I[IH][I-16] Chemical compound CC1=CC(NC2=CC(NC3=CC4=C(C=C3)C=NN4)=CN=N2)=NN1.I[IH][I-16] XFQHDUOATASYGN-UHFFFAOYSA-N 0.000 description 1
- CJKSCVLZOUKXFI-UHFFFAOYSA-N CC1=CC(NC2=CC(NCC3=CC=CN=C3)=NN=C2)=NN1.I[IH][I-24] Chemical compound CC1=CC(NC2=CC(NCC3=CC=CN=C3)=NN=C2)=NN1.I[IH][I-24] CJKSCVLZOUKXFI-UHFFFAOYSA-N 0.000 description 1
- IDMVDFJKXSZKMP-UHFFFAOYSA-N CC1=CC(NC2=CC(OC3=CC=C(CC#N)C=C3)=NN=C2)=NN1.I[IH][I-26] Chemical compound CC1=CC(NC2=CC(OC3=CC=C(CC#N)C=C3)=NN=C2)=NN1.I[IH][I-26] IDMVDFJKXSZKMP-UHFFFAOYSA-N 0.000 description 1
- NNXLKDBOWJCZJW-UHFFFAOYSA-N CC1=CC(NC2=CC(SC3=CC4=C(C=C3)N=CS4)=NN=C2)=NN1.I[IH][I-25] Chemical compound CC1=CC(NC2=CC(SC3=CC4=C(C=C3)N=CS4)=NN=C2)=NN1.I[IH][I-25] NNXLKDBOWJCZJW-UHFFFAOYSA-N 0.000 description 1
- RXTNHKLOUTZLLX-UHFFFAOYSA-N CC1=CC(NC2=NC(NC3=CC4=C(C=C3)C=NN4)=CC(CC3=CC=CC=C3)=N2)=NN1 Chemical compound CC1=CC(NC2=NC(NC3=CC4=C(C=C3)C=NN4)=CC(CC3=CC=CC=C3)=N2)=NN1 RXTNHKLOUTZLLX-UHFFFAOYSA-N 0.000 description 1
- COIXQCXRUKOLCE-UHFFFAOYSA-N CC1=CC(NC2=NC(NC3=CC4=C(C=C3)C=NN4)=CN=N2)=NN1.I[IH][IH-] Chemical compound CC1=CC(NC2=NC(NC3=CC4=C(C=C3)C=NN4)=CN=N2)=NN1.I[IH][IH-] COIXQCXRUKOLCE-UHFFFAOYSA-N 0.000 description 1
- OKPNIPFZIIYESG-UHFFFAOYSA-N CC1=CC(NC2=NC(NC3=CC4=C(C=C3)C=NN4)=NC(CC3=CC=CC=C3)=N2)=NN1 Chemical compound CC1=CC(NC2=NC(NC3=CC4=C(C=C3)C=NN4)=NC(CC3=CC=CC=C3)=N2)=NN1 OKPNIPFZIIYESG-UHFFFAOYSA-N 0.000 description 1
- OWRXXVWRBXBBNC-UHFFFAOYSA-N CC1=CC(NC2=NC(NC3=CC=C(NS(C)(=O)=O)C=C3)=CC(NCC3=CN=CC=C3)=N2)=NN1 Chemical compound CC1=CC(NC2=NC(NC3=CC=C(NS(C)(=O)=O)C=C3)=CC(NCC3=CN=CC=C3)=N2)=NN1 OWRXXVWRBXBBNC-UHFFFAOYSA-N 0.000 description 1
- UTVMLZIQIOZBJO-UHFFFAOYSA-N CC1=CC(NC2=NC(NC3=CC=C(NS(C)(=O)=O)C=C3)=NC(NCC3=CN=CC=C3)=N2)=NN1 Chemical compound CC1=CC(NC2=NC(NC3=CC=C(NS(C)(=O)=O)C=C3)=NC(NCC3=CN=CC=C3)=N2)=NN1 UTVMLZIQIOZBJO-UHFFFAOYSA-N 0.000 description 1
- ISUIOPILDPYVJT-UHFFFAOYSA-N CC1=CC(NC2=NC(NCC3=CC=CN=C3)=CC(C)=N2)=NN1 Chemical compound CC1=CC(NC2=NC(NCC3=CC=CN=C3)=CC(C)=N2)=NN1 ISUIOPILDPYVJT-UHFFFAOYSA-N 0.000 description 1
- IYWVPQIXYAGPFI-UHFFFAOYSA-N CC1=CC(NC2=NC(NCC3=CC=CN=C3)=NC(C)=N2)=NN1 Chemical compound CC1=CC(NC2=NC(NCC3=CC=CN=C3)=NC(C)=N2)=NN1 IYWVPQIXYAGPFI-UHFFFAOYSA-N 0.000 description 1
- BRLSFWKIEUDTAX-UHFFFAOYSA-N CC1=CC(NC2=NC(NCC3=CC=CN=C3)=NN=C2)=NN1.I[IH][I-9] Chemical compound CC1=CC(NC2=NC(NCC3=CC=CN=C3)=NN=C2)=NN1.I[IH][I-9] BRLSFWKIEUDTAX-UHFFFAOYSA-N 0.000 description 1
- DONQQZOQRLCEFD-UHFFFAOYSA-N CC1=CC(NC2=NC(OC3=CC=C(CC#N)C=C3)=NN=C2)=NN1.I[IH][I-11] Chemical compound CC1=CC(NC2=NC(OC3=CC=C(CC#N)C=C3)=NN=C2)=NN1.I[IH][I-11] DONQQZOQRLCEFD-UHFFFAOYSA-N 0.000 description 1
- PSFOGVGFUDIZKB-UHFFFAOYSA-N CC1=CC(NC2=NC(SC3=CC4=C(C=C3)N=CS4)=C3C=CC=CC3=N2)=NN1 Chemical compound CC1=CC(NC2=NC(SC3=CC4=C(C=C3)N=CS4)=C3C=CC=CC3=N2)=NN1 PSFOGVGFUDIZKB-UHFFFAOYSA-N 0.000 description 1
- BBPOYUQRXAVVPK-UHFFFAOYSA-N CC1=CC(NC2=NC(SC3=CC4=C(C=C3)N=CS4)=NC(SC3=CC=CC=C3)=N2)=NN1 Chemical compound CC1=CC(NC2=NC(SC3=CC4=C(C=C3)N=CS4)=NC(SC3=CC=CC=C3)=N2)=NN1 BBPOYUQRXAVVPK-UHFFFAOYSA-N 0.000 description 1
- RFRBNXNKQTZVIG-UHFFFAOYSA-N CC1=CC(NC2=NC(SC3=CC4=C(C=C3)N=CS4)=NN=C2)=NN1.I[IH][I-10] Chemical compound CC1=CC(NC2=NC(SC3=CC4=C(C=C3)N=CS4)=NN=C2)=NN1.I[IH][I-10] RFRBNXNKQTZVIG-UHFFFAOYSA-N 0.000 description 1
- LFLOVERXCWEWNY-UHFFFAOYSA-N CC1=CC(NC2=NC(SCC3=CC=CS3)=NC(OCCCN(C)C)=N2)=NN1 Chemical compound CC1=CC(NC2=NC(SCC3=CC=CS3)=NC(OCCCN(C)C)=N2)=NN1 LFLOVERXCWEWNY-UHFFFAOYSA-N 0.000 description 1
- GASRWHOOYFTVCJ-UHFFFAOYSA-N CC1=NC(NC2=NNC3=C2C=CC=C3)=NC(OCC2=CC=CC=C2)=C1 Chemical compound CC1=NC(NC2=NNC3=C2C=CC=C3)=NC(OCC2=CC=CC=C2)=C1 GASRWHOOYFTVCJ-UHFFFAOYSA-N 0.000 description 1
- QLGPWJIEXUTVAB-UHFFFAOYSA-N CC1=NC(NC2=NNC3=C2C=CC=C3)=NC(OCC2=CC=CC=C2)=N1 Chemical compound CC1=NC(NC2=NNC3=C2C=CC=C3)=NC(OCC2=CC=CC=C2)=N1 QLGPWJIEXUTVAB-UHFFFAOYSA-N 0.000 description 1
- JMVDDSJNDJWOOA-UHFFFAOYSA-N CN(C)CCCCC1=NC(NC2=NNC(C3CC3)=C2)=NC(SC2=CC3=C(C=C2)N=CS3)=C1 Chemical compound CN(C)CCCCC1=NC(NC2=NNC(C3CC3)=C2)=NC(SC2=CC3=C(C=C2)N=CS3)=C1 JMVDDSJNDJWOOA-UHFFFAOYSA-N 0.000 description 1
- CZUNCVQXMCXPTN-UHFFFAOYSA-N CN(C)CCCOC1=NC(NC2=NNC(C3CC3)=C2)=NC(SC2=CC3=C(C=C2)N=CS3)=N1 Chemical compound CN(C)CCCOC1=NC(NC2=NNC(C3CC3)=C2)=NC(SC2=CC3=C(C=C2)N=CS3)=N1 CZUNCVQXMCXPTN-UHFFFAOYSA-N 0.000 description 1
- UFJIYOPEBSOIMK-UHFFFAOYSA-N CN1CCC(OC2=NC(NC3=NNC(C4CC4)=C3)=NC(NC3=CC4=C(C=C3)C=NN4)=N2)CC1 Chemical compound CN1CCC(OC2=NC(NC3=NNC(C4CC4)=C3)=NC(NC3=CC4=C(C=C3)C=NN4)=N2)CC1 UFJIYOPEBSOIMK-UHFFFAOYSA-N 0.000 description 1
- HMNUPOFGUVBAPC-UHFFFAOYSA-N COC1=CC=CC(CC2=C3C=CC=CC3=NC(NC3=NNC(C4CC4)=C3)=N2)=C1 Chemical compound COC1=CC=CC(CC2=C3C=CC=CC3=NC(NC3=NNC(C4CC4)=C3)=N2)=C1 HMNUPOFGUVBAPC-UHFFFAOYSA-N 0.000 description 1
- AXYAFQPKSONLTE-UHFFFAOYSA-N COC1=CC=CC(CC2=CN=NC(NC3=NNC(C)=C3)=C2)=C1.I[IH][I-18] Chemical compound COC1=CC=CC(CC2=CN=NC(NC3=NNC(C)=C3)=C2)=C1.I[IH][I-18] AXYAFQPKSONLTE-UHFFFAOYSA-N 0.000 description 1
- FAJPEZASVVBHFA-UHFFFAOYSA-N COC1=CC=CC(CC2=CN=NC(NC3=NNC(C)=C3)=N2)=C1.I[IH][IH-3] Chemical compound COC1=CC=CC(CC2=CN=NC(NC3=NNC(C)=C3)=N2)=C1.I[IH][IH-3] FAJPEZASVVBHFA-UHFFFAOYSA-N 0.000 description 1
- DCSDOAZMJCSNFP-UHFFFAOYSA-N COC1=CC=CC(CC2=NC(SC3=CC=CC=C3)=NC(NC3=NNC4=C3C=CC=C4)=N2)=C1 Chemical compound COC1=CC=CC(CC2=NC(SC3=CC=CC=C3)=NC(NC3=NNC4=C3C=CC=C4)=N2)=C1 DCSDOAZMJCSNFP-UHFFFAOYSA-N 0.000 description 1
- NLURYEKJBLKMDC-UHFFFAOYSA-N COC1=CC=CC(SC2=NN=CC(NC3=NNC4=C3C=CC=C4)=C2)=C1.I[IH][I-30] Chemical compound COC1=CC=CC(SC2=NN=CC(NC3=NNC4=C3C=CC=C4)=C2)=C1.I[IH][I-30] NLURYEKJBLKMDC-UHFFFAOYSA-N 0.000 description 1
- BAUDNWNHDKAVCO-UHFFFAOYSA-N COC1=CC=CC(SC2=NN=CC(NC3=NNC4=C3C=CC=C4)=N2)=C1.I[IH][I-15] Chemical compound COC1=CC=CC(SC2=NN=CC(NC3=NNC4=C3C=CC=C4)=N2)=C1.I[IH][I-15] BAUDNWNHDKAVCO-UHFFFAOYSA-N 0.000 description 1
- CGXAVZNMOFVLFE-UHFFFAOYSA-N COCCNC1=NC(NC2=NNC(C)=C2)=NC(SC2=CC=C(NC(C)=O)C=C2)=N1 Chemical compound COCCNC1=NC(NC2=NNC(C)=C2)=NC(SC2=CC=C(NC(C)=O)C=C2)=N1 CGXAVZNMOFVLFE-UHFFFAOYSA-N 0.000 description 1
- JOKKHJKQHGPAPK-UHFFFAOYSA-N COCCNC1=NC(NC2=NNC(C3CC3)=C2)=NC(SCC2=CC=CS2)=C1 Chemical compound COCCNC1=NC(NC2=NNC(C3CC3)=C2)=NC(SCC2=CC=CS2)=C1 JOKKHJKQHGPAPK-UHFFFAOYSA-N 0.000 description 1
- VNHBDJFKXNKLIQ-UHFFFAOYSA-N COCCNC1=NC(NC2=NNC(C3CC3)=C2)=NC(SCC2=CC=CS2)=N1 Chemical compound COCCNC1=NC(NC2=NNC(C3CC3)=C2)=NC(SCC2=CC=CS2)=N1 VNHBDJFKXNKLIQ-UHFFFAOYSA-N 0.000 description 1
- OJVYETXBFCWLDZ-UHFFFAOYSA-N CS(=O)(=O)NC1=CC=C(NC2=CN=NC(NC3=NNC4=C3C=CC=C4)=C2)C=C1.I[IH][I-22] Chemical compound CS(=O)(=O)NC1=CC=C(NC2=CN=NC(NC3=NNC4=C3C=CC=C4)=C2)C=C1.I[IH][I-22] OJVYETXBFCWLDZ-UHFFFAOYSA-N 0.000 description 1
- UKNJBMKSYZRTER-UHFFFAOYSA-N CS(=O)(=O)NC1=CC=C(NC2=CN=NC(NC3=NNC4=C3C=CC=C4)=N2)C=C1.I[IH][I-7] Chemical compound CS(=O)(=O)NC1=CC=C(NC2=CN=NC(NC3=NNC4=C3C=CC=C4)=N2)C=C1.I[IH][I-7] UKNJBMKSYZRTER-UHFFFAOYSA-N 0.000 description 1
- OFTYIHYESKIYBD-UHFFFAOYSA-N Cc1cc(Nc2cc(Cc3cccc(OC)c3)cnn2)n[nH]1 Chemical compound Cc1cc(Nc2cc(Cc3cccc(OC)c3)cnn2)n[nH]1 OFTYIHYESKIYBD-UHFFFAOYSA-N 0.000 description 1
- SVGISGBLIXJJNX-UHFFFAOYSA-N Cc1cc(Nc2nc(Nc3ccc(cn[nH]4)c4c3)cnn2)n[nH]1 Chemical compound Cc1cc(Nc2nc(Nc3ccc(cn[nH]4)c4c3)cnn2)n[nH]1 SVGISGBLIXJJNX-UHFFFAOYSA-N 0.000 description 1
- RXKGSALPZYDBQC-UHFFFAOYSA-N Cc1n[nH]c2c1CCCC2 Chemical compound Cc1n[nH]c2c1CCCC2 RXKGSALPZYDBQC-UHFFFAOYSA-N 0.000 description 1
- LFCYVJLCBBOYQV-UHFFFAOYSA-N I[IH][I-21].N#CCC1=CC=C(OC2=CN=NC(NC3=NNC(C4CC4)=C3)=C2)C=C1 Chemical compound I[IH][I-21].N#CCC1=CC=C(OC2=CN=NC(NC3=NNC(C4CC4)=C3)=C2)C=C1 LFCYVJLCBBOYQV-UHFFFAOYSA-N 0.000 description 1
- IOCLLMURVUCODP-UHFFFAOYSA-N I[IH][I-6].N#CCC1=CC=C(OC2=CN=NC(NC3=NNC(C4CC4)=C3)=N2)C=C1 Chemical compound I[IH][I-6].N#CCC1=CC=C(OC2=CN=NC(NC3=NNC(C4CC4)=C3)=N2)C=C1 IOCLLMURVUCODP-UHFFFAOYSA-N 0.000 description 1
- DYSHLIDXEJIJCJ-UHFFFAOYSA-N N#CCC1=CC=C(OC2=CC(CC3=CC=CC=C3)=NC(NC3=NNC4=C3C=CC=C4)=N2)C=C1 Chemical compound N#CCC1=CC=C(OC2=CC(CC3=CC=CC=C3)=NC(NC3=NNC4=C3C=CC=C4)=N2)C=C1 DYSHLIDXEJIJCJ-UHFFFAOYSA-N 0.000 description 1
- SNZFRYUFMAILRB-UHFFFAOYSA-N N#CCC1=CC=C(OC2=NC(CC3=CC=CC=C3)=NC(NC3=NNC4=C3C=CC=C4)=N2)C=C1 Chemical compound N#CCC1=CC=C(OC2=NC(CC3=CC=CC=C3)=NC(NC3=NNC4=C3C=CC=C4)=N2)C=C1 SNZFRYUFMAILRB-UHFFFAOYSA-N 0.000 description 1
- FAHYAGPWMOSPJH-UHFFFAOYSA-N N#CCC1=CC=C(OC2=NC(NCC3=CN=CC=C3)=NC(NC3=NNC(C4CC4)=C3)=N2)C=C1 Chemical compound N#CCC1=CC=C(OC2=NC(NCC3=CN=CC=C3)=NC(NC3=NNC(C4CC4)=C3)=N2)C=C1 FAHYAGPWMOSPJH-UHFFFAOYSA-N 0.000 description 1
- GLZANXWXHCDZGA-UHFFFAOYSA-N N#CCc(cc1)ccc1Oc1cnnc(Nc2n[nH]c(C3CC3)c2)c1 Chemical compound N#CCc(cc1)ccc1Oc1cnnc(Nc2n[nH]c(C3CC3)c2)c1 GLZANXWXHCDZGA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Definitions
- the present invention is in the field of medicinal chemistry and relates to compounds that are protein kinase inhibitors, compositions containing such compounds and methods of use. More particularly, this invention relates to compounds that are inhibitors of Aurora-2 protein kinase. The invention also relates to methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
- Protein kinases mediate intracellular signal transduction. They do this by effecting a phosphoryl transfer from a nucleoside triphosphate to a protein acceptor that is involved in a signaling pathway.
- kinases and pathways through which extracellular and other stimuli cause a variety of cellular responses to occur inside the cell. Examples of such stimuli include environmental and chemical stress signals (e.g. osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, H 2 O 2 ), cytokines (e.g. interleukin-1 (IL-1) and tumor necrosis factor ⁇ (TNF- ⁇ )), and growth factors (e.g.
- environmental and chemical stress signals e.g. osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, H 2 O 2
- cytokines e.g. interleukin-1 (IL-1) and tumor necrosis factor ⁇ (TNF- ⁇ )
- growth factors e.g.
- GM-CSF granulocyte macrophage-colony-stimulating factor
- FGF fibroblast growth factor
- Aurora-2 is a serine/threonine protein kinase that has been implicated in human cancer, such as colon, breast and other solid tumors. This kinase is believed to be involved in protein phosphorylation events that regulate the cell cycle. Specifically, Aurora-2 may play a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell cycle can lead to cellular proliferation and other abnormalities. In human colon cancer tissue, the aurora-2 protein has been found to be overexpressed. See Bischoff et al., EMBO J., 1998, 17, 3052-3065; Schumacher et al., J. Cell Biol., 1998, 143, 1635-1646; Kimura et al., J. Biol. Chem., 1997, 272, 13766-13771.
- Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase comprised of ⁇ and ⁇ isoforms that are each encoded by distinct genes [Coghlan et al., Chemistry & Biology, 7, 793-803 (2000); Kim and Kimmel, Curr. Opinion Genetics Dev., 10, 508-514 (2000)].
- GSK-3 has been implicated in various diseases including diabetes, Alzheimer's disease, CNS disorders such as manic depressive disorder and neurodegenerative diseases, and cardiomyocete hypertrophy [WO 99/65897; WO 00/38675; and Haq et al., J. Cell Biol . (2000) 151, 117].
- GSK-3 has been found to phosphorylate and modulate the activity of a number of regulatory proteins. These proteins include glycogen synthase which is the rate limiting enzyme necessary for glycogen synthesis, the microtubule associated protein Tau, the gene transcription factor ⁇ -catenin, the translation initiation factor e1F2B, as well as ATP citrate lyase, axin, heat shock factor-1, c-Jun, c-Myc, c-Myb, CREB, and CEPB ⁇ . These diverse protein targets implicate GSK-3 in many aspects of cellular metabolism, proliferation, differentiation and development.
- GSK-3 a GSK-3 mediated pathway that is relevant for the treatment of type II diabetes
- insulin-induced signaling leads to cellular glucose uptake and glycogen synthesis.
- GSK-3 is a negative regulator of the insulin-induced signal.
- the presence of insulin causes inhibition of GSK-3 mediated phosphorylation and deactivation of glycogen synthase.
- the inhibition of GSK-3 leads to increased glycogen synthesis and glucose uptake [Klein et al., PNAS, 93, 8455-9 (1996); Cross et al., Biochem. J., 303, 21-26 (1994); Cohen, Biochem. Soc. Trans., 21, 555-567 (1993); Massillon et al., Biochem J.
- GSK-3 activity has also been associated with Alzheimer's disease. This disease is characterized by the well-known ⁇ -amyloid peptide and the formation of intracellular neurofibrillary tangles.
- the neurofibrillary tangles contain hyperphosphorylated Tau protein where Tau is phosphorylated on abnormal sites. GSK-3 has been shown to phosphorylate these abnormal sites in cell and animal models. Furthermore, inhibition of GSK-3 has been shown to prevent hyperphosphorylation of Tau in cells [Lovestone et al., Current Biology 4, 1077-86 (1994); Brownlees et al., Neuroreport 8, 3251-55 (1997)]. Therefore, it is believed that GSK-3 activity may promote generation of the neurofibrillary tangles and the progression of Alzheimer's disease.
- ⁇ -catenin Another substrate of GSK-3 is ⁇ -catenin which is degradated after phosphorylation by GSK-3.
- Reduced levels of ⁇ -catenin have been reported in schizophrenic patients and have also been associated with other diseases related to increase in neuronal cell death [Zhong et al., Nature, 395, 698-702 (1998); Takashima et al., PNAS, 90, 7789-93 (1993); Pei et al., J. Neuropathol. Exp, 56, 70-78 (1997)].
- Z 1 to Z 4 are as described below;
- Ring A is selected from the group consisting of:
- R x is T-R 3 or L-Z-R 3 ;
- R y is Z-R 3′ or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms, or R y and R 8 are taken together to form a fused, optionally substituted 5-7 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur;
- Q is selected from —N(R 4 )—, —O—, —S—, or —CH(R 6 )—;
- R 1 is T-(Ring D);
- Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R 5 , or V-Z-R 5 , and each substitutable-ring nitrogen of Ring D is independently substituted by —R 4 ;
- T is a valence bond or a C 1-4 alkylidene chain, wherein when Q is —CH(R 6 )—, a methylene unit of said C 1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —;
- Z is a C 1-4 alkylidene chain
- L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R)CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )——C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6
- R 2 and R 2 are independently selected from —R, -T-W—R 6 , or R 2 and R 2 ′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated-or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2 is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2 ′ is independently substituted by R 4 ;
- R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )N(
- R 3′ is selected from -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, —OC( ⁇ O)N(R 7 ) 2 ,
- each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
- each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
- V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 5 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )——C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(
- W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R)CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )——C(R 6 )SO 2 N(R 6 )—C(R 6 )—C(R 6 )—C
- each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
- each R 7 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
- R 8 is selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 .
- aliphatic as used herein means straight-chain, branched or cyclic C 1-12 hydrocarbons which are completely saturated or which contain one or more units of unsaturation but which are not aromatic.
- suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
- alkyl used alone or as part of a larger moiety includes both straight and branched chains containing one to twelve carbon atoms.
- alkenyl and “alkynyl” used alone or as part of a larger moiety shall include both straight and branched chains containing two to twelve carbon atoms.
- cycloalkyl used alone or as part of a larger moiety shall include cyclic C 3 -C 12 hydrocarbons which are completely saturated or which contain one or more units of unsaturation, but which are not aromatic.
- haloalkyl means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms.
- halogen means F, Cl, Br, or I.
- heteroatom means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen.
- nitrogen includes a substitutable nitrogen of a heterocyclic ring.
- the nitrogen in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl).
- carrier means an aliphatic ring system having three to fourteen members.
- carrier refers to rings that are optionally substituted.
- carrier also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as in a decahydronaphthyl or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring.
- aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to aromatic ring groups having five to fourteen members, such as phenyl, benzyl, phenethyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl.
- aryl also refers to rings that are optionally substituted.
- aryl may be used interchangeably with the term “aryl ring”.
- Aryl also includes fused polycyclic aromatic ring systems in which an aromatic ring is fused to one or more rings.
- aryl is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as in an indanyl, phenanthridinyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring.
- heterocycle includes non-aromatic ring systems having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, or S.
- heterocyclic rings examples include 3-1H-benzimidazol-2-one, (1-substituted)-2-oxo-benzimidazol-3-yl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, [1,3]-dioxalanyl, [1,3]-dithiolanyl, [1,3]-dioxanyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 2-thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidiny
- heterocyclyl or “heterocyclic”, as it is used herein, is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic or non-aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the non-aromatic heteroatom-containing ring.
- heterocycle “heterocyclyl”, or “heterocyclic” whether saturated or partially unsaturated, also refers to rings that are optionally substituted.
- heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to heteroaromatic ring groups having five to fourteen members.
- heteroaryl rings include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl,
- heteroaryl is a group in which a heteroatomic ring is fused to one or more aromatic or nonaromatic rings where the radical or point of attachment is on the heteroaromatic ring. Examples include tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[3,4-d]pyrimidinyl.
- heteroaryl also refers to rings that are optionally substituted.
- heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
- An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or-heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents.
- Suitable substituents on the unsaturated carbon atom of an aryl, heteroaryl, aralkyl, or heteroaralkyl group include a halogen, —R o , —OR o , —SR o , 1,2-methylene-dioxy, 1,2-ethylenedioxy, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, —O(Ph), substituted —O(Ph), —CH 2 (Ph), substituted —CH 2 (Ph), —CH 2 CH 2 (Ph), substituted —CH 2 CH 2 (Ph), —NO 2 , —CN, —N(R o ) 2 , —NR o C(O)R o , —NR o C(O)N(R o ) 2 , —NR o CO 2 R o , —NR o NR o C(O)R o , —NR o NR NR
- substituents on the aliphatic group or the phenyl ring of R o include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
- An aliphatic group or a non-aromatic heterocyclic ring may contain one or more substituents.
- suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring include those listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: ⁇ O, ⁇ S, ⁇ NNHR*, ⁇ NN(R*) 2 , ⁇ N—, ⁇ NNHC(O)R*, ⁇ NNHCO 2 (alkyl), ⁇ NNHSO 2 (alkyl), or ⁇ NR*, where each R* is independently selected from hydrogen, an unsubstituted aliphatic group or a substituted aliphatic group.
- substituents on the aliphatic group include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
- Suitable substituents on the nitrogen of a non-aromatic heterocyclic ring include —R + , —N(R + ) 2 , —C(O)R + , —CO 2 R + , —C(O)C(O)R + , —C(O)CH 2 C(O)R + , —SO 2 R + , —SO 2 N(R + ) 2 , —C( ⁇ S)N(R + ) 2 , —C( ⁇ NH)—N(R + ) 2 , and —NR + SO 2 R + ; wherein R + is hydrogen, an aliphatic group, a substituted aliphatic group, phenyl (Ph), substituted Ph, —O(Ph), substituted —O(Ph), CH 2 (Ph), substituted CH 2 (Ph), or an unsubstituted heteroaryl or heterocyclic ring.
- substituents on the aliphatic group or the phenyl ring include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
- linker group means an organic moiety that connects two parts of a compound.
- Linkers are typically comprised of an atom such as oxygen or sulfur, a unit such as —NH—, —CH 2 —, —C(O)—, —C(O)NH—, or a chain of atoms, such as an alkylidene chain.
- the molecular mass of a linker is typically in the range of about 14 to 200, preferably in the range of 14 to 96 with a length of up to about six atoms.
- linkers include a saturated or unsaturated C 1-6 alkylidene chain which is optionally substituted, and wherein one or two saturated carbons of the chain are optionally replaced by —C(O)—, —C(O)C(O)—, —CONH—, —CONHNH—, —CO 2 —, —OC(O)—, —NHCO 2 —, —O—, —NHCONH—, —OC(O)NH—, —NHNH—, —NHCO—, —S—, —SO—, —SO 2 —, —NH—, —SO 2 NH—, or —NHSO 2 —.
- alkylidene chain refers to an optionally substituted, straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation.
- the optional substituents are as described above for an aliphatic group.
- a combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound.
- a stable compound or chemically feasible compound is one in which the chemical structure is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
- structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.
- structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13 C— or 14 C-enriched carbon are within the scope of this invention.
- compositions may be formulated into compositions.
- the composition is a pharmaceutical composition.
- the composition comprises an amount of the protein kinase inhibitor effective to inhibit a protein kinase, particularly Aurora-2, in a biological sample or in a patient.
- compounds of this invention and pharmaceutical compositions thereof which comprise an amount of the protein kinase inhibitor effective to treat or prevent an Aurora-2-mediated condition and a pharmaceutically acceptable carrier, adjuvant, or vehicle, may be formulated for administration to a patient.
- Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
- Aurora-2-mediated condition or “disease”, as used herein, means any disease or other deleterious condition in which Aurora is known to play a role.
- the term “Aurora-2-mediated condition” or “disease” also means those diseases or conditions that are alleviated by treatment with an Aurora-2 inhibitor. Such conditions include, without limitation, cancer.
- cancer includes, but is not limited to the following cancers: colon, breast, stomach, and ovarian.
- Another aspect of the invention relates to inhibiting Aurora-2 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 inhibitor of formula I, or a composition thereof.
- Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
- Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
- GSK-3-mediated condition or “disease”, as used herein, means any disease or other deleterious condition or state in which GSK-3 is known to play a role.
- diseases or conditions include, without limitation, diabetes, Alzheimer's disease, Huntington's Disease, Parkinson's Disease, AIDS-associated dementia, amyotrophic lateral sclerosis (AML), multiple sclerosis (MS), schizophrenia, cardiomycete hypertrophy, reperfusion/ischemia, and baldness.
- One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
- Another aspect of the invention relates to inhibiting GSK-3 activity in a biological sample, which method comprises contacting the biological sample with a GSK-3 inhibitor of formula I.
- Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
- pharmaceutically acceptable carrier, adjuvant, or vehicle refers to a non-toxic carrier, adjuvant, or vehicle that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof.
- patient includes human and veterinary subjects.
- biological sample includes, without limitation, cell cultures or extracts thereof; preparations of an enzyme suitable for in vitro assay; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
- the amount effective to inhibit protein kinase is one that measurably inhibits the kinase activity where compared to the activity of the enzyme in the absence of an inhibitor. Any method may be used to determine inhibition, such as, for example, the Biological Testing Examples described below.
- Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
- ion exchangers alumina, aluminum stearate, lecithin
- serum proteins such as human serum albumin
- buffer substances such as phosphates, glycine, sorb
- compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
- the compositions are administered orally, intraperitoneally or intravenously.
- Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides.
- Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
- These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
- a long-chain alcohol diluent or dispersant such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
- Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
- compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
- carriers commonly used include lactose and corn starch.
- Lubricating agents such as magnesium stearate, are also typically added.
- useful diluents include lactose and dried cornstarch.
- aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
- compositions of this invention may be administered in the form of suppositories for rectal administration.
- suppositories for rectal administration.
- a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
- suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
- compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
- Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
- the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
- Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
- the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
- Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride.
- the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
- compositions of this invention may also be administered by nasal aerosol or inhalation.
- Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- compositions to treat or prevent the above-identified diseases or disorders.
- a “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
- Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
- compositions of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
- suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate
- Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N + (C 1-4 alkyl) 4 salts.
- alkali metal e.g., sodium and potassium
- alkaline earth metal e.g., magnesium
- ammonium and N + (C 1-4 alkyl) 4 salts This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
- compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
- a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body-weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
- the amount of the inhibitor will also depend upon the particular compound in the composition.
- additional therapeutic agents which are normally administered to treat or prevent that condition, may be administered together with the inhibitors of this invention.
- additional therapeutic agents which are normally administered to treat or prevent that condition, may be administered together with the inhibitors of this invention.
- chemotherapeutic agents or other anti-proliferative agents may be combined with the Aurora-2 inhibitors of this invention to treat cancer.
- these agents include, without limitation, adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum derivatives.
- agents for treating diabetes such as insulin or insulin analogues, in injectable or inhalation form, glitazones, alpha glucosidase inhibitors, biguanides, insulin sensitizers, and sulfonyl ureas
- anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine
- immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine
- neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers,
- those additional agents may be administered separately from the protein kinase inhibitor-containing composition, as part of a multiple dosage regimen.
- those agents may be part of a single dosage form, mixed together with the protein kinase inhibitor of this invention in a single composition.
- R x groups when present, include hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
- R y groups when present, include Z-R 3 or an optionally substituted group selected from C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R 3 is —N(R 4 ) 2 , —OR, or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms.
- R y groups include 5-6 membered heteroaryl or heterocyclyl rings, such as 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl; C 1-6 aliphatic, such as methyl, ethyl, cyclopropyl, isopropyl., or t-butyl; alkoxyalkylamino such as methoxyethylamino; alkoxyalkyl such as methoxymethyl or methoxyethyl; alkyl- or dialkylamino such as ethylamino or dimethylamino; alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy; acetamido; and optionally substituted phenyl such as phenyl or halo-substituted phenyl.
- C 1-6 aliphatic such as methyl, ethyl,
- R 2 and R 2 may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
- Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring, wherein said fused ring is optionally substituted.
- Preferred substituents on the R 2 /R 2 ′ fused ring include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-3 alkyl, —C 1-3 haloalkyl, —NO 2 , —O(C 1-3 alkyl), —CO 2 (C 1-3 alkyl), —CN, —SO 2 (C 1-3 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-3 alkyl), —NHC(O) (C 1-3 alkyl), —C(O)NH 2 , and —CO(C 1-3 alkyl), wherein the (C 1-3 alkyl) is most preferably methyl.
- preferred R 2 groups include hydrogen, C 1-4 aliphatic, alkoxycarbonyl, (un)substituted phenyl, hydroxyalkyl, alkoxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, phenylaminocarbonyl, and (N-heterocyclyl)carbonyl.
- R 2 substituents include methyl, cyclopropyl, ethyl, isopropyl, propyl, t-butyl, cyclopentyl, phenyl, CO 2 H, CO 2 CH 3 , CH 2 OH, CH 2 OCH 3 , CH 2 CH 2 CH 2 OH, CH 2 CH 2 CH 2 OCH 3 , CH 2 CH 2 CH 2 OCH 2 Ph, CH 2 CH 2 CH 2 NH 2 , CH 2 CH 2 CH 2 NHCOOC(CH 3 ) 3 , CONHCH(CH 3 ) 2 , CONHCH 2 CH ⁇ CH 2 , CONHCH 2 CH 2 OCH 3 , CONHCH 2 Ph, CONH(cyclohexyl), CON(Et) 2 , CON(CH 3 )CH 2 Ph, CONH(n-C 3 H 7 ), CON(Et)CH 2 CH 2 CH 3 , CONHCH 2 CH(CH 3 ) 2 , CON(n-C 3 H 7 ) 2 , CO(
- Preferred Q groups of formula I include —S—, —NH—, and —CH 2 —. More preferred Q groups of formula I include —S— and —NH—.
- Another embodiment of this invention relates to compounds of formula II:
- Z 1 is nitrogen or CR 8 ;
- R y is Z-R 3′ or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl., a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms, or R y and R 8 are taken together to form a fused, optionally substituted 5-7 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur;
- Q is selected from —N(R 4 )—, —O—, —S—, or —CH(R 6 )—;
- R 1 is T-(Ring D)
- Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R 5 , or V-Z-R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
- T is a valence bond or a C 1-4 alkylidene chain, wherein when Q is —CH(R 6 )—, a methylene unit of said C 1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —;
- Z is a C 1-4 alkylidene chain
- L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )——C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )_, —C(R 6 ) 2 N(
- R 2 and R 2 ′ are independently selected from —R, -T-W—R 6 , or R 2 and R 2 ′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2′ is independently substituted by halo, oxo, CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2 ′ is independently substituted by R 4 ;
- R 3′ is selected from -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, —OC( ⁇ O)N(R 7 ) 2 ,
- each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
- each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
- V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )——C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO 2 N
- W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —C(R 6 )OC(O)—, —C(R 6 )OC(O)NR 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 ) 2 N(R 6 )SO 2 N(R 6 )——C(R 6 )
- each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
- each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
- R 8 is selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ; provided that when Q
- Another embodiment of this invention relates to compounds of formula IIa:
- R y is Z-R 3′ or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- Q is selected from —N(R 4 )—, —O—, —S—, or —CH(R 6 )—;
- R 1 is T-(Ring D);
- Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R 5 , or V-Z-R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
- T is a valence bond or a C 1-4 alkylidene chain, wherein when Q is —CH(R 6 )—, a methylene unit of said C 1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —;
- Z is a C 1-4 alkylidene chain
- L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
- R 2 and R 2 are independently selected from —R, -T-W—R 6 , or R 2 and R 2 ′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2 ′ is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2 ′ is independently substituted by R 4 ;
- R 3 ′ is selected from -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, —OC( ⁇ O)N(R 7 ) 2
- each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-1-O ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
- each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
- V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—, —C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO
- W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )—,
- each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
- each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
- R y groups of formula IIa include Z-R 3′ or an optionally substituted group selected from C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R 3 ′ is —N(R 4 ) 2 , —OR, or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms.
- R y groups examples include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
- R 2 and R 2 groups of formula IIa may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
- Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIa compounds having a pyrazole-containing bicyclic ring system:
- Preferred substituents on the R 2 /R 2′ fused ring of formula IIa include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O) (C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
- the (C 1-4 alkyl) group is methyl.
- preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
- preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
- a preferred R 2 ′ group is hydrogen.
- Ring D of formula IIa is monocyclic
- preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
- Ring D of formula IIa is bicyclic
- preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
- preferred T-R 5 or V-Z-R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
- R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
- Preferred formula IIa compounds have one or more, and more preferably all, of the features selected from the group consisting of:
- R y is Z-R 3′ or an optionally substituted group selected from C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R 3 is —N(R 4 ) 2 , —OR, or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring-atoms;
- R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
- Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
- R 2 is —R or -T-W—R 6 and R 2 ′ is hydrogen, or R 2 and R 2 ′ are taken together to form an optionally substituted benzo ring.
- More preferred compounds of formula IIa have one or more, and more preferably all, of the features selected from the group consisting of:
- R y is an optionally substituted group selected from C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
- R 1 is T-(Ring D), wherein T is a valence bond and Q is —S—, —NH—, or —CH 2 —;
- Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
- R 2 is —R and R 2 is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
- R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl;
- R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 !
- C 1-6 aliphatic group optionally substituted C 1-6 aliphatic group, —OR, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )SO 2 R, —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , and Q is —S— or —NH—; and
- R 2 is hydrogen or a substituted or unsubstituted C 1-6 aliphatic, and L is —O—, —S—, or —NH—.
- this invention provides a composition comprising a compound of formula IIa and a pharmaceutically acceptable carrier.
- Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof.
- Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIa or a composition comprising said compound.
- Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such-treatment a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof.
- One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
- Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIa or a composition comprising said compound.
- Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IIa, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
- Another embodiment of this invention relates to compounds of formula IIb:
- R y is Z-R 3′ or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms, or R y and Re are taken together to form a fused, optionally substituted 5-7 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur;
- Q is selected from —N(R 4 )—, —O—, —S—, or —CH(R 6 )—;
- R 1 is T-(Ring D);
- Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R 5 , or V-Z-R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
- T is a valence bond or a C 1-4 alkylidene chain, wherein when Q is —CH(R 6 )—, a methylene unit of said C 1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —;
- Z is a C 1-4 alkylidene chain
- L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )—C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6
- R 2 and R 2 ′ are independently selected from —R, -T-W—R 6 , or R 2 and R 2 ′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R 2 and R 2 is independently substituted by halo, oxo, —CN, —NO 2 , —R 7 , or —V—R 6 , and each substitutable ring nitrogen of said ring formed by R 2 and R 2 is independently substituted by R 4 ;
- R 3′ is selected from -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 7 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 ′—C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, —OC( ⁇ O)N(R 7 ) 2 , or
- each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-0 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C 1-6 aliphatic)-CON(R 7 ) 2 , or —SO 2 R 7 ;
- each R 5 is independently selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
- V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )——C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO 2 N
- W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —, —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R)CO—, —C(R 6 ) 2 N(R 6 )C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O——C(R 6 ) 2 N(R 6 )N(R 6 )——C(R 6 )SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 ) 2 N(R 6 )SO
- each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
- each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
- R 8 is selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ; provided that when Q
- R y groups of formula IIb include Z-R 3 or an optionally substituted group selected from C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R 3 ′ is —N(R 4 ) 2 , —OR, or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms.
- R y groups examples include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
- R 2 and R 2′ groups of formula IIb may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
- Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula IIb compounds having a pyrazole-containing bicyclic ring system:
- Preferred substituents on the R 2 /R 2′ fused ring of formula IIb include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O) (C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
- the (C 1-4 alkyl) group is methyl.
- preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
- preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
- a preferred R 2 group is hydrogen.
- Ring D of formula IIb is monocyclic
- preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
- Ring D of formula IIb is bicyclic
- preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
- preferred T-R 5 or V-Z-R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic
- R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAC, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 CH 2 (morpholin-4-yl
- R y and R 8 When R y and R 8 are taken together to form a fused ring, preferred rings formed by R y and R 8 include 5-6 membered unsaturated or partially unsaturated rings having 0-2 heteroatoms. More preferred fused rings formed by R y and R 8 include benzo, cyclohexo, and pyrido.
- R 8 groups of formula IIb when present, include R, OR, and N(R 4 ) 2 .
- R 8 include methyl, ethyl, NH 2 , NH 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 O, (piperidin-1-yl)CH 2 CH 2 O, and NH 2 CH 2 CH 2 O.
- Preferred formula IIb compounds have one or more, and more preferably all, of the features selected from the group consisting of:
- R y is Z-R 3′ or an optionally substituted group selected from C 1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R 3 ′ is —N(R 4 ) 2 , —OR, or an optionally substituted group selected from C 1-6 aliphatic, C 6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
- Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
- R 2 is —R or -T-W—R 6 and R 2 is hydrogen, or R 2 and R 2 are taken together to form an optionally substituted benzo ring.
- More preferred compounds of formula IIb have one or more, and more preferably all, of the features selected from the group consisting of:
- R y is an optionally substituted group selected from C 1-6 aliphatic, 5-6-membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
- R 1 is T-(Ring D), wherein T is a valence bond, and Q is —S—, —NH—, or —CH 2 —;
- Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
- R 2 is —R and R 2 is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
- R y is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl, or R y and R 8 are taken together to form a 5-6 membered unsaturated or partially unsaturated ring having 0-2 heteroatoms selected from nitrogen, oxygen, or sulfur;
- R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —CO 2 R, —CONH(R 4 ), —N(R 4 )COR, —N(R 4 )SO 2 R, —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , and Q is —S— or —NH—; and
- R 2 is hydrogen or a substituted or unsubstituted C 1-6 aliphatic, and L is —O—, —S—, or —NH—.
- this invention provides a composition comprising a compound of formula IIb and a pharmaceutically acceptable carrier.
- Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIb or a pharmaceutical composition thereof.
- Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIb or a composition comprising said compound.
- Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIb or a pharmaceutical composition thereof.
- One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIb or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
- Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIb or a composition comprising said compound.
- Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IIb, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2-or GSK-3.
- Another embodiment of this invention relates to compounds of formula III:
- Z 1 is nitrogen or CR 8
- Z 2 is nitrogen or CH
- Z 3 is nitrogen or CR x , provided that one of Z 1 and Z 3 is nitrogen;
- R x is T-R 3 or L-Z-R 3 ;
- Q is selected from —N(R 4 )—, —O—, —S—, or —CH(R 6 )—;
- R 1 is T-(Ring D);
- Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R 5 , or V-Z-R 5 , and each substitutable ring nitrogen of Ring D is independently substituted by —R 4 ;
- T is a valence bond or a C 1-4 alkylidene chain, wherein when Q is —CH(R 6 )—, a methylene unit of said C 1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R 4 )—, —CO—, —CONH—, —NHCO—, —SO 2 —, —SO 2 NH—, —NHSO 2 —, —CO 2 —, —OC(O)—, —OC(O)NH—, or —NHCO 2 —;
- Z is a C 1-4 alkylidene chain
- L is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 )—, —N(R 6 )N(R 6 )——C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 SO 2 N
- R 3 is selected from —R, -halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —COCH 2 COR, —NO 2 , —CN, —S(O)R, —S(O) 2 R, —SR, —N(R 4 ) 2 , —CON(R 7 ) 2 , —SO 2 N(R 7 ) 2 , —OC( ⁇ O)R, —N(R 7 )COR, —N(R 1 )CO 2 (C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 7 )CON(R 7 ) 2 , —N(R 7 )SO 2 N(R 7 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 7 )
- each R is independently selected from hydrogen or an optionally substituted group selected from C 1-6 aliphatic, C 6-0 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R 4 is independently selected from —R 7 , —COR 7 , —CO 2 (optionally substituted C-6 aliphatic), —CON(R 7 ) 2 , or —SO 2 R 7 ;
- each R 5 is independently selected from —R halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 ;
- V is —O—, —S—, —SO—, —SO 2 —, —N(R 6 )SO 2 —, —SO 2 N(R 6 )—, —N(R 6 )—, —CO—, —CO 2 —, —N(R 6 )CO—, —N(R 6 )C(O)O—, —N(R 6 )CON(R 6 )—, —N(R 6 )SO 2 N(R 6 ), —N(R 6 )N(R 6 )-2—C(O)N(R 6 )—, —OC(O)N(R 6 )—, —C—(R 6 )N 2 , —C(R 6 )R 2 S —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, C(R 6 ) 2 SO 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 ) 2
- W is —C(R 6 ) 2 O—, —C(R 6 ) 2 S—, —C(R 6 ) 2 SO—, —C(R 6 ) 2 SO 2 —, —C(R 6 ) 2 O 2 N(R 6 )—, —C(R 6 ) 2 N(R 6 )—, —CO—, —CO 2 —C(R 6 )OC(O)—, —C(R 6 )OC(O)N(R 6 )—, —C(R 6 ) 2 N(R 6 )CO—, —C(R 6 ) 2 N(R 6 )C(O)O—, —C(R 6 ) ⁇ NN(R 6 )—, —C(R 6 ) ⁇ N—O—, —C(R 6 ) 2 N(R 6 )N(R 6 )—, —C(R 6 )SO 2 N(R 6 )—,
- each R 6 is independently selected from hydrogen or an optionally substituted C 1-4 aliphatic group, or two R 6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
- each R 7 is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group, or two R 7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring;
- R 8 is selected from —R, halo, —OR, —C( ⁇ O)R, —CO 2 R, —COCOR, —NO 2 , —CN, —S(O)R, —SO 2 R, —SR, —N(R 4 ) 2 , —CON(R 4 ) 2 , —SO 2 N(R 4 ) 2 , —OC( ⁇ O)R, —N(R 4 )COR, —N(R 4 )CO 2 (optionally substituted C 1-6 aliphatic), —N(R 4 )N(R 4 ) 2 , —C ⁇ NN(R 4 ) 2 , —C ⁇ N—OR, —N(R 4 )CON(R 4 ) 2 , —N(R 4 )SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, or —OC( ⁇ O)N(R 4 ) 2 .
- the present invention relates to compounds of formula IIIa, IIIb, IIIc and IIId as shown below:
- R x groups of formula III include T-R 3 wherein T is a valence bond or a methylene and R 3 is CN, —R, or —OR.
- R 3 is —R
- preferred R 3 groups include an optionally substituted group selected from C 1-6 aliphatic, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring.
- R 3 is —OR
- preferred R groups include an optionally substituted group C 1-6 aliphatic group such as alkyl- or dialkylaminoalkyl and aminoalkyl.
- RX examples include acetamido, CN, piperidinyl, piperazinyl, phenyl, pyridinyl, imidazol-1-yl, imidazol-2-yl, cyclohexyl, cyclopropyl, methyl, ethyl, isopropyl, t-butyl, NH 2 CH 2 CH 2 NH, and NH 2 CH 2 CH 2 O.
- R 8 groups of formula III when present, include R, OR, and N(R 4 ) 2 .
- R 8 include methyl, ethyl, NH 2 , NH 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 NH, N(CH 3 ) 2 CH 2 CH 2 O, (piperidin-1-yl) CH 2 CH 2 O, and NH 2 CH 2 CH 2 O.
- R 2 and R 2 groups of formula III may be taken together to form a fused ring, thus providing a bicyclic ring system containing a pyrazole ring.
- Preferred fused rings include benzo, pyrido, pyrimido, and a partially unsaturated 6-membered carbocyclo ring. These are exemplified in the following formula III compounds having a pyrazole-containing bicyclic ring system:
- R 2 /R 2 fused ring include one or more of the following: -halo, —N(R 4 ) 2 , —C 1-4 alkyl, —C 1-4 haloalkyl, —NO 2 , —O(C 1-4 alkyl), —CO 2 (C 1-4 alkyl), —CN, —SO 2 (C 1-4 alkyl), —SO 2 NH 2 , —OC(O)NH 2 , —NH 2 SO 2 (C 1-4 alkyl), —NHC(O) (C 1-4 alkyl), —C(O)NH 2 , and —CO(C 1-4 alkyl), wherein the (C 1-4 alkyl) is a straight, branched, or cyclic alkyl group.
- the (C 1-4 alkyl) group is methyl.
- preferred R 2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C 1-6 aliphatic group.
- preferred R 2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl.
- a preferred R 2 group is hydrogen.
- Ring D of formula III is monocyclic
- preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
- Ring D of formula III is bicyclic
- preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
- preferred T-R 5 or V-Z-R 5 substituents include -halo, —CN, —NO 2 , —N(R 4 ) 21 optionally substituted C 1-6 aliphatic group, —OR, —C(O)R, —CO 2 R, —CON(R 4 ) 2 , —OCO(R 4 ) 2 , —N(R 4 )COR, —N(R 4 )CO 2 R, —SO 2 N(R 4 ) 2 , —N(R 4 )SO 2 R, —N(R 6 )COCH 2 N(R 4 ) 2 , —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , and —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or
- R 5 substituents include —Cl, —Br, —F, —CN, —CF 3 , —COOH, —CONHMe, —CONHEt, —NH 2 , —NHAc, —NHSO 2 Me, —NHSO 2 Et, —NHSO 2 (n-propyl), —NHSO 2 (isopropyl), —NHCOEt, —NHCOCH 2 NHCH 3 , —NHCOCH 2 N(CO 2 t-Bu)CH 3 , —NHCOCH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 N(CH 3 ) 2 , —NHCOCH 2 CH 2 CH 2 N(CH 3 ) 2 , —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl), —NHCOCH 2 CH 2 (morpholin-4-yl),
- Preferred compounds of formula IIIa, IIIb, IIIc, or IIId have one or more, and more preferably all, of the features selected from the group consisting of:
- R x is hydrogen, alkyl- or dialkylamino, acetamido, or a C 1-4 aliphatic group
- R 1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
- Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
- R 2 is —R or -T-W—R 6 and R 2 is hydrogen, or R 2 and R 2 are taken together to form an optionally substituted benzo ring.
- More preferred compounds of formula IIIa, IIIb, IIIc, or IIId have one or more, and more preferably all, of the features selected from the group consisting of:
- R 1 is T-(Ring D), wherein T is a valence bond, and Q is —S—, —NH—, or —CH 2 —;
- Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring;
- R 2 is —R and R 2 is hydrogen, wherein R is selected from hydrogen, C 1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
- R x is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetimido;
- R 1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO 2 , —N(R 4 ) 2 , optionally substituted C 1-6 aliphatic group, —OR, —CO 2 R, —CON(R 4 ) 2 , —OCO(R 4 ) 2 , 10—N(R 4 )COR, —N(R 4 )SO 2 R, —N(R 6 )COCH 2 CH 2 N(R 4 ) 2 , or —N(R 6 )COCH 2 CH 2 CH 2 N(R 4 ) 2 , and Q is —S— or —NH—; and
- R 2 is hydrogen or a substituted or unsubstituted C 1-6 aliphatic.
- this invention provides a composition comprising a compound of formula III and a pharmaceutically acceptable carrier.
- Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula III or a pharmaceutical composition thereof.
- Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula III or a composition comprising said compound.
- Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula III or a pharmaceutical composition thereof.
- One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula III or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of ⁇ -catenin, which is useful for treating schizophrenia.
- Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula III or a composition comprising said compound.
- Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula III, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
- Scheme I above shows a general route for the preparation of compounds of formula IIb.
- the dichloro intermediate 1 (prepared using methods similar to those reported in J. Indian. Chem. Soc., 61, 690-693 (1984) or in J. Med. Chem., 37, 3828-3833 (1994)) is sequentially reacted with two nucleophiles: R 1 -QH to displace the chloride at position 4 to afford intermediate 2; and then 2 is treated with an aminopyrazole (or aminoindazole) to displace the chloride at position 2, using procedures similar to those described in J. Med. Chem, 38, 14, 2763-2773, (1995) to afford compounds of formula IIb.
- Scheme II above shows a general route for the preparation of compounds of formula IIb wherein Q is an N, O or S linker and R y is a group attached to the pyrimidine core via a heteroatom.
- Starting material 4,6-dihydroxy-2-methylsulfanylpyrimidine (4) is prepared using procedures similar to those reported in J. Med. Chem., 27, 12, 1621-1629 (1984). Chlorination of 4 with POCl 3 affords the dichloro intermediate 5. The two chlorides of 5 are sequentially displaced with the appropriate R 1 -QH, to afford compound 6, and then with R y -H (amine, alcohol, or thiol) to afford compound 7 using procedures similar to those reported in U.S. Pat. No. 2,585,906.
- the order of displacement may be reversed by first displacing with R y -H and then with R 1 -QH.
- the methyl sulfanyl group of compound 7 is then oxidized (for example, with oxone) to afford compound 8 and the resulting methylsulfonyl is finally displaced with the amino moiety of aminopyrazole (or aminoindazole) by methods substantially similar to those described above for Scheme 1 step (b) to afford compounds of formula IIb.
- Scheme III above shows a general route for the preparation of compounds of formula IIa.
- the three chlorides of starting material 8 are sequentially displaced with (a) the amino moiety of aminopyrazole (or aminoindazole) to afford compound 9, (b) the R 1 -QH group to afford compound 10, and (c) R y -H (amine, alcohol, or thiol) using procedures similar to the ones reported in J. Indian Chem. Soc., 53, 207-208, (1976) to afford compounds of formula IIa.
- These three steps can also be performed in different order to afford compounds of formula IIa.
- Scheme IV above shows a general route for the preparation of compounds of formula IIIa.
- Treatment of 11 with aminopyrazole (or aminoindazole) to provide 12 may be performed in a manner similar to that described in Heterocycles, 51, 5, 1999, 1035-1050.
- the intermediate 13 is obtained by displacement with R 1 -QH in a manner similar to that described in Farmaco. Ed. Sci., 27, 1972, 591-600.
- the chlorine may be removed by reduction.
- the chlorine may be displaced by methods known to those skilled in the art to afford compounds with a variety of R x substituents.
- Scheme V above shows a general route for the preparation of the compounds of formula IIIb. Displacement of the bromide with R 1 -QH to afford compound 15 may be performed in a manner similar to that described in Heterocycles, 51, 5, 1999, 1035-1050. Displacement of the chlorines may be carried out sequentially as described above.
- the activity of the compounds as protein kinase inhibitors may be assayed in vitro, in vivo or in a cell line.
- In vitro assays include assays that determine inhibition of either the phosphorylation activity or ATPase activity of the activated protein kinase. Alternate in vitro assays quantitate the ability of the inhibitor to bind to the protein kinase. Inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/protein kinase complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with the protein kinase bound to known radioligands.
- An assay stock buffer solution is prepared containing all of the reagents listed above with the exception of ATP and the test compound of interest.
- the assay stock buffer solution (175 ⁇ l) is incubated in a 96 well plate with 5 ⁇ l of the test compound of interest at final concentrations spanning 0.002 ⁇ M to 30 ⁇ M at 30° C. for 10 min.
- a 12 point titration is conducted by preparing serial dilutions (from 10 mM compound stocks) with DMSO of the test compounds in daughter plates.
- the reaction is initiated by the addition of 20 ⁇ l of ATP (final concentration 20 ⁇ M). Rates of reaction are obtained using a Molecular Devices Spectramax plate reader (Sunnyvale, Calif.) over 10 min at 30° C.
- the K i values are determined from the rate data as a function of inhibitor concentration.
- the reaction is initiated by the addition of 10 ⁇ L of Aurora-2 stock solution to give a final concentration of 70 nM in the assay.
- the rates of reaction are obtained by monitoring absorbance at 340 nm over a 5 minute read time at 30° C. using a BioRad Ultramark plate reader (Hercules, Calif.).
- the K i values are determined from the rate data as a function of inhibitor concentration.
Abstract
wherein Z1, Z2 and Z3 are as described in the specification; Q is —S—, —O—, —N(R4)—, or —CH(R6)—; R1 is T-Ring D, wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; and R2 and R2′ are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease.
Description
- This application claims priority to U.S. Provisional Patent Application 60/257,887 filed Dec. 21, 2000 and US Provisional Patent Application 60/286,949 filed Apr. 27, 2001, the contents of which are incorporated herein by reference.
- The present invention is in the field of medicinal chemistry and relates to compounds that are protein kinase inhibitors, compositions containing such compounds and methods of use. More particularly, this invention relates to compounds that are inhibitors of Aurora-2 protein kinase. The invention also relates to methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.
- The search for new therapeutic agents has been greatly aided in recent years by better understanding of the structure of enzymes and other biomolecules associated with target diseases. One important class of enzymes that has been the subject of extensive study is the protein kinases.
- Protein kinases mediate intracellular signal transduction. They do this by effecting a phosphoryl transfer from a nucleoside triphosphate to a protein acceptor that is involved in a signaling pathway. There are a number of kinases and pathways through which extracellular and other stimuli cause a variety of cellular responses to occur inside the cell. Examples of such stimuli include environmental and chemical stress signals (e.g. osmotic shock, heat shock, ultraviolet radiation, bacterial endotoxin, H2O2), cytokines (e.g. interleukin-1 (IL-1) and tumor necrosis factor α (TNF-α)), and growth factors (e.g. granulocyte macrophage-colony-stimulating factor (GM-CSF), and fibroblast growth factor (FGF). An extracellular stimulus may effect one or more cellular responses related to cell growth, migration, differentiation, secretion of hormones, activation of transcription factors, muscle contraction, glucose metabolism, control of protein synthesis and regulation of cell cycle.
- Many diseases are associated with abnormal cellular responses triggered by protein kinase-mediated events. These diseases include autoimmune diseases, inflammatory diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies and asthma, Alzheimer's disease or hormone-related diseases. Accordingly, there has been a substantial effort in medicinal chemistry to find protein kinase inhibitors that are effective as therapeutic agents.
- Aurora-2 is a serine/threonine protein kinase that has been implicated in human cancer, such as colon, breast and other solid tumors. This kinase is believed to be involved in protein phosphorylation events that regulate the cell cycle. Specifically, Aurora-2 may play a role in controlling the accurate segregation of chromosomes during mitosis. Misregulation of the cell cycle can lead to cellular proliferation and other abnormalities. In human colon cancer tissue, the aurora-2 protein has been found to be overexpressed. See Bischoff et al.,EMBO J., 1998, 17, 3052-3065; Schumacher et al., J. Cell Biol., 1998, 143, 1635-1646; Kimura et al., J. Biol. Chem., 1997, 272, 13766-13771.
- Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase comprised of α and β isoforms that are each encoded by distinct genes [Coghlan et al.,Chemistry & Biology, 7, 793-803 (2000); Kim and Kimmel, Curr. Opinion Genetics Dev., 10, 508-514 (2000)]. GSK-3 has been implicated in various diseases including diabetes, Alzheimer's disease, CNS disorders such as manic depressive disorder and neurodegenerative diseases, and cardiomyocete hypertrophy [WO 99/65897; WO 00/38675; and Haq et al., J. Cell Biol. (2000) 151, 117]. These diseases may be caused by, or result in, the abnormal operation of certain cell signaling pathways in which GSK-3 plays a role. GSK-3 has been found to phosphorylate and modulate the activity of a number of regulatory proteins. These proteins include glycogen synthase which is the rate limiting enzyme necessary for glycogen synthesis, the microtubule associated protein Tau, the gene transcription factor β-catenin, the translation initiation factor e1F2B, as well as ATP citrate lyase, axin, heat shock factor-1, c-Jun, c-Myc, c-Myb, CREB, and CEPBα. These diverse protein targets implicate GSK-3 in many aspects of cellular metabolism, proliferation, differentiation and development.
- In a GSK-3 mediated pathway that is relevant for the treatment of type II diabetes, insulin-induced signaling leads to cellular glucose uptake and glycogen synthesis. Along this pathway, GSK-3 is a negative regulator of the insulin-induced signal. Normally, the presence of insulin causes inhibition of GSK-3 mediated phosphorylation and deactivation of glycogen synthase. The inhibition of GSK-3 leads to increased glycogen synthesis and glucose uptake [Klein et al.,PNAS, 93, 8455-9 (1996); Cross et al., Biochem. J., 303, 21-26 (1994); Cohen, Biochem. Soc. Trans., 21, 555-567 (1993); Massillon et al., Biochem J. 299, 123-128 (1994)]. However, in a diabetic patient where the insulin response is impaired, glycogen synthesis and glucose uptake fail to increase despite the presence of relatively high blood levels of insulin. This leads to abnormally high blood levels of glucose with acute and long term effects that may ultimately result in cardiovascular disease, renal failure and blindness. In such patients, the normal insulin-induced inhibition of GSK-3 fails to occur. It has also been reported that in patients with type II diabetes, GSK-3 is overexpressed [WO 00/38675). Therapeutic inhibitors of GSK-3 are therefore potentially useful for treating diabetic patients suffering from an impaired response to insulin.
- GSK-3 activity has also been associated with Alzheimer's disease. This disease is characterized by the well-known β-amyloid peptide and the formation of intracellular neurofibrillary tangles. The neurofibrillary tangles contain hyperphosphorylated Tau protein where Tau is phosphorylated on abnormal sites. GSK-3 has been shown to phosphorylate these abnormal sites in cell and animal models. Furthermore, inhibition of GSK-3 has been shown to prevent hyperphosphorylation of Tau in cells [Lovestone et al.,Current Biology 4, 1077-86 (1994); Brownlees et al., Neuroreport 8, 3251-55 (1997)]. Therefore, it is believed that GSK-3 activity may promote generation of the neurofibrillary tangles and the progression of Alzheimer's disease.
- Another substrate of GSK-3 is β-catenin which is degradated after phosphorylation by GSK-3. Reduced levels of β-catenin have been reported in schizophrenic patients and have also been associated with other diseases related to increase in neuronal cell death [Zhong et al.,Nature, 395, 698-702 (1998); Takashima et al., PNAS, 90, 7789-93 (1993); Pei et al., J. Neuropathol. Exp, 56, 70-78 (1997)].
- As a result of the biological importance of GSK-3, there is current interest in therapeutically effective GSK-3 inhbitors. Small molecules that inhibit GSK-3 have recently been reported [WO 99/65897 (Chiron) and WO 00/38675 (SmithKline Beecham)].
- For many of the aforementioned diseases associated with abnormal GSK-3 activity, other protein kinases have also been targeted for treating the same diseases. However, the various protein kinases often act through different biological pathways. For example, certain quinazoline derivatives have been reported recently as inhibitors of p38 kinase (WO 00/12497 to Scios). The compounds are reported to be useful for treating conditions characterized by enhanced p38-α activity and/or enhanced TGF-β activity. While p38 activity has been implicated in a wide variety of diseases, including diabetes, p38 kinase is not reported to be a constituent of an insulin signaling pathway that regulates glycogen synthesis or glucose uptake. Therefore, unlike GSK-3, p38 inhibition would not be expected to enhance glycogen synthesis and/or glucose uptake.
- There is a continued need to find new therapeutic agents to treat human diseases. The protein kinases Aurora-2 and GSK-3 are especially attractive targets for the discovery of new therapeutics due to their important roles in cancer and diabetes, respectively.
-
- or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
- Z1 to Z4 are as described below;
-
- Rx is T-R3 or L-Z-R3;
- Ry is Z-R3′ or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms, or Ry and R8 are taken together to form a fused, optionally substituted 5-7 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur;
- Q is selected from —N(R4)—, —O—, —S—, or —CH(R6)—;
- R1 is T-(Ring D);
- Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R5, or V-Z-R5, and each substitutable-ring nitrogen of Ring D is independently substituted by —R4;
- T is a valence bond or a C1-4 alkylidene chain, wherein when Q is —CH(R6)—, a methylene unit of said C1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R4)—, —CO—, —CONH—, —NHCO—, —SO2—, —SO2NH—, —NHSO2—, —CO2—, —OC(O)—, —OC(O)NH—, or —NHCO2—;
- Z is a C1-4 alkylidene chain;
- L is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R)CON(R6)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)——C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —C(R6)2N(R6)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, or —C(R6)2N(R6)CON(R6)—;
- R2 and R2 are independently selected from —R, -T-W—R6, or R2 and R2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated-or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R2 and R2 is independently substituted by halo, oxo, —CN, —NO2, —R7, or —V—R6, and each substitutable ring nitrogen of said ring formed by R2 and R2′ is independently substituted by R4;
- R3 is selected from —R, -halo, —OR, —C(═O)R, —CO2R, —COCOR, —COCH2COR, —NO2, —CN, —S(O)R, —S(O)2R, —SR, —N(R4)2, —CON(R7)2, —SO2N(R7)2, —OC(═O)R, —N(R7)COR, —N(R7)CO2(C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R7)CON(R7)2, —N(R7)SO2N(R7)2, —N(R4)SO2R, or —OC(═O)N(R7)2;
- R3′ is selected from -halo, —OR, —C(═O)R, —CO2R, —COCOR, —COCH2COR, —NO2, —CN, —S(O)R, —S(O)2R, —SR, —N(R4)2, —CON(R7)2, —SO2N(R7)2, —OC(═O)R, —N(R7)COR, —N(R7)CO2(C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R7)CON(R7)2, —N(R7)SO2N(R7)2, —N(R4)SO2R, —OC(═O)N(R7)2, or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R is independently selected from hydrogen or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R4 is independently selected from —R7, —COR7, —CO2(optionally substituted C-6 aliphatic), —CON(R7)2, or —SO2R7;
- each R5 is independently selected from —R, halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2, —CON(R4)2, —SO2N(R4)2, —OC(═O)R, —N(R4)COR, —N(R4)CO2 (optionally substituted C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2;
- V is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R5)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)——C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —C(R6)2N(R6)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)——C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, or —C(R6)2N(R6)CON(R6)—;
- W is —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —CO—, —CO2—, —C(R6)OC(O)—, —C(R6)OC(O)N(R6)—, —C(R6)2N(R)CO—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)——C(R6)2N(R6)SO2N(R6)—C(R6)2N(R6)CON(R6)—, or —CON(R)—;
- each R6 is independently selected from hydrogen or an optionally substituted C1-4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
- each R7 is independently selected from hydrogen or an optionally substituted C1-4 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and
- R8 is selected from —R, halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2, —CON(R4)2, —SO2N(R4)2, —OC(═O)R, —N(R4)COR, —N(R4)CO2(optionally substituted C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2.
- As used herein, the following definitions shall apply unless otherwise indicated. The phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted” or with the term “(un)substituted.” Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and each substitution is independent of the other.
- The term “aliphatic” as used herein means straight-chain, branched or cyclic C1-12 hydrocarbons which are completely saturated or which contain one or more units of unsaturation but which are not aromatic. For example, suitable aliphatic groups include substituted or unsubstituted linear, branched or cyclic alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl. The terms “alkyl”, “alkoxy”, “hydroxyalkyl”, “alkoxyalkyl”, and “alkoxycarbonyl”, used alone or as part of a larger moiety includes both straight and branched chains containing one to twelve carbon atoms. The terms “alkenyl” and “alkynyl” used alone or as part of a larger moiety shall include both straight and branched chains containing two to twelve carbon atoms. The term “cycloalkyl” used alone or as part of a larger moiety shall include cyclic C3-C12 hydrocarbons which are completely saturated or which contain one or more units of unsaturation, but which are not aromatic.
- The terms “haloalkyl”, “haloalkenyl” and “haloalkoxy” means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms. The term “halogen” means F, Cl, Br, or I.
- The term “heteroatom” means nitrogen, oxygen, or sulfur and includes any oxidized form of nitrogen and sulfur, and the quaternized form of any basic nitrogen. Also the term “nitrogen” includes a substitutable nitrogen of a heterocyclic ring. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+ (as in N-substituted pyrrolidinyl).
- The terms “carbocycle”, “carbocyclyl”, “carbocyclo”, or “carbocyclic” as used herein means an aliphatic ring system having three to fourteen members. The terms “carbocycle”, “carbocyclyl”, “carbocyclo”, or “carbocyclic” whether saturated or partially unsaturated, also refers to rings that are optionally substituted. The terms “carbocycle”, “carbocyclyl”, “carbocyclo”, or “carbocyclic” also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as in a decahydronaphthyl or tetrahydronaphthyl, where the radical or point of attachment is on the aliphatic ring.
- The term “aryl” used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to aromatic ring groups having five to fourteen members, such as phenyl, benzyl, phenethyl, 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl. The term “aryl” also refers to rings that are optionally substituted. The term “aryl” may be used interchangeably with the term “aryl ring”. “Aryl” also includes fused polycyclic aromatic ring systems in which an aromatic ring is fused to one or more rings. Examples include 1-naphthyl, 2-naphthyl, 1-anthracyl and 2-anthracyl. Also included within the scope of the term “aryl”, as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as in an indanyl, phenanthridinyl, or tetrahydronaphthyl, where the radical or point of attachment is on the aromatic ring.
- The term “heterocycle”, “heterocyclyl”, or “heterocyclic” as used herein includes non-aromatic ring systems having five to fourteen members, preferably five to ten, in which one or more ring carbons, preferably one to four, are each replaced by a heteroatom such as N, O, or S. Examples of heterocyclic rings include 3-1H-benzimidazol-2-one, (1-substituted)-2-oxo-benzimidazol-3-yl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl, [1,3]-dioxalanyl, [1,3]-dithiolanyl, [1,3]-dioxanyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholinyl, 3-morpholinyl, 4-morpholinyl, 2-thiomorpholinyl, 3-thiomorpholinyl, 4-thiomorpholinyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-piperazinyl, 2-piperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 4-thiazolidinyl, diazolonyl, N-substituted diazolonyl, 1-phthalimidinyl, benzoxanyl, benzopyrrolidinyl, benzopiperidinyl, benzoxolanyl, benzothiolanyl, and benzothianyl. Also included within the scope of the term “heterocyclyl” or “heterocyclic”, as it is used herein, is a group in which a non-aromatic heteroatom-containing ring is fused to one or more aromatic or non-aromatic rings, such as in an indolinyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where the radical or point of attachment is on the non-aromatic heteroatom-containing ring. The term “heterocycle”, “heterocyclyl”, or “heterocyclic” whether saturated or partially unsaturated, also refers to rings that are optionally substituted.
- The term “heteroaryl”, used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to heteroaromatic ring groups having five to fourteen members. Examples of heteroaryl rings include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxadiazolyl, 5-oxadiazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 3-pyridazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 5-tetrazolyl, 2-triazolyl, 5-triazolyl, 2-thienyl, 3-thienyl, carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, benzotriazolyl, benzothiazolyl, benzooxazolyl, benzimidazolyl, isoquinolinyl, indazolyl, isoindolyl, acridinyl, or benzoisoxazolyl. Also included within the scope of the term “heteroaryl”, as it is used herein, is a group in which a heteroatomic ring is fused to one or more aromatic or nonaromatic rings where the radical or point of attachment is on the heteroaromatic ring. Examples include tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[3,4-d]pyrimidinyl. The term “heteroaryl” also refers to rings that are optionally substituted. The term “heteroaryl” may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
- An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or-heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents. Examples of suitable substituents on the unsaturated carbon atom of an aryl, heteroaryl, aralkyl, or heteroaralkyl group include a halogen, —Ro, —ORo, —SRo, 1,2-methylene-dioxy, 1,2-ethylenedioxy, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, —O(Ph), substituted —O(Ph), —CH2(Ph), substituted —CH2(Ph), —CH2CH2(Ph), substituted —CH2CH2(Ph), —NO2, —CN, —N(Ro)2, —NRo C(O)Ro, —NRoC(O)N(Ro)2, —NRoCO2Ro, —NRoNRoC(O)Ro, —NRoNRoC(O)N(Ro)2, —NRoNRoCO2Ro, —C(O)C(O)Ro, —C(O)CH2C(O)Ro, —CO2Ro, —C(O)Ro, —C(O)N(Ro)2, —OC(O)N(Ro)2, —S(O)2Ro, —SO2N(Ro)2, —S(O)Ro, —NRoSO2N(Ro)2, —NRoSO2RO, —C(═S)N(Ro)2, —C(═NH)—N(Ro)2, —(CH2)yNHC(O)Ro, —(CH2)yNHC(O)CH(V—RO)(Ro); wherein Ro is hydrogen, a substituted or unsubstituted aliphatic group, an unsubstituted heteroaryl or heterocyclic ring, phenyl (Ph), substituted Ph, —O(Ph), substituted —O(Ph), —CH2(Ph), or substituted —CH2(Ph); y is 0-6; and V is a linker group. Examples of substituents on the aliphatic group or the phenyl ring of Ro include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
- An aliphatic group or a non-aromatic heterocyclic ring may contain one or more substituents. Examples of suitable substituents on the saturated carbon of an aliphatic group or of a non-aromatic heterocyclic ring include those listed above for the unsaturated carbon of an aryl or heteroaryl group and the following: ═O, ═S, ═NNHR*, ═NN(R*)2, ═N—, ═NNHC(O)R*, ═NNHCO2(alkyl), ═NNHSO2(alkyl), or ═NR*, where each R* is independently selected from hydrogen, an unsubstituted aliphatic group or a substituted aliphatic group. Examples of substituents on the aliphatic group include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
- Suitable substituents on the nitrogen of a non-aromatic heterocyclic ring include —R+, —N(R+)2, —C(O)R+, —CO2R+, —C(O)C(O)R+, —C(O)CH2C(O)R+, —SO2R+, —SO2N(R+)2, —C(═S)N(R+)2, —C(═NH)—N(R+)2, and —NR+SO2R+; wherein R+ is hydrogen, an aliphatic group, a substituted aliphatic group, phenyl (Ph), substituted Ph, —O(Ph), substituted —O(Ph), CH2(Ph), substituted CH2(Ph), or an unsubstituted heteroaryl or heterocyclic ring. Examples of substituents on the aliphatic group or the phenyl ring include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
- The term “linker group” or “linker” means an organic moiety that connects two parts of a compound. Linkers are typically comprised of an atom such as oxygen or sulfur, a unit such as —NH—, —CH2—, —C(O)—, —C(O)NH—, or a chain of atoms, such as an alkylidene chain. The molecular mass of a linker is typically in the range of about 14 to 200, preferably in the range of 14 to 96 with a length of up to about six atoms. Examples of linkers include a saturated or unsaturated C1-6 alkylidene chain which is optionally substituted, and wherein one or two saturated carbons of the chain are optionally replaced by —C(O)—, —C(O)C(O)—, —CONH—, —CONHNH—, —CO2—, —OC(O)—, —NHCO2—, —O—, —NHCONH—, —OC(O)NH—, —NHNH—, —NHCO—, —S—, —SO—, —SO2—, —NH—, —SO2NH—, or —NHSO2—.
- The term “alkylidene chain” refers to an optionally substituted, straight or branched carbon chain that may be fully saturated or have one or more units of unsaturation. The optional substituents are as described above for an aliphatic group.
- A combination of substituents or variables is permissible only if such a combination results in a stable or chemically feasible compound. A stable compound or chemically feasible compound is one in which the chemical structure is not substantially altered when kept at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
- Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a13C— or 14C-enriched carbon are within the scope of this invention.
- Compounds of formula I or salts thereof may be formulated into compositions. In a preferred embodiment, the composition is a pharmaceutical composition. In one embodiment, the composition comprises an amount of the protein kinase inhibitor effective to inhibit a protein kinase, particularly Aurora-2, in a biological sample or in a patient. In another embodiment, compounds of this invention and pharmaceutical compositions thereof, which comprise an amount of the protein kinase inhibitor effective to treat or prevent an Aurora-2-mediated condition and a pharmaceutically acceptable carrier, adjuvant, or vehicle, may be formulated for administration to a patient.
- Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
- The term “Aurora-2-mediated condition” or “disease”, as used herein, means any disease or other deleterious condition in which Aurora is known to play a role. The term “Aurora-2-mediated condition” or “disease” also means those diseases or conditions that are alleviated by treatment with an Aurora-2 inhibitor. Such conditions include, without limitation, cancer. The term “cancer” includes, but is not limited to the following cancers: colon, breast, stomach, and ovarian.
- Another aspect of the invention relates to inhibiting Aurora-2 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 inhibitor of formula I, or a composition thereof.
- Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
- Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
- The term “GSK-3-mediated condition” or “disease”, as used herein, means any disease or other deleterious condition or state in which GSK-3 is known to play a role. Such diseases or conditions include, without limitation, diabetes, Alzheimer's disease, Huntington's Disease, Parkinson's Disease, AIDS-associated dementia, amyotrophic lateral sclerosis (AML), multiple sclerosis (MS), schizophrenia, cardiomycete hypertrophy, reperfusion/ischemia, and baldness.
- One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of β-catenin, which is useful for treating schizophrenia.
- Another aspect of the invention relates to inhibiting GSK-3 activity in a biological sample, which method comprises contacting the biological sample with a GSK-3 inhibitor of formula I.
- Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula I or a composition comprising said compound.
- The term “pharmaceutically acceptable carrier, adjuvant, or vehicle” refers to a non-toxic carrier, adjuvant, or vehicle that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof.
- The term “patient” includes human and veterinary subjects.
- The term “biological sample”, as used herein, includes, without limitation, cell cultures or extracts thereof; preparations of an enzyme suitable for in vitro assay; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
- The amount effective to inhibit protein kinase, for example, Aurora-2 and GSK-3, is one that measurably inhibits the kinase activity where compared to the activity of the enzyme in the absence of an inhibitor. Any method may be used to determine inhibition, such as, for example, the Biological Testing Examples described below.
- Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
- The compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously.
- Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
- The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
- Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
- The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
- Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
- For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
- The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
- In addition to the compounds of this invention, pharmaceutically acceptable derivatives or prodrugs of the compounds of this invention may also be employed in compositions to treat or prevent the above-identified diseases or disorders.
- A “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a patient (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
- Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.
- Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and N+(C1-4 alkyl)4 salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
- The amount of the protein kinase inhibitor that may be combined with the carrier materials to produce a single dosage form will vary depending upon the patient treated and the particular mode of administration. Preferably, the compositions should be formulated so that a dosage of between 0.01-100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.
- It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body-weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of the inhibitor will also depend upon the particular compound in the composition.
- Depending upon the particular protein kinase-mediated condition to be treated or prevented, additional therapeutic agents, which are normally administered to treat or prevent that condition, may be administered together with the inhibitors of this invention. For example, in the treatment of cancer other chemotherapeutic agents or other anti-proliferative agents may be combined with the Aurora-2 inhibitors of this invention to treat cancer. These agents include, without limitation, adriamycin, dexamethasone, vincristine, cyclophosphamide, fluorouracil, topotecan, taxol, interferons, and platinum derivatives.
- Other examples of agents the inhibitors of this invention may also be combined with include, without limitation, agents for treating diabetes such as insulin or insulin analogues, in injectable or inhalation form, glitazones, alpha glucosidase inhibitors, biguanides, insulin sensitizers, and sulfonyl ureas; anti-inflammatory agents such as corticosteroids, TNF blockers, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; immunomodulatory and immunosuppressive agents such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, interferons, corticosteroids, cyclophophamide, azathioprine, and sulfasalazine; neurotrophic factors such as acetylcholinesterase inhibitors, MAO inhibitors, interferons, anti-convulsants, ion channel blockers, riluzole, and anti-Parkinsonian agents; agents for treating cardiovascular disease such as beta-blockers, ACE inhibitors, diuretics, nitrates, calcium channel blockers, and statins; agents for treating liver disease such as corticosteroids, cholestyramine, interferons, and anti-viral agents; agents for treating blood disorders such as corticosteroids, anti-leukemic agents, and growth factors; and agents for treating immunodeficiency disorders such as gamma globulin.
- Those additional agents may be administered separately from the protein kinase inhibitor-containing composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with the protein kinase inhibitor of this invention in a single composition.
-
- Preferred Rx groups, when present, include hydrogen, alkyl- or dialkylamino, acetamido, or a C1-4 aliphatic group such as methyl, ethyl, cyclopropyl, or isopropyl.
- Preferred Ry groups, when present, include Z-R3 or an optionally substituted group selected from C1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R3 is —N(R4)2, —OR, or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms. Preferred Ry groups include 5-6 membered heteroaryl or heterocyclyl rings, such as 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, or piperazinyl; C1-6 aliphatic, such as methyl, ethyl, cyclopropyl, isopropyl., or t-butyl; alkoxyalkylamino such as methoxyethylamino; alkoxyalkyl such as methoxymethyl or methoxyethyl; alkyl- or dialkylamino such as ethylamino or dimethylamino; alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy; acetamido; and optionally substituted phenyl such as phenyl or halo-substituted phenyl.
-
- Preferred substituents on the R2/R2′ fused ring include one or more of the following: -halo, —N(R4)2, —C1-3 alkyl, —C1-3 haloalkyl, —NO2, —O(C1-3 alkyl), —CO2(C1-3 alkyl), —CN, —SO2(C1-3 alkyl), —SO2NH2, —OC(O)NH2, —NH2SO2(C1-3 alkyl), —NHC(O) (C1-3 alkyl), —C(O)NH2, and —CO(C1-3 alkyl), wherein the (C1-3 alkyl) is most preferably methyl.
- When the pyrazole ring system is monocyclic, preferred R2 groups include hydrogen, C1-4 aliphatic, alkoxycarbonyl, (un)substituted phenyl, hydroxyalkyl, alkoxyalkyl, aminocarbonyl, mono- or dialkylaminocarbonyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, phenylaminocarbonyl, and (N-heterocyclyl)carbonyl. Examples of such preferred R2 substituents include methyl, cyclopropyl, ethyl, isopropyl, propyl, t-butyl, cyclopentyl, phenyl, CO2H, CO2CH3, CH2OH, CH2OCH3, CH2CH2CH2OH, CH2CH2CH2OCH3, CH2CH2CH2OCH2Ph, CH2CH2CH2NH2, CH2CH2CH2NHCOOC(CH3)3, CONHCH(CH3)2, CONHCH2CH═CH2, CONHCH2CH2OCH3, CONHCH2Ph, CONH(cyclohexyl), CON(Et)2, CON(CH3)CH2Ph, CONH(n-C3H7), CON(Et)CH2CH2CH3, CONHCH2CH(CH3)2, CON(n-C3H7)2, CO(3-methoxymethylpyrrolidin-1-yl), CONH(3-tolyl), CONH(4-tolyl), CONHCH3, CO(morpholin-1-yl), CO(4-methylpiperazin-1-yl), CONHCH2CH2OH, CONH2, and CO(piperidin-1-yl). A preferred R2 group is hydrogen.
- Preferred Q groups of formula I include —S—, —NH—, and —CH2—. More preferred Q groups of formula I include —S— and —NH—.
-
- or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
- Z1 is nitrogen or CR8;
- Ry is Z-R3′ or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl., a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms, or Ry and R8 are taken together to form a fused, optionally substituted 5-7 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur;
- Q is selected from —N(R4)—, —O—, —S—, or —CH(R6)—;
- R1 is T-(Ring D)
- Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R5, or V-Z-R5, and each substitutable ring nitrogen of Ring D is independently substituted by —R4;
- T is a valence bond or a C1-4 alkylidene chain, wherein when Q is —CH(R6)—, a methylene unit of said C1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R4)—, —CO—, —CONH—, —NHCO—, —SO2—, —SO2NH—, —NHSO2—, —CO2—, —OC(O)—, —OC(O)NH—, or —NHCO2—;
- Z is a C1-4 alkylidene chain;
- L is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R6)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)——C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)_, —C(R6)2N(R6)—, —C(R6)2N(R6)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)_—C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, or —C(R6)2N(R6)CON(R6)—;
- R2 and R2′ are independently selected from —R, -T-W—R6, or R2 and R2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R2 and R2′ is independently substituted by halo, oxo, CN, —NO2, —R7, or —V—R6, and each substitutable ring nitrogen of said ring formed by R2 and R2′ is independently substituted by R4;
- R3′ is selected from -halo, —OR, —C(═O)R, —CO2R, —COCOR, —COCH2COR, —NO2, —CN, —S(O)R, —S(O)2R, —SR, —N(R4)2, —CON(R7)2, —SO2N(R7)2, —OC(═O)R, —N(R7)COR, —N(R7)CO2 (C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R7)CON(R7)2, —N(R7)SO2N(R7)2, —N(R4)SO2R, —OC(═O)N(R7)2, or an optionally substituted group selected from C1]6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R is independently selected from hydrogen or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R4 is independently selected from —R7, —COR7, —CO2 (optionally substituted C1-6 aliphatic), —CON(R7)2, or —SO2R7;
- each R5 is independently selected from —R, halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2, —CON(R4)2, —SO2N(R4)2, —OC(═O)R, —N(R4)COR, —N(R4)CO2(optionally substituted C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2;
- V is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R6)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)——C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —C(R6)2N(R6)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)——C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, or —C(R6)2N(R6)CON(R6)—;
- W is —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —CO—, —CO2—C(R6)OC(O)—, —C(R6)OC(O)NR6)—, —C(R6)2N(R6)CO—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)——C(R6)2N(R6)CON(R6)—, or —CON(R6)—;
- each R6 is independently selected from hydrogen or an optionally substituted C1-4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
- each R7 is independently selected from hydrogen or an optionally substituted C1-6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and
- R8 is selected from —R, halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2, —CON(R4)2, —SO2N(R4)2, —OC(═O)R, —N(R4)COR, —N(R4)CO2 (optionally substituted C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2; provided that when Q is —NH— and Ry and R8 are taken together to form a fused ring, R1 is other than a pyrazol-3-yl ring or a pyrazol-3-yl-containing bicyclic ring system.
-
- or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
- Ry is Z-R3′ or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- Q is selected from —N(R4)—, —O—, —S—, or —CH(R6)—;
- R1 is T-(Ring D);
- Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R5, or V-Z-R5, and each substitutable ring nitrogen of Ring D is independently substituted by —R4;
- T is a valence bond or a C1-4 alkylidene chain, wherein when Q is —CH(R6)—, a methylene unit of said C1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R4)—, —CO—, —CONH—, —NHCO—, —SO2—, —SO2NH—, —NHSO2—, —CO2—, —OC(O)—, —OC(O)NH—, or —NHCO2—;
- Z is a C1-4 alkylidene chain;
- L is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R6)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)—, —C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, C(R6)2N(R)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, or —C(R6)2N(R6)CON(R6)—;
- R2 and R2 are independently selected from —R, -T-W—R6, or R2 and R2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R2 and R2′ is independently substituted by halo, oxo, —CN, —NO2, —R7, or —V—R6, and each substitutable ring nitrogen of said ring formed by R2 and R2′ is independently substituted by R4;
- R3′ is selected from -halo, —OR, —C(═O)R, —CO2R, —COCOR, —COCH2COR, —NO2, —CN, —S(O)R, —S(O)2R, —SR, —N(R4)2, —CON(R7)2, —SO2N(R7)2, —OC(═O)R, —N(R7)COR, —N(R7)CO2 (C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R7)CON(R7)2, —N(R7)SO2N(R7)2, —N(R4)SO2R, —OC(═O)N(R7)2, or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R is independently selected from hydrogen or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-1-O ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R4 is independently selected from —R7, —COR7, —CO2 (optionally substituted C1-6 aliphatic), —CON(R7)2, or —SO2R7;
- each R5 is independently selected from —R, halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2, —CON(R4)2, —SO2N(R4)2, —OC(═O)R, —N(R4)COR, —N(R4)CO2(optionally substituted C1 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2;
- V is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R6)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)—, —C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —C(R6)2N(R6)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, or —C(R6)2N(R6)CON(R6)—;
- W is —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —CO—, —CO2—C(R6)OC(O)—, —C(R6)OC(O)N(R6)—, —C(R6)2N(R6)CO—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, —C(R6)2N(R6)CON(R6)—, or —CON(R6)—;
- each R6 is independently selected from hydrogen or an optionally substituted C1-4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring; and
- each R7 is independently selected from hydrogen or an optionally substituted C1-6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring.
- Preferred Ry groups of formula IIa include Z-R3′ or an optionally substituted group selected from C1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R3′ is —N(R4)2, —OR, or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms.
- Examples of preferred Ry groups include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
-
- Preferred substituents on the R2/R2′ fused ring of formula IIa include one or more of the following: -halo, —N(R4)2, —C1-4 alkyl, —C1-4 haloalkyl, —NO2, —O(C1-4 alkyl), —CO2(C1-4 alkyl), —CN, —SO2(C1-4 alkyl), —SO2NH2, —OC(O)NH2, —NH2SO2(C1-4 alkyl), —NHC(O) (C1-4 alkyl), —C(O)NH2, and —CO(C1-4 alkyl), wherein the (C1-4 alkyl) is a straight, branched, or cyclic alkyl group. Preferably, the (C1-4 alkyl) group is methyl.
- When the pyrazole ring system of formula IIa is monocyclic, preferred R2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C1-6 aliphatic group. Examples of such preferred R2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl. A preferred R2′ group is hydrogen.
- When Ring D of formula IIa is monocyclic, preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
- When Ring D of formula IIa is bicyclic, preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
- On Ring D of formula IIa, preferred T-R5 or V-Z-R5 substituents include -halo, —CN, —NO2, —N(R4)2, optionally substituted C1-6 aliphatic group, —OR, —C(O)R, —CO2R, —CONH(R4), —N(R4)COR, —N(R4)CO2R, —SO2N(R4)2, —N(R4)SO2R, —N(R6)COCH2N(R4)2, —N(R6)COCH2CH2N(R4)2, and —N(R6)COCH2CH2CH2N(R4)2, wherein R is selected from hydrogen, C1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring. More preferred R5 substituents include —Cl, —Br, —F, —CN, —CF3, —COOH, —CONHMe, —CONHEt, —NH2, —NHAc, —NHSO2Me, —NHSO2Et, —NHSO2(n-propyl), —NHSO2(isopropyl), —NHCOEt, —NHCOCH2NHCH3, —NHCOCH2N(CO2t-Bu)CH3, —NHCOCH2N(CH3)2, —NHCOCH2CH2N(CH3)2, —NHCOCH2CH2CH2N(CH3)2, —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH2(morpholin-4-yl), —NHCOCH2CH2(morpholin-4-yl), —NHCOCH2CH2CH2(morpholin-4-yl), —NHCO2(t-butyl), —NH(C1-4 aliphatic) such as NHME, —N(C1-4 aliphatic)2 such as —NMe2, OH, —O(C1-4 aliphatic) such as —OMe, C1-4 aliphatic such as methyl, ethyl, cyclopropyl, isopropyl, or t-butyl, and —CO2(C1-4 aliphatic).
- Preferred formula IIa compounds have one or more, and more preferably all, of the features selected from the group consisting of:
- (a) Ry is Z-R3′ or an optionally substituted group selected from C1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R3 is —N(R4)2, —OR, or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring-atoms;
- (b) R1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
- (c) Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
- (d) R2 is —R or -T-W—R6 and R2′ is hydrogen, or R2 and R2′ are taken together to form an optionally substituted benzo ring.
- More preferred compounds of formula IIa have one or more, and more preferably all, of the features selected from the group consisting of:
- (a) Ry is an optionally substituted group selected from C1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
- (b) R1 is T-(Ring D), wherein T is a valence bond and Q is —S—, —NH—, or —CH2—;
- (c) Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
- (d) R2 is —R and R2 is hydrogen, wherein R is selected from hydrogen, C1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
- Even more preferred compounds of formula IIa have one or more, and more preferably all, of the features selected from the group consisting of:
- (a) Ry is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl;
- (b) R1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO2, —N(R4)2! optionally substituted C1-6 aliphatic group, —OR, —CO2R, —CONH(R4), —N(R4)COR, —N(R4)SO2R, —N(R6)COCH2CH2N(R4)2, or —N(R6)COCH2CH2CH2N(R4)2, and Q is —S— or —NH—; and
- (c) R2 is hydrogen or a substituted or unsubstituted C1-6 aliphatic, and L is —O—, —S—, or —NH—.
-
- In another embodiment, this invention provides a composition comprising a compound of formula IIa and a pharmaceutically acceptable carrier.
- Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof.
- Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIa or a composition comprising said compound.
- Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such-treatment a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof.
- One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIa or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of β-catenin, which is useful for treating schizophrenia.
- Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIa or a composition comprising said compound.
- Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IIa, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
- Each of the aforementioned methods directed to the inhibition of Aurora-2 or GSK-3, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula IIa, as described above.
-
- or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
- Ry is Z-R3′ or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms, or Ry and Re are taken together to form a fused, optionally substituted 5-7 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur;
- Q is selected from —N(R4)—, —O—, —S—, or —CH(R6)—;
- R1 is T-(Ring D);
- Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R5, or V-Z-R5, and each substitutable ring nitrogen of Ring D is independently substituted by —R4;
- T is a valence bond or a C1-4 alkylidene chain, wherein when Q is —CH(R6)—, a methylene unit of said C1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R4)—, —CO—, —CONH—, —NHCO—, —SO2—, —SO2NH—, —NHSO2—, —CO2—, —OC(O)—, —OC(O)NH—, or —NHCO2—;
- Z is a C1-4 alkylidene chain;
- L is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R6)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)—C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —C(R6)2N(R6)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, or —C(R6)2N(R6)CON(R6)—;
- R2 and R2′ are independently selected from —R, -T-W—R6, or R2 and R2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R2 and R2 is independently substituted by halo, oxo, —CN, —NO2, —R7, or —V—R6, and each substitutable ring nitrogen of said ring formed by R2 and R2 is independently substituted by R4;
- R3′ is selected from -halo, —OR, —C(═O)R, —CO2R, —COCOR, —COCH2COR, —NO2, —CN, —S(O)R, —S(O)2R, —SR, —N(R4)2, —CON(R7)2, —SO2N(R7)2, —OC(═O)R, —N(R7)COR, —N(R7)CO2(C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2′—C═N—OR, —N(R7)CON(R7)2, —N(R7)SO2N(R7)2, —N(R4)SO2R, —OC(═O)N(R7)2, or an optionally-substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R is independently selected from hydrogen or an optionally substituted group selected from C1-6 aliphatic, C6-0 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R4 is independently selected from —R7, —COR7, —CO2 (optionally substituted C1-6 aliphatic)-CON(R7)2, or —SO2R7;
- each R5 is independently selected from —R, halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2, —CON(R4)2, —SO2N(R4)2, —OC(═O)R, —N(R4)COR, —N(R4)CO2 (optionally substituted C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2;
- V is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R6)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)——C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —C(R6)2N(R6)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, or —C(R6)2N(R6)CON(R6)—;
- W is —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —CO—, —CO2—, —C(R6)OC(O)—, —C(R6)OC(O)N(R6)—, —C(R6)2N(R)CO—, —C(R6)2N(R6)C(R6)═NN(R6)—, —C(R6)═N—O——C(R6)2N(R6)N(R6)——C(R6)2N(R6)SO2N(R6)—, —C(R6)2N(R6)CON(R6)—, or —CON(R6)—;
- each R6 is independently selected from hydrogen or an optionally substituted C1-4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
- each R7 is independently selected from hydrogen or an optionally substituted C1-6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and
- R8 is selected from —R, halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2, —CON(R4)2, —SO2N(R4)2, —OC(═O)R, —N(R4)COR, —N(R4)CO2(optionally substituted C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2; provided that when Q is —NH— and Ry and R8 are taken together to form a fused ring, R1 is other than a pyrazol-3-yl ring or a pyrazol-3-yl-containing bicyclic ring system.
- Preferred Ry groups of formula IIb include Z-R3 or an optionally substituted group selected from C1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R3′ is —N(R4)2, —OR, or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms.
- Examples of preferred Ry groups include 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino such as methoxyethylamino, alkoxyalkyl such as methoxymethyl or methoxyethyl, alkyl- or dialkylamino such as ethylamino or dimethylamino, alkyl- or dialkylaminoalkoxy such as dimethylaminopropyloxy, acetamido, optionally substituted phenyl such as phenyl or halo-substituted phenyl.
-
- Preferred substituents on the R2/R2′ fused ring of formula IIb include one or more of the following: -halo, —N(R4)2, —C1-4 alkyl, —C1-4 haloalkyl, —NO2, —O(C1-4 alkyl), —CO2(C1-4 alkyl), —CN, —SO2(C1-4 alkyl), —SO2NH2, —OC(O)NH2, —NH2SO2(C1-4 alkyl), —NHC(O) (C1-4 alkyl), —C(O)NH2, and —CO(C1-4 alkyl), wherein the (C1-4 alkyl) is a straight, branched, or cyclic alkyl group. Preferably, the (C1-4 alkyl) group is methyl.
- When the pyrazole ring system of formula IIb is monocyclic, preferred R2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C1-6 aliphatic group. Examples of such preferred R2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl. A preferred R2 group is hydrogen.
- When Ring D of formula IIb is monocyclic, preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
- When Ring D of formula IIb is bicyclic, preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
- On Ring D of formula IIb, preferred T-R5 or V-Z-R5 substituents include -halo, —CN, —NO2, —N(R4)2, optionally substituted C1-6 aliphatic group, —OR, —C(O)R, —CO2R, —CONH(R4), —N(R4)COR, —N(R4)CO2R, —SO2N(R4)2, —N(R4)SO2R, —N(R6)COCH2N(R4)2, —N(R6)COCH2CH2N(R4)2, and —N(R6)COCH2CH2CH2N(R4)2, wherein R is selected from hydrogen, C1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring. More preferred R5 substituents include —Cl, —Br, —F, —CN, —CF3, —COOH, —CONHMe, —CONHEt, —NH2, —NHAC, —NHSO2Me, —NHSO2Et, —NHSO2 (n-propyl), —NHSO2 (isopropyl), —NHCOEt, —NHCOCH2NHCH3, —NHCOCH2N(CO2t-Bu)CH3, —NHCOCH2N(CH3)2, —NHCOCH2CH2N(CH3)2, —NHCOCH2CH2CH2N(CH3)2, —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH2(morpholin-4-yl), —NHCOCH2CH2(morpholin-4-yl), —NHCOCH2CH2CH2(morpholin-4-yl), —NHCO2(t-butyl), —NH(C1-4 aliphatic) such as —NHMe, —N(C1-4 aliphatic)2 such as —NMe2, OH, —O(C1-4 aliphatic) such as —OMe, C1-4 aliphatic such as methyl, ethyl, cyclopropyl, isopropyl, or t-butyl, and —CO2(C1-4 aliphatic).
- When Ry and R8 are taken together to form a fused ring, preferred rings formed by Ry and R8 include 5-6 membered unsaturated or partially unsaturated rings having 0-2 heteroatoms. More preferred fused rings formed by Ry and R8 include benzo, cyclohexo, and pyrido.
- Preferred R8 groups of formula IIb, when present, include R, OR, and N(R4)2. Examples of preferred R8 include methyl, ethyl, NH2, NH2CH2CH2NH, N(CH3)2CH2CH2NH, N(CH3)2CH2CH2O, (piperidin-1-yl)CH2CH2O, and NH2CH2CH2O.
- Preferred formula IIb compounds have one or more, and more preferably all, of the features selected from the group consisting of:
- (a) Ry is Z-R3′ or an optionally substituted group selected from C1-6 aliphatic, 5-6 membered heterocyclyl, phenyl, or 5-6 membered heteroaryl, wherein Z is a methylene and R3′ is —N(R4)2, —OR, or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- (b) R1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
- (c) Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
- (d) R2 is —R or -T-W—R6 and R2 is hydrogen, or R2 and R2 are taken together to form an optionally substituted benzo ring.
- More preferred compounds of formula IIb have one or more, and more preferably all, of the features selected from the group consisting of:
- (a) Ry is an optionally substituted group selected from C1-6 aliphatic, 5-6-membered heterocyclyl, phenyl, or 5-6 membered heteroaryl;
- (b) R1 is T-(Ring D), wherein T is a valence bond, and Q is —S—, —NH—, or —CH2—;
- (c) Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
- (d) R2 is —R and R2 is hydrogen, wherein R is selected from hydrogen, C1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
- Even more preferred compounds of formula IIb have one or more, and more preferably all, of the features selected from the group consisting of:
- (a) Ry is selected from 2-pyridyl, 4-pyridyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, methyl, ethyl, cyclopropyl, isopropyl, t-butyl, alkoxyalkylamino, alkoxyalkyl, alkyl- or dialkylamino, alkyl- or dialkylaminoalkoxy, acetamido, optionally substituted phenyl, or methoxymethyl, or Ry and R8 are taken together to form a 5-6 membered unsaturated or partially unsaturated ring having 0-2 heteroatoms selected from nitrogen, oxygen, or sulfur;
- (b) R1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO2, —N(R4)2, optionally substituted C1-6 aliphatic group, —OR, —CO2R, —CONH(R4), —N(R4)COR, —N(R4)SO2R, —N(R6)COCH2CH2N(R4)2, or —N(R6)COCH2CH2CH2N(R4)2, and Q is —S— or —NH—; and
- (c) R2 is hydrogen or a substituted or unsubstituted C1-6 aliphatic, and L is —O—, —S—, or —NH—.
-
- In another embodiment, this invention provides a composition comprising a compound of formula IIb and a pharmaceutically acceptable carrier.
- Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIb or a pharmaceutical composition thereof.
- Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula IIb or a composition comprising said compound.
- Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula IIb or a pharmaceutical composition thereof.
- One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula IIb or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of β-catenin, which is useful for treating schizophrenia.
- Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula IIb or a composition comprising said compound.
- Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula IIb, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2-or GSK-3.
- Each of the aforementioned methods directed to the inhibition of Aurora-2 or GSK-3, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula IIb, as described above.
-
- or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
- Z1 is nitrogen or CR8, Z2 is nitrogen or CH, and Z3 is nitrogen or CRx, provided that one of Z1 and Z3 is nitrogen;
- Rx is T-R3 or L-Z-R3;
- Q is selected from —N(R4)—, —O—, —S—, or —CH(R6)—;
- R1 is T-(Ring D);
- Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R5, or V-Z-R5, and each substitutable ring nitrogen of Ring D is independently substituted by —R4;
- T is a valence bond or a C1-4 alkylidene chain, wherein when Q is —CH(R6)—, a methylene unit of said C1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R4)—, —CO—, —CONH—, —NHCO—, —SO2—, —SO2NH—, —NHSO2—, —CO2—, —OC(O)—, —OC(O)NH—, or —NHCO2—;
- Z is a C1-4 alkylidene chain;
- L is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R6)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)——C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —C(R6)2N(R6)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, or —C(R6)2N(R6)CON(R6)—; R2 and R2′ are independently selected from —R, -T-W—R6, or R2 and R2′ are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R2 and R2′ is independently substituted by halo, oxo, —CN, —NO2, —R7, or —V—R6, and each substitutable ring nitrogen of said ring formed by R2 and R2′ is independently substituted by R4;
- R3 is selected from —R, -halo, —OR, —C(═O)R, —CO2R, —COCOR, —COCH2COR, —NO2, —CN, —S(O)R, —S(O)2R, —SR, —N(R4)2, —CON(R7)2, —SO2N(R7)2, —OC(═O)R, —N(R7)COR, —N(R1)CO2(C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R7)CON(R7)2, —N(R7)SO2N(R7)2, —N(R4)SO2R, or —OC(═O)N(R7)2;
- each R is independently selected from hydrogen or an optionally substituted group selected from C1-6 aliphatic, C6-0 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
- each R4 is independently selected from —R7, —COR7, —CO2(optionally substituted C-6 aliphatic), —CON(R7)2, or —SO2R7;
- each R5 is independently selected from —R halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2, —CON(R4)2, —SO2N(R4)2, —OC(═O)R, —N(R4)COR, —N(R4)CO2(optionally substituted C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2;
- V is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R6)—, —N(R6)SO2N(R6), —N(R6)N(R6)-2—C(O)N(R6)—, —OC(O)N(R6)—, —C—(R6)N2, —C(R6)R2S —C(R6)2SO—, —C(R6)2SO2—, C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —C(R6)2N(R6) C(O)—, —C(R6)2N(R6) C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, 2C(R6)2N(R6)SO2N(R6)—, or C(R6)2N(R6)CON(R6)—;
- W is —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2O2N(R6)—, —C(R6)2N(R6)—, —CO—, —CO2—C(R6)OC(O)—, —C(R6)OC(O)N(R6)—, —C(R6)2N(R6)CO—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, —C(R6)N(R6)CON(R6)—, or —CON(R6)—;
- each R6 is independently selected from hydrogen or an optionally substituted C1-4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
- each R7 is independently selected from hydrogen or an optionally substituted C1-6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and
- R8 is selected from —R, halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2, —CON(R4)2, —SO2N(R4)2, —OC(═O)R, —N(R4)COR, —N(R4)CO2(optionally substituted C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2.
-
- Preferred Rx groups of formula III include T-R3 wherein T is a valence bond or a methylene and R3 is CN, —R, or —OR. When R3 is —R, preferred R3 groups include an optionally substituted group selected from C1-6 aliphatic, phenyl, or a 5-6 membered heteroaryl or heterocyclyl ring. When R3 is —OR, preferred R groups include an optionally substituted group C1-6 aliphatic group such as alkyl- or dialkylaminoalkyl and aminoalkyl. Examples of preferred RX include acetamido, CN, piperidinyl, piperazinyl, phenyl, pyridinyl, imidazol-1-yl, imidazol-2-yl, cyclohexyl, cyclopropyl, methyl, ethyl, isopropyl, t-butyl, NH2CH2CH2NH, and NH2CH2CH2O.
- Preferred. R8 groups of formula III, when present, include R, OR, and N(R4)2. Examples of preferred R8 include methyl, ethyl, NH2, NH2CH2CH2NH, N(CH3)2CH2CH2NH, N(CH3)2CH2CH2O, (piperidin-1-yl) CH2CH2O, and NH2CH2CH2O.
-
- Preferred substituents on the formula III R2/R2 fused ring include one or more of the following: -halo, —N(R4)2, —C1-4 alkyl, —C1-4 haloalkyl, —NO2, —O(C1-4 alkyl), —CO2(C1-4 alkyl), —CN, —SO2 (C1-4 alkyl), —SO2NH2, —OC(O)NH2, —NH2SO2(C1-4 alkyl), —NHC(O) (C1-4 alkyl), —C(O)NH2, and —CO(C1-4 alkyl), wherein the (C1-4 alkyl) is a straight, branched, or cyclic alkyl group. Preferably, the (C1-4 alkyl) group is methyl.
- When the pyrazole ring system of formula III is monocyclic, preferred R2 groups include hydrogen or a substituted or unsubstituted group selected from aryl, heteroaryl, or a C1-6 aliphatic group. Examples of such preferred R2 groups include H, methyl, ethyl, propyl, cyclopropyl, i-propyl, cyclopentyl, hydroxypropyl, methoxypropyl, and benzyloxypropyl. A preferred R2 group is hydrogen.
- When Ring D of formula III is monocyclic, preferred Ring D groups include phenyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl.
- When Ring D of formula III is bicyclic, preferred bicyclic Ring D groups include naphthyl, tetrahydronaphthyl, indanyl, benzimidazolyl, quinolinyl, indolyl, isoindolyl, indolinyl, benzo[b]furyl, benzo[b]thiophenyl, indazolyl, benzothiazolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, 1,8-naphthyridinyl and isoquinolinyl.
- On Ring D of formula III, preferred T-R5 or V-Z-R5 substituents include -halo, —CN, —NO2, —N(R4)21 optionally substituted C1-6 aliphatic group, —OR, —C(O)R, —CO2R, —CON(R4)2, —OCO(R4)2, —N(R4)COR, —N(R4)CO2R, —SO2N(R4)2, —N(R4)SO2R, —N(R6)COCH2N(R4)2, —N(R6)COCH2CH2N(R4)2, and —N(R6)COCH2CH2CH2N(R4)2, wherein R is selected from hydrogen, C1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring. More preferred R5 substituents include —Cl, —Br, —F, —CN, —CF3, —COOH, —CONHMe, —CONHEt, —NH2, —NHAc, —NHSO2Me, —NHSO2Et, —NHSO2(n-propyl), —NHSO2(isopropyl), —NHCOEt, —NHCOCH2NHCH3, —NHCOCH2N(CO2t-Bu)CH3, —NHCOCH2N(CH3)2, —NHCOCH2CH2N(CH3)2, —NHCOCH2CH2CH2N(CH3)2, —NHCO(cyclopropyl), —NHCO(isobutyl), —NHCOCH2(morpholin-4-yl), —NHCOCH2CH2(morpholin-4-yl), —NHCOCH2CH2CH2 (morpholin-4-yl), —NHCO2 (t-butyl), —NH(C1-4 aliphatic) such as —NHMe, —N(C1-4 aliphatic)2 such as —NMe2, OH, —O(C1-4 aliphatic) such as —OMe, C1-4 aliphatic such as methyl, ethyl, cyclopropyl, isopropyl, or t-butyl, and —CO2(C1-4 aliphatic).
- Preferred compounds of formula IIIa, IIIb, IIIc, or IIId have one or more, and more preferably all, of the features selected from the group consisting of:
- (a) Rx is hydrogen, alkyl- or dialkylamino, acetamido, or a C1-4 aliphatic group;
- (b) R1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
- (c) Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
- (d) R2 is —R or -T-W—R6 and R2 is hydrogen, or R2 and R2 are taken together to form an optionally substituted benzo ring.
- More preferred compounds of formula IIIa, IIIb, IIIc, or IIId have one or more, and more preferably all, of the features selected from the group consisting of:
- (a) R1 is T-(Ring D), wherein T is a valence bond, and Q is —S—, —NH—, or —CH2—;
- (b) Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
- (c) R2 is —R and R2 is hydrogen, wherein R is selected from hydrogen, C1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
- Even more preferred compounds of formula IIIa, IIIb, IIIc, or IIId have one or more, and more preferably all, of the features selected from the group consisting of:
- (a) Rx is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetimido;
- (b) R1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO2, —N(R4)2, optionally substituted C1-6 aliphatic group, —OR, —CO2R, —CON(R4)2, —OCO(R4)2, 10—N(R4)COR, —N(R4)SO2R, —N(R6)COCH2CH2N(R4)2, or —N(R6)COCH2CH2CH2N(R4)2, and Q is —S— or —NH—; and
- (c) R2 is hydrogen or a substituted or unsubstituted C1-6 aliphatic.
-
- In another embodiment, this invention provides a composition comprising a compound of formula III and a pharmaceutically acceptable carrier.
- Another aspect of this invention relates to a method of treating or preventing an Aurora-2-mediated disease with an Aurora-2 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula III or a pharmaceutical composition thereof.
- Another aspect of this invention relates to a method of inhibiting Aurora-2 activity in a patient, which method comprises administering to the patient a compound of formula III or a composition comprising said compound.
- Another aspect of this invention relates to a method of treating or preventing a GSK-3-mediated disease with a GSK-3 inhibitor, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a compound of formula III or a pharmaceutical composition thereof.
- One aspect of this invention relates to a method of enhancing glycogen synthesis and/or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to the patient a therapeutically effective amount of a compound of formula III or a pharmaceutical composition thereof. This method is especially useful for diabetic patients. Another method relates to inhibiting the production of hyperphosphorylated Tau protein, which is useful in halting or slowing the progression of Alzheimer's disease. Another method relates to inhibiting the phosphorylation of β-catenin, which is useful for treating schizophrenia.
- Another aspect of this invention relates to a method of inhibiting GSK-3 activity in a patient, which method comprises administering to the patient a compound of formula III or a composition comprising said compound.
- Another method relates to inhibiting Aurora-2 or GSK-3 activity in a biological sample, which method comprises contacting the biological sample with the Aurora-2 or GSK-3 inhibitor of formula III, or a pharmaceutical composition thereof, in an amount effective to inhibit Aurora-2 or GSK-3.
- Each of the aforementioned methods directed to the inhibition of Aurora-2 or GSK-3, or the treatment of a disease alleviated thereby, is preferably carried out with a preferred compound of formula III as described above.
-
-
-
-
-
-
- Scheme VI above shows a general route for the preparation of the compounds of formulae IIIc and IIId. The displacement with aminopyrazole (or aminoindazole) followed by the displacement with R1-QH may be performed in a manner similar to that described in Indian J. Chem. Sect. B. 29, 5, 1990, 435-439.
- In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
- The activity of the compounds as protein kinase inhibitors may be assayed in vitro, in vivo or in a cell line. In vitro assays include assays that determine inhibition of either the phosphorylation activity or ATPase activity of the activated protein kinase. Alternate in vitro assays quantitate the ability of the inhibitor to bind to the protein kinase. Inhibitor binding may be measured by radiolabelling the inhibitor prior to binding, isolating the inhibitor/protein kinase complex and determining the amount of radiolabel bound. Alternatively, inhibitor binding may be determined by running a competition experiment where new inhibitors are incubated with the protein kinase bound to known radioligands.
- Compounds are screened for their ability to inhibit GSK-3β (AA 1-420) activity using a standard coupled enzyme system (Fox et al. (1998)Protein Sci. 7, 2249). Reactions are carried out in a solution containing 100 mM HEPES (pH 7.5), 10 mM MgCl2, 25 mM NaCl, 300 μM NADH, 1 mM DTT and 1.5% DMSO. Final substrate concentrations in the assay are 20 μM ATP (Sigma Chemicals, St Louis, Mo.) and 300 μM peptide (HSSPHQS(PO3H2)EDEEE, American Peptide, Sunnyvale, Calif.). Reactions are carried out at 30° C. and 20 nM GSK-3β. Final concentrations of the components of the coupled enzyme system are 2.5 mM phosphoenolpyruvate, 300 μM NADH, 30 μg/ml pyruvate kinase and 10 μg/ml lactate dehydrogenase.
- An assay stock buffer solution is prepared containing all of the reagents listed above with the exception of ATP and the test compound of interest. The assay stock buffer solution (175 μl) is incubated in a 96 well plate with 5 μl of the test compound of interest at final concentrations spanning 0.002 μM to 30 μM at 30° C. for 10 min. Typically, a 12 point titration is conducted by preparing serial dilutions (from 10 mM compound stocks) with DMSO of the test compounds in daughter plates. The reaction is initiated by the addition of 20 μl of ATP (final concentration 20 μM). Rates of reaction are obtained using a Molecular Devices Spectramax plate reader (Sunnyvale, Calif.) over 10 min at 30° C. The Ki values are determined from the rate data as a function of inhibitor concentration.
- Compounds are screened in the following manner for their ability to inhibit Aurora-2 using a standard coupled enzyme assay (Fox et al (1998)Protein Sci 7, 2249).
- To an assay stock buffer solution containing 0.1M HEPES 7.5, 10 mM MgCl2, 1 mM DTT, 25 mM NaCl, 2.5 mM phosphoenolpyruvate, 300 mM NADH, 30 mg/ml pyruvate kinase, 10 mg/ml lactate dehydrogenase, 40 mM ATP, and 800 μM peptide (LRRASLG, American Peptide, Sunnyvale, Calif.) is added a DMSO solution of a compound of the present invention to a final concentration of 30 μM. The resulting mixture is incubated at 30° C. for 10 min. The reaction is initiated by the addition of 10 μL of Aurora-2 stock solution to give a final concentration of 70 nM in the assay. The rates of reaction are obtained by monitoring absorbance at 340 nm over a 5 minute read time at 30° C. using a BioRad Ultramark plate reader (Hercules, Calif.). The Ki values are determined from the rate data as a function of inhibitor concentration.
- While we have presented a number of embodiments of this invention, it is apparent that our basic construction can be altered to provide other embodiments which utilize the compounds and methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments which have been represented by way of example.
Claims (26)
1. A compound of formula III:
or a pharmaceutically acceptable derivative or prodrug thereof, wherein:
Z1 is nitrogen or CR8, Z2 is nitrogen or CH, and Z3 is nitrogen or CRx, provided that one of Z1 and Z3 is nitrogen;
Rx is T-R3 or L-Z-R3;
Q is selected from —N(R4)—, —O—, —S—, or —CH(R6)—;
R1 is T-(Ring D);
Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl, said heteroaryl or heterocyclyl ring having 1-4 ring heteroatoms selected from nitrogen, oxygen or sulfur, wherein each substitutable ring carbon of Ring D is independently substituted by oxo, T-R5, or V-Z-R5, and each substitutable ring nitrogen of Ring D is independently substituted by —R4;
T is a valence bond or a C1-4 alkylidene chain, wherein when Q is —CH(R6)—, a methylene unit of said C1-4 alkylidene chain is optionally replaced by —O—, —S—, —N(R4)—, —CO—, —OC(O)NH—, or —NHCO2—;
Z is a C1-4 alkylidene chain;
L is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R6)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)——C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)——C(R6)2N(R6)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, —C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)O2N(R6)—, or —C(R6)2N(R6)CON(R6)—;
R2 and R2 are independently selected from —R, -T-W—R6, or R2 and R are taken together with their intervening atoms to form a fused, 5-8 membered, unsaturated or partially unsaturated, ring having 0-3 ring heteroatoms selected from nitrogen, oxygen, or sulfur, wherein each substitutable ring carbon of said fused ring formed by R2 and R2′ is independently substituted by halo, oxo, —CN, —NO2, —R7, or —V—R6, and each substitutable ring nitrogen of said ring formed by R2 and R2′ is independently substituted by R4;
R3 is selected from —R, -halo, —OR, —C(═O)R, —CO2R, —COCOR, —COCH2COR, —NO2, —CN, —S(O)R, —S(O)2R, —SR, —N(R4)2, —CON(R7)2, —SO2N(R7)2, —OC(═O)R, —N(R7)COR, —N(R7)CO2(C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R7)CON(R7)2, —N(R7)SO2N(R7)2, —N(R4)SO2R, or —OC(═O)N(R7)2;
each R is independently selected from hydrogen or an optionally substituted group selected from C1-6 aliphatic, C6-10 aryl, a heteroaryl ring having 5-10 ring atoms, or a heterocyclyl ring having 5-10 ring atoms;
each R4 is independently selected from —R7, —COR7, —CO2 (optionally substituted C1-6 aliphatic), —CON(R7)2, or —SO2R7;
each R5 is independently selected from —R, halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2, —CON(R4)2, —SO2N(R4)2, —OC(—O)R, —N(R4)COR, —N(R4)CO2 (optionally substituted C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2;
V is —O—, —S—, —SO—, —SO2—, —N(R6)SO2—, —SO2N(R6)—, —N(R6)—, —CO—, —CO2—, —N(R6)CO—, —N(R6)C(O)O—, —N(R6)CON(R6)—, —N(R6)SO2N(R6)—, —N(R6)N(R6)—, —C(O)N(R6)—, —OC(O)N(R6)—, —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, —C(R6)2N(R6)—, —C(R6)2N(R6)C(O)—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)——C(R6)═N—O—, —C(R6)2N(R6)N(R)—, —C(R6)2N(R6)SO2N(R6)—, or —C(R6)2N(R6)CON(R6)—;
W is —C(R6)2O—, —C(R6)2S—, —C(R6)2SO—, —C(R6)2SO2—, —C(R6)2SO2N(R6)—, C(R6)2N(R6)—, —CO—, —CO2—, —C(R6)OC(O)—, —C(R6)OC(O)N(R6)—, —C(R6)2N(R6)CO—, —C(R6)2N(R6)C(O)O—, —C(R6)═NN(R6)—, —C(R6)═N—O—, C(R6)2N(R6)N(R6)—, —C(R6)2N(R6)SO2N(R6)—, —C(R6)2N(R6)CON(R6)—, or —CON(R6)—;
each R7 is independently selected from hydrogen or an optionally substituted C1-4 aliphatic group, or two R6 groups on the same nitrogen atom are taken together with the nitrogen atom to form a 5-6 membered heterocyclyl or heteroaryl ring;
each R7 is independently selected from hydrogen or an optionally substituted C1-6 aliphatic group, or two R7 on the same nitrogen are taken together with the nitrogen to form a 5-8 membered heterocyclyl or heteroaryl ring; and
R8 is selected from —R, halo, —OR, —C(═O)R, —CO2R, —COCOR, —NO2, —CN, —S(O)R, —SO2R, —SR, —N(R4)2; —CON(R4)2, —SO2N(R4)2, —OC(═O)R, —N(R4)COR, —N(R4)CO2(optionally substituted C1-6 aliphatic), —N(R4)N(R4)2, —C═NN(R4)2, —C═N—OR, —N(R4)CON(R4)2, —N(R4)SO2N(R4)2, —N(R4)SO2R, or —OC(═O)N(R4)2.
3. The compound according to claim 2 , wherein said compound has one or more features selected from the group consisting of:
(a) Rx is hydrogen, alkyl- or dialkylamino, acetamido, or a C1-4 aliphatic group;
(b) R1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
(c) Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
(d) R2 is —R or -T-W—R and R2 is hydrogen, or R2 and R2 are taken together to form an optionally substituted benzo ring.
4. The compound according to claim 3 , wherein:
(a) Rx is hydrogen, alkyl- or dialkylamino, acetamido, or a C1-4 aliphatic group;
(b) R1 is T-(Ring D), wherein T is a valence bond or a methylene unit;
(c) Ring D is a 5-7 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
(d) R2 is —R or -T-W—R1 and R2 is hydrogen, or R2 and R2 are taken together to form an optionally substituted benzo ring.
5. The compound according to claim 3 , wherein said compound has one or more features selected from the group consisting of:
(a) R1 is T-(Ring D), wherein T is a valence bond, and Q is —S— or —NH—;
(b) Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
(c) R is —R and R2 is hydrogen, wherein R is selected from hydrogen, C1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
6. The compound according to claim 5 , wherein:
(a) R1 is T-(Ring D), wherein T is a valence bond, and Q is —S— or —NH—;
(b) Ring D is a 5-6 membered monocyclic or an 8-10 membered bicyclic aryl or heteroaryl ring; and
(c) R2 is —R and R2 is hydrogen, wherein R is selected from hydrogen, C1-6 aliphatic, phenyl, a 5-6 membered heteroaryl ring, or a 5-6 membered heterocyclic ring.
7. The compound according to claim 5 , wherein said compound has one or more features selected from the group consisting of:
(a) Rx is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetamido;
(b) R1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO2, —N(R4)2, optionally substituted C1-6 aliphatic group, —OR, —CO2R, —CON(R4)2, —OCO(R4) 2-N(R4)COR, —N(R4)SO2R, —N(R6)COCH2CH2N(R4)2, or —N(R6)COCH2CH2CH2N(R4)2; and
(c) R2 is hydrogen or a substituted or unsubstituted C1-6 aliphatic.
8. The compound according to claim 7 , wherein:
(a) Rx is hydrogen methyl, ethyl, propyl, cyclopropyl, isopropyl, methylamino or acetamido;
(b) R1 is T-(Ring D), wherein T is a valence bond and Ring D is a 5-6 membered aryl or heteroaryl ring, wherein Ring D is optionally substituted with one to two groups selected from -halo, —CN, —NO2, —N(R4)2, optionally substituted C1-6 aliphatic group, —OR, —CO2R, —CON(R4)2, —OCO(R4?2, —N(R4)COR, —N(R4)SO2R, —N(R6)COCH2CH2N(R4)21 or —N(R6)COCH2CH2CH2N(R4)2; and
(c) R2 is hydrogen or a substituted or unsubstituted C1-6 aliphatic.
9. A compound selected from the group consisting of:
N5-(1H-Indazol-6-yl)-N3-(5-methyl-1H-pyrazol-3-yl)-[1,2,4]triazine-3,5-diamine;
N-{4-[3-(5-Methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazin-5-ylsulfanyl]-phenyl}-acetamide;
[5-(3-Methoxy-benzyl)-[1,2,4]triazin-3-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;
N3-(5-Cyclopropyl-1H-pyrazol-3-yl)-N5-pyridin-3-ylmethyl-[1,2,4]triazine-3,5-diamine;
[5-(Benzothiazol-6-ylsulfanyl)-[1,2,4]triazin-3-yl]-(5-cyclopropyl-1H-pyrazol-3-yl)-amine;
{4-[3-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-[1,2,4]triazin-5-yloxy]-phenyl}-acetonitrile;
N-{4-[3-(1H-Indazol-3-ylamino)-[1,2,4]triazin-5-ylamino]-phenyl}-methanesulfonamide;
(1H-Indazol-3-yl)-[5-(thiophen-2-ylmethylsulfanyl)-[1,2,4]triazin-3-yl]-amine;
N5-(5-Methyl-1H-pyrazol-3-yl)-N3-pyridin-3-ylmethyl-[1,2,4]triazine-3,5-diamine;
[3-(Benzothiazol-6-ylsulfanyl)-[1,2,4]triazin-5-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;
{4-[5-(5-Methyl-H-pyrazol-3-ylamino)-[1,2,4]triazin-3-yloxy]-phenyl}-acetonitrile;
N5-(5-Cyclopropyl-1H-pyrazol-3-yl)-N3-(1H-indazol-6-yl)-[1,2,4]triazine-3,5-diamine;
N-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-[1,2,4]triazin-3-ylsulfanyl]-phenyl}-acetamide;
N5-(1H-Indazol-3-yl)-N3-(1H-indazol-6-yl)-[1,2,4]triazine-3,5-diamine;
(1H-Indazol-3-yl)-[3-(3-methoxy-phenylsulfanyl)-[1,2,4]triazin-5-yl]-amine; N5(1H-Indazol-6-yl)-N3-(5-methyl-1H-pyrazol-3-yl)-pyridazine-3,5-diamine;
N-{4-[6-(5-Methyl-1H-pyrazol-3-ylamino)-pyridazin-4-ylsulfanyl]-phenyl}-acetamide;
[5-(3-Methoxy-benzyl)-pyridazin-3-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;
N3-(5-Cyclopropyl-1H-pyrazol-3-yl)-N5-pyridin-3-ylmethyl-pyridazine-3,5-diamine;
[5-(Benzothiazol-6-ylsulfanyl)-pyridazin-3-yl]-(5-cyclopropyl-1H-pyrazol-3-yl)-amine;
{4-[6-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-pyridazin-4-yloxy]-phenyl}-acetonitrile;
N-{4-[6-(1H-Indazol-3-ylamino)-pyridazin-4-ylamino]-phenyl}-methanesulfonamide;
(1H-Indazol-3-yl)-[5-(thiophen-2-ylmethylsulfanyl)-pyridazin-3-yl]-amine;
N5-(5-Methyl-1H-pyrazol-3-yl)-N3-pyridin-3-ylmethyl-pyridazine-3,5-diamine;
[6-(Benzothiazol-6-ylsulfanyl)-pyridazin-4-yl]-(5-methyl-1H-pyrazol-3-yl)-amine;
{4-[5-(5-Methyl-1H-pyrazol-3-ylamino)-pyridazin-3-yloxy]-phenyl}-acetonitrile;
N5-(5-Cyclopropyl-1H-pyrazol-3-yl)-N3-(1H-indazol-6-yl)-pyridazine-3,5-diamine;
N-{4-[5-(5-Cyclopropyl-1H-pyrazol-3-ylamino)-pyridazin-3-ylsulfanyl]-phenyl}-acetamide;
N5-(1H-Indazol-3-yl)-N3-(1H-indazol-6-yl)-pyridazine-3,5-diamine; and
(1H-Indazol-3-yl)-[6-(3-methoxy-phenylsulfanyl)-pyridazin-4-yl]-amine.
10. A composition comprising a compound according to any of claims 1-9, and a pharmaceutically acceptable carrier.
11. The composition according to claim 10 , further comprising an additional therapeutic agent.
12. A method of inhibiting Aurora-2 or GSK-3 activity in a biological sample comprising the step of contacting said biological sample with a compound according to any one of claims 1-9.
13. A method of inhibiting Aurora-2 activity in a patient comprising the step of administering to said patient a composition according to claim 10 .
14. A method of inhibiting Aurora-2 activity in a patient comprising the step of administering to said patient a composition according to claim 11 .
15. A method of treating an Aurora-2-mediated disease, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a composition according to claim 10 .
16. The method according to claim 15 , wherein said disease is selected from colon, breast, stomach, or ovarian cancer.
17. The method according to claim 16 , wherein said method further comprises administering an additional therapeutic agent.
18. The method according to claim 17 , wherein said additional therapeutic agent is a chemotherapeutic agent.
19. A method of inhibiting GSK-3 activity in a patient comprising the step of administering to said patient a composition according to claim 10 .
20. A method of inhibiting GSK-3 activity in a patient comprising the step of administering to said patient a composition according to claim 11 .
21. A method of method of treating a GSK-3-mediated disease, which method comprises administering to a patient in need of such a treatment a therapeutically effective amount of a composition according to claim 10 .
22. The method according to claim 21 , wherein said GSK-3-mediated disease is selected from diabetes, Alzheimer's disease, Huntington's Disease, Parkinson's Disease, AIDS-associated dementia, amyotrophic lateral sclerosis (AML), multiple sclerosis (MS), schizophrenia, cardiomycete hypertrophy, reperfusion/ischemia, or baldness.
23. The method according to claim 22 , wherein said GSK-3-mediated disease is diabetes.
24. A method of enhancing glycogen synthesis or lowering blood levels of glucose in a patient in need thereof, which method comprises administering to said patient a therapeutically effective amount of a composition according to claim 10 .
25. A method of inhibiting the production of hyperphosphorylated Tau protein in a patient, which method comprises administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 10 .
26. A method of inhibiting the phosphorylation of β-catenin, which method comprises administering to a patient in need thereof a therapeutically effective amount of a composition according to claim 10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/722,374 US20040157893A1 (en) | 2000-12-21 | 2003-11-25 | Pyrazole compounds useful as protein kinase inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25788700P | 2000-12-21 | 2000-12-21 | |
US28694901P | 2001-04-27 | 2001-04-27 | |
US10/034,683 US6656939B2 (en) | 2000-12-21 | 2001-12-20 | Pyrazole compounds useful as protein kinase inhibitors |
US10/722,374 US20040157893A1 (en) | 2000-12-21 | 2003-11-25 | Pyrazole compounds useful as protein kinase inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/034,683 Continuation US6656939B2 (en) | 2000-12-21 | 2001-12-20 | Pyrazole compounds useful as protein kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040157893A1 true US20040157893A1 (en) | 2004-08-12 |
Family
ID=26946273
Family Applications (16)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/027,001 Expired - Fee Related US6653301B2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/025,164 Expired - Fee Related US6664247B2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/026,975 Expired - Fee Related US6653300B2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/026,992 Expired - Fee Related US7625913B2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/026,966 Abandoned US20030105090A1 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/026,967 Expired - Fee Related US6989385B2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/034,019 Expired - Fee Related US6727251B2 (en) | 2000-12-21 | 2001-12-20 | Pyrazole compounds useful as protein kinase inhibitors |
US10/034,683 Expired - Fee Related US6656939B2 (en) | 2000-12-21 | 2001-12-20 | Pyrazole compounds useful as protein kinase inhibitors |
US10/632,428 Expired - Fee Related US7531536B2 (en) | 2000-12-21 | 2003-08-01 | Pyrazole compounds useful as protein kinase inhibitors |
US10/722,374 Abandoned US20040157893A1 (en) | 2000-12-21 | 2003-11-25 | Pyrazole compounds useful as protein kinase inhibitors |
US10/736,426 Expired - Fee Related US7087603B2 (en) | 2000-12-21 | 2003-12-15 | Pyrazole compounds useful as protein kinase inhibitors |
US10/775,699 Expired - Fee Related US7427681B2 (en) | 2000-12-21 | 2004-02-10 | Pyrazole compounds useful as protein kinase inhibitors |
US12/109,598 Expired - Fee Related US8304414B2 (en) | 2000-12-21 | 2008-04-25 | Pyrazole compounds useful as protein kinase inhibitors |
US12/545,347 Expired - Fee Related US7982037B2 (en) | 2000-12-21 | 2009-08-21 | Pyrazole compounds useful as protein kinase inhibitors |
US13/631,488 Expired - Fee Related US8697698B2 (en) | 2000-12-21 | 2012-09-28 | Pyrazole compounds useful as protein kinase inhibitors |
US14/139,889 Abandoned US20140187772A1 (en) | 2000-12-21 | 2013-12-24 | Pyrazole compounds useful as protein kinase inhibitors |
Family Applications Before (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/027,001 Expired - Fee Related US6653301B2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/025,164 Expired - Fee Related US6664247B2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/026,975 Expired - Fee Related US6653300B2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/026,992 Expired - Fee Related US7625913B2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/026,966 Abandoned US20030105090A1 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/026,967 Expired - Fee Related US6989385B2 (en) | 2000-12-21 | 2001-12-19 | Pyrazole compounds useful as protein kinase inhibitors |
US10/034,019 Expired - Fee Related US6727251B2 (en) | 2000-12-21 | 2001-12-20 | Pyrazole compounds useful as protein kinase inhibitors |
US10/034,683 Expired - Fee Related US6656939B2 (en) | 2000-12-21 | 2001-12-20 | Pyrazole compounds useful as protein kinase inhibitors |
US10/632,428 Expired - Fee Related US7531536B2 (en) | 2000-12-21 | 2003-08-01 | Pyrazole compounds useful as protein kinase inhibitors |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/736,426 Expired - Fee Related US7087603B2 (en) | 2000-12-21 | 2003-12-15 | Pyrazole compounds useful as protein kinase inhibitors |
US10/775,699 Expired - Fee Related US7427681B2 (en) | 2000-12-21 | 2004-02-10 | Pyrazole compounds useful as protein kinase inhibitors |
US12/109,598 Expired - Fee Related US8304414B2 (en) | 2000-12-21 | 2008-04-25 | Pyrazole compounds useful as protein kinase inhibitors |
US12/545,347 Expired - Fee Related US7982037B2 (en) | 2000-12-21 | 2009-08-21 | Pyrazole compounds useful as protein kinase inhibitors |
US13/631,488 Expired - Fee Related US8697698B2 (en) | 2000-12-21 | 2012-09-28 | Pyrazole compounds useful as protein kinase inhibitors |
US14/139,889 Abandoned US20140187772A1 (en) | 2000-12-21 | 2013-12-24 | Pyrazole compounds useful as protein kinase inhibitors |
Country Status (28)
Country | Link |
---|---|
US (16) | US6653301B2 (en) |
EP (10) | EP1345927B1 (en) |
JP (19) | JP4234435B2 (en) |
KR (8) | KR100875091B1 (en) |
CN (6) | CN100436452C (en) |
AP (2) | AP1588A (en) |
AR (4) | AR042397A1 (en) |
AT (9) | ATE340172T1 (en) |
AU (7) | AU2002234047A1 (en) |
BR (2) | BR0116411A (en) |
CA (8) | CA2432799C (en) |
CY (1) | CY1106297T1 (en) |
DE (8) | DE60119774T2 (en) |
DK (3) | DK1353916T3 (en) |
ES (7) | ES2280313T3 (en) |
HK (8) | HK1059776A1 (en) |
HU (5) | HUP0400639A3 (en) |
IL (8) | IL156368A0 (en) |
MX (8) | MXPA03005609A (en) |
MY (1) | MY140377A (en) |
NO (5) | NO328537B1 (en) |
NZ (8) | NZ526473A (en) |
PL (2) | PL210414B1 (en) |
PT (3) | PT1353916E (en) |
RU (1) | RU2355688C2 (en) |
SI (2) | SI1353916T1 (en) |
TW (2) | TWI313269B (en) |
WO (8) | WO2002066461A1 (en) |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030064982A1 (en) * | 2000-09-15 | 2003-04-03 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US20040116454A1 (en) * | 2000-09-15 | 2004-06-17 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US20040167141A1 (en) * | 2000-12-21 | 2004-08-26 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20060270660A1 (en) * | 2002-06-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Processes for preparing substituted pyrimidines |
US20070142368A1 (en) * | 2005-09-30 | 2007-06-21 | Xiao-Yi Xiao | Substituted pyrazole compounds |
US20070173516A1 (en) * | 2005-08-18 | 2007-07-26 | Michael Mortimore | Pyrazine kinase inhibitors |
US20070190634A1 (en) * | 2002-03-15 | 2007-08-16 | David Bebbington | Compositions useful as inhibitors of protein kinases |
US20070249031A1 (en) * | 2005-11-03 | 2007-10-25 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US20070270444A1 (en) * | 2000-09-15 | 2007-11-22 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20070270420A1 (en) * | 2002-02-06 | 2007-11-22 | Harbeson Scott L | Heteroaryl compounds useful as inhibitors of gsk-3 |
US20080004302A1 (en) * | 2006-06-30 | 2008-01-03 | Astrazeneca Ab | Novel Compounds |
US20090029992A1 (en) * | 2007-06-11 | 2009-01-29 | Agoston Gregory E | Substituted pyrazole compounds |
US7491730B2 (en) | 2002-08-02 | 2009-02-17 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of GSK-3 |
US7550598B2 (en) | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20090325968A1 (en) * | 2003-02-06 | 2009-12-31 | Vertex Pharmaceuticals Incorporated | Compositions Useful as Inhibitors of Protein Kinases |
US20100022502A1 (en) * | 2006-11-02 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
US20100022507A1 (en) * | 2006-12-19 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
US20100081657A1 (en) * | 2003-12-04 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100184980A1 (en) * | 2007-07-31 | 2010-07-22 | Juan-Miguel Jimenez | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof |
US20100197761A1 (en) * | 2006-06-27 | 2010-08-05 | Tsuneo Yasuma | Fused cyclic compounds |
US20100215772A1 (en) * | 2007-05-02 | 2010-08-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US20100317641A1 (en) * | 2007-05-02 | 2010-12-16 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
US20110020376A1 (en) * | 2007-03-09 | 2011-01-27 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
US20110021559A1 (en) * | 2007-03-09 | 2011-01-27 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
US20110020377A1 (en) * | 2007-03-09 | 2011-01-27 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
US20110046104A1 (en) * | 2007-05-02 | 2011-02-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US20110060013A1 (en) * | 2007-05-24 | 2011-03-10 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
US20110236478A1 (en) * | 2008-09-03 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8153630B2 (en) | 2004-11-17 | 2012-04-10 | Miikana Therapeutics, Inc. | Kinase inhibitors |
US8278450B2 (en) | 2007-04-18 | 2012-10-02 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8455507B2 (en) | 2007-04-13 | 2013-06-04 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US8633207B2 (en) | 2010-09-01 | 2014-01-21 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
US8637537B2 (en) | 2011-08-25 | 2014-01-28 | Genentech, Inc. | Serine/threonine kinase inhibitors |
US8815877B2 (en) | 2011-12-22 | 2014-08-26 | Genentech, Inc. | Serine/threonine kinase inhibitors |
US8916555B2 (en) | 2012-03-16 | 2014-12-23 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
US9540351B2 (en) | 2013-09-18 | 2017-01-10 | Axikin Pharmaceuticals, Inc. | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
US9546163B2 (en) | 2014-12-23 | 2017-01-17 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
WO2017165255A1 (en) * | 2016-03-25 | 2017-09-28 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
US10819726B2 (en) | 2008-05-27 | 2020-10-27 | The Trustees Of Columbia University In The City Of New York | Detecting network anomalies by probabilistic modeling of argument strings with markov chains |
US10822311B2 (en) | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
US11737463B2 (en) | 2017-05-30 | 2023-08-29 | Basf Se | Pyridine and pyrazine compounds |
Families Citing this family (323)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982260B1 (en) | 1999-11-22 | 2006-01-03 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
EP1343781B1 (en) * | 2000-12-05 | 2008-09-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
ATE325795T1 (en) * | 2001-03-23 | 2006-06-15 | Bayer Corp | RHO KINASE INHIBITORS |
WO2002083138A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
US7105667B2 (en) * | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
US7138404B2 (en) * | 2001-05-23 | 2006-11-21 | Hoffmann-La Roche Inc. | 4-aminopyrimidine derivatives |
US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
NZ531765A (en) | 2001-09-26 | 2006-02-24 | Pharmacia Italia S | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
SE0104140D0 (en) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
WO2003055866A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
EP1465610B1 (en) * | 2002-01-10 | 2008-12-31 | F. Hoffmann-La Roche Ag | Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
EP1485381B8 (en) | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
ATE466580T1 (en) * | 2002-03-15 | 2010-05-15 | Vertex Pharma | AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITORS |
US7223738B2 (en) | 2002-04-08 | 2007-05-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
JPWO2003104230A1 (en) | 2002-06-07 | 2005-10-06 | 協和醗酵工業株式会社 | Bicyclic pyrimidine derivatives |
JP2005536517A (en) * | 2002-07-23 | 2005-12-02 | スミスクライン ビーチャム コーポレーション | Pyrazolopyrimidines as kinase inhibitors |
IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
SI1532145T1 (en) * | 2002-08-02 | 2007-02-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of gsk-3 |
MXPA05001807A (en) * | 2002-09-05 | 2005-04-19 | Aventis Pharma Sa | Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same. |
FR2844267B1 (en) * | 2002-09-05 | 2008-02-15 | Aventis Pharma Sa | NOVEL DERIVATIVES OF AMINOINDAZOLES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM |
AU2003255482A1 (en) * | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
BR0315008A (en) * | 2002-10-04 | 2005-08-09 | Prana Biotechnology Ltd | Neurologically Active Compounds |
KR100490893B1 (en) * | 2002-10-11 | 2005-05-23 | (주) 비엔씨바이오팜 | 2-methoxy-1,3,5-triazine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same |
GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
US7309701B2 (en) | 2002-11-19 | 2007-12-18 | Sanofi-Aventis Deutschland Gmbh | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them |
US7462613B2 (en) | 2002-11-19 | 2008-12-09 | Sanofi-Aventis Deutschland Gmbh | Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them |
FR2847253B1 (en) * | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | NOVEL DERIVATIVES OF PYRIDAZINONES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM |
TWI339204B (en) * | 2002-11-21 | 2011-03-21 | Novartis Vaccines & Diagnostic | Small molecule pi 3-kinase inhibitors and methods of their use |
US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
WO2004087679A1 (en) * | 2003-04-01 | 2004-10-14 | Aponetics Ag | 2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases |
EP1635837B1 (en) * | 2003-06-02 | 2008-07-16 | AstraZeneca AB | (3-((quinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer |
US7560467B2 (en) | 2003-06-19 | 2009-07-14 | Smithkline Beecham Corporation | Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
US7618975B2 (en) * | 2003-07-03 | 2009-11-17 | Myriad Pharmaceuticals, Inc. | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
GB0315966D0 (en) * | 2003-07-08 | 2003-08-13 | Cyclacel Ltd | Compounds |
EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
DK1656372T3 (en) | 2003-07-30 | 2013-07-01 | Rigel Pharmaceuticals Inc | 2,4-PYRIMIDINE DIAMINE COMPOUNDS FOR USING TREATMENT OR PREVENTION OF AUTO-IMMUNE DISEASES |
EP1648875A1 (en) * | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
US20050221357A1 (en) * | 2003-09-19 | 2005-10-06 | Mark Shannon | Normalization of gene expression data |
US20060024690A1 (en) * | 2003-09-19 | 2006-02-02 | Kao H P | Normalization of data using controls |
US7417726B2 (en) * | 2003-09-19 | 2008-08-26 | Applied Biosystems Inc. | Normalization of data using controls |
US20050124562A1 (en) * | 2003-09-23 | 2005-06-09 | Joseph Guiles | Bis-quinazoline compounds for the treatment of bacterial infections |
JP2007510626A (en) | 2003-10-17 | 2007-04-26 | アストラゼネカ アクチボラグ | 4- (Pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer |
WO2005056552A1 (en) * | 2003-12-09 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Naphthyridine derivatives and their use as modulators of muscarinic receptors |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
JP2007522233A (en) | 2004-02-11 | 2007-08-09 | アムジエン・インコーポレーテツド | Vanilloid receptor ligands and their use in therapy |
WO2005083105A2 (en) * | 2004-02-26 | 2005-09-09 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b) |
EP1726580A4 (en) * | 2004-03-15 | 2008-02-13 | Takeda Pharmaceutical | Aminophenylpropanoic acid derivative |
EP2522670A1 (en) * | 2004-04-07 | 2012-11-14 | Takeda Pharmaceutical Company Limited | Heterocyclic CRF receptor antagonists |
EP1742921A2 (en) * | 2004-04-21 | 2007-01-17 | AstraZeneca AB | Pyrazole derivatives useful for the treatment of cancer |
EP1763524A1 (en) * | 2004-04-23 | 2007-03-21 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
AU2005245386B2 (en) * | 2004-05-07 | 2008-11-27 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
US7793137B2 (en) | 2004-10-07 | 2010-09-07 | Cisco Technology, Inc. | Redundant power and data in a wired data telecommunincations network |
AU2012200416B2 (en) * | 2004-05-14 | 2014-07-31 | Millennium Pharmaceuticals, Inc. | "Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase" |
US20050255485A1 (en) * | 2004-05-14 | 2005-11-17 | Livak Kenneth J | Detection of gene duplications |
CN104193750B (en) * | 2004-05-14 | 2018-04-27 | 千禧药品公司 | Suppress mitotic Compounds and methods for by suppressing aurora kinase |
UA84929C2 (en) * | 2004-05-14 | 2008-12-10 | Вертекс Фармасьютикалс Инкорпорейтед | Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors |
EP1905773B1 (en) * | 2004-05-14 | 2012-07-18 | Millennium Pharmaceuticals, Inc. | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
CA2567352A1 (en) * | 2004-05-20 | 2005-12-01 | Bayer Pharmaceuticals Corporation | 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes |
EP1756673A1 (en) * | 2004-05-27 | 2007-02-28 | E.I.Du pont de nemours and company | Developer for a photopolymer protective layer |
EP1765325A4 (en) * | 2004-07-01 | 2009-08-12 | Synta Pharmaceuticals Corp | 2-substituted heteroaryl compounds |
CN101031551A (en) * | 2004-07-06 | 2007-09-05 | 安吉永生物制药公司 | Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer |
US7285569B2 (en) | 2004-09-24 | 2007-10-23 | Hoff Hoffmann-La Roche Inc. | Tricycles, their manufacture and use as pharmaceutical agents |
TW200624431A (en) | 2004-09-24 | 2006-07-16 | Hoffmann La Roche | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents |
CN101027288B (en) * | 2004-09-30 | 2013-04-17 | 泰博特克药品有限公司 | HIV inhibiting 5-substituted pyrimidines |
CA2577467C (en) * | 2004-09-30 | 2013-05-28 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 5-heterocyclyl pyrimidines |
MX2007003798A (en) * | 2004-09-30 | 2007-04-23 | Tibotec Pharm Ltd | Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines. |
US7491720B2 (en) | 2004-10-29 | 2009-02-17 | Banyu Pharmaceutical Co., Ltd. | Aminopyridine derivatives having Aurora A selective inhibitory action |
JP4973190B2 (en) * | 2004-10-29 | 2012-07-11 | Msd株式会社 | Novel aminopyridine derivatives having selective inhibition of Aurora A |
EP1809290A2 (en) | 2004-11-03 | 2007-07-25 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as ion channel modulators and methods of use |
ES2380550T3 (en) | 2004-11-24 | 2012-05-16 | Rigel Pharmaceuticals, Inc. | Spiro-2,4-pyrimidinediamine compounds and their uses |
US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
JP2008525422A (en) * | 2004-12-23 | 2008-07-17 | ファイザー・プロダクツ・インク | Heteroaromatic derivatives useful as anticancer agents |
US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
EP1833819A1 (en) * | 2004-12-30 | 2007-09-19 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
AR054425A1 (en) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO. |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
US7528132B2 (en) * | 2005-01-26 | 2009-05-05 | Schering Corporation | Kinase inhibitors |
CN101155800B (en) | 2005-02-04 | 2012-05-23 | 阿斯利康(瑞典)有限公司 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
BRPI0608160A2 (en) * | 2005-02-16 | 2010-11-09 | Astrazeneca Ab | isolated antibody, host cell, method of inhibiting psma + cell growth, and use of a defucosylated anti-psma antibody |
DK1853588T3 (en) * | 2005-02-16 | 2008-09-15 | Astrazeneca Ab | Chemical compounds |
WO2006101783A2 (en) * | 2005-03-15 | 2006-09-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2006100461A1 (en) * | 2005-03-23 | 2006-09-28 | Astrazeneca Ab | 2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY |
US7297700B2 (en) * | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
EP1869032B8 (en) * | 2005-04-05 | 2009-03-25 | AstraZeneca AB | Pyrimidine derivatives for use as anticancer agents |
GB0507347D0 (en) * | 2005-04-12 | 2005-05-18 | Astrazeneca Ab | Chemical compounds |
MX2007012477A (en) | 2005-04-14 | 2007-11-08 | Hoffmann La Roche | Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents. |
CN101208093A (en) * | 2005-04-27 | 2008-06-25 | 阿斯利康(瑞典)有限公司 | Use of pyrazolyl-pyrimidine derivatives in the treatment of pain |
JP5075624B2 (en) * | 2005-04-28 | 2012-11-21 | 田辺三菱製薬株式会社 | Cyanopyridine derivatives and their pharmaceutical use |
WO2006117212A2 (en) | 2005-05-04 | 2006-11-09 | Develogen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
MX2007013595A (en) | 2005-05-04 | 2008-01-24 | Renovis Inc | Fused heterocyclic compounds, and compositions and uses thereof. |
CN101218229A (en) * | 2005-05-05 | 2008-07-09 | 阿斯利康(瑞典)有限公司 | Pyrazolyl-amino-substituted pyrimidines and their use in the treatment of cancer |
BRPI0610184A2 (en) * | 2005-05-16 | 2012-09-25 | Astrazeneca Ab | compound, pharmaceutically acceptable salt of a compound, process for preparing a compound or a pharmaceutically acceptable salt thereof, use of a compound or a pharmaceutically acceptable salt thereof, methods for inhibiting trk activity, for cancer treatment or prophylaxis and for producing an antiproliferative effect on a warm-blooded animal, and, pharmaceutical composition |
KR101312225B1 (en) | 2005-06-08 | 2013-09-26 | 리겔 파마슈티칼스, 인크. | Compositions and methods for inhibition of the jak pathway |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
EP1890703B1 (en) | 2005-06-14 | 2016-05-11 | Taigen Biotechnology | Pyrimidine compounds as chemokine receptors inhibitors |
EP1746096A1 (en) | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
WO2007023382A2 (en) * | 2005-08-25 | 2007-03-01 | Pfizer Inc. | Pyrimidine amino pyrazole compounds, potent kinase inhibitors |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
UA96427C2 (en) * | 2005-09-30 | 2011-11-10 | Мийкана Терапьютикс, Инк. | Substituted pyrazole compounds |
JP2009512711A (en) | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Regulation of neurogenesis by PDE inhibition |
CA2626375A1 (en) | 2005-10-28 | 2007-05-03 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer |
AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
CA2628274A1 (en) * | 2005-11-01 | 2007-05-10 | Array Biopharma Inc. | Glucokinase activators |
US20070179125A1 (en) * | 2005-11-16 | 2007-08-02 | Damien Fraysse | Aminopyrimidines useful as kinase inhibitors |
US8546404B2 (en) * | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
US7572809B2 (en) | 2005-12-19 | 2009-08-11 | Hoffmann-La Roche Inc. | Isoquinoline aminopyrazole derivatives |
JP5474354B2 (en) | 2005-12-30 | 2014-04-16 | アステックス、セラピューティックス、リミテッド | Pharmaceutical compounds |
US20070213319A1 (en) * | 2006-01-11 | 2007-09-13 | Angion Biomedica Corporation | Modulators of hepatocyte growth factor/c-Met activity |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
DE602007009932D1 (en) | 2006-02-16 | 2010-12-02 | Schering Corp | PYRROLIDIN DERIVATIVES AS ERK HEMMER |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
PE20080145A1 (en) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | TETRAHYDRO-PYRIMIDOAZEPINE AS MODULATORS OF TRPV1 |
RU2480464C2 (en) | 2006-03-30 | 2013-04-27 | Тиботек Фармасьютикалз Лтд. | Hiv-inhibiting 5-amido-substituted pyrimidines |
JP5255559B2 (en) * | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | Indazole compound |
AU2007235900A1 (en) | 2006-04-07 | 2007-10-18 | Novartis Ag | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor |
WO2007118276A1 (en) | 2006-04-14 | 2007-10-25 | Prana Biotechnology Ltd | Method of treatment of age-related macular degeneration(amd) |
AU2007244183B2 (en) * | 2006-04-27 | 2012-05-10 | Msd K.K. | Novel aminopyridine derivative having aurora-a-selective inhibitory activity |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
WO2008001101A2 (en) * | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations |
EP2049119A2 (en) | 2006-06-29 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea |
US20090209537A1 (en) * | 2006-06-30 | 2009-08-20 | Kyowa Hakko Kirin Co., Ltd. | Aurora inhibitors |
US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
US7718648B2 (en) * | 2006-08-09 | 2010-05-18 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
US7635168B2 (en) * | 2006-08-11 | 2009-12-22 | Hall David R | Degradation assembly shield |
JP2008081492A (en) * | 2006-08-31 | 2008-04-10 | Banyu Pharmaceut Co Ltd | New aminopyridine derivative having aurora a selective inhibitory action |
AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
JP2010505961A (en) * | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | Kinase inhibitor |
JP5528806B2 (en) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | Compound drug |
US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
WO2008053812A1 (en) * | 2006-10-27 | 2008-05-08 | Mitsubishi Tanabe Pharma Corporation | Cyanopyridine derivative and medicinal use thereof |
CL2007003244A1 (en) | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER. |
BRPI0722079B8 (en) * | 2006-12-29 | 2021-05-25 | Janssen R & D Ireland | 5,6-substituted hiv-inhibiting pyrimidines and pharmaceutical composition comprising them |
CN101573343B (en) * | 2006-12-29 | 2016-02-24 | 爱尔兰詹森科学公司 | The pyrimidine of the 6-replacement of HIV inhibiting |
WO2008098058A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
CN101622015A (en) | 2007-03-05 | 2010-01-06 | 协和发酵麒麟株式会社 | Pharmaceutical composition |
EP2142537A2 (en) * | 2007-03-20 | 2010-01-13 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
DK2146779T3 (en) | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid derivatives to treat abnormal cell growth. |
JP2010524911A (en) * | 2007-04-18 | 2010-07-22 | アストラゼネカ アクチボラグ | 5-Aminopyrazol-3-yl-3H-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer |
UA99459C2 (en) * | 2007-05-04 | 2012-08-27 | Астразенека Аб | 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer |
WO2008135786A1 (en) * | 2007-05-04 | 2008-11-13 | Astrazeneca Ab | Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer |
KR101294731B1 (en) * | 2007-06-04 | 2013-08-16 | 삼성디스플레이 주식회사 | Array substrate, display panel having the array substrate and method of manufacturing the array substrate |
JP2010532756A (en) * | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | Combination anti-cancer therapy comprising inhibitors of both mTORC1 and mTORC2 |
WO2009007753A2 (en) * | 2007-07-11 | 2009-01-15 | Astrazeneca Ab | 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer |
AU2008279097B2 (en) * | 2007-07-25 | 2013-05-02 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
WO2009013545A2 (en) * | 2007-07-26 | 2009-01-29 | Astrazeneca Ab | Chemical compounds |
TW200906818A (en) * | 2007-07-31 | 2009-02-16 | Astrazeneca Ab | Chemical compounds |
EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
WO2009027736A2 (en) * | 2007-08-27 | 2009-03-05 | Astrazeneca Ab | 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer |
MY180558A (en) | 2007-09-21 | 2020-12-02 | Array Biopharma Inc | Pyridin-2-yl-amino-1,2,4- theiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
JP5372943B2 (en) | 2007-10-11 | 2013-12-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Novel sEH inhibitors and their use |
TW200942549A (en) | 2007-12-17 | 2009-10-16 | Janssen Pharmaceutica Nv | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 |
US20090270418A1 (en) * | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
EP2242745A1 (en) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Novel phenyl-substituted imidazolidines, method for the production thereof, medicaments containing said compounds and use thereof |
US8716483B2 (en) * | 2008-02-21 | 2014-05-06 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
JP5411152B2 (en) * | 2008-02-22 | 2014-02-12 | Msd株式会社 | Novel aminopyridine derivatives having selective inhibition of Aurora A |
DK2268635T3 (en) | 2008-04-21 | 2015-09-14 | Taigen Biotechnology Co Ltd | Heterocyclic Compounds |
BRPI0915101A2 (en) * | 2008-06-11 | 2017-03-21 | Astrazeneca Ab | compound, use thereof, method for treating cancer in a warm-blooded animal, pharmaceutical composition, and process for preparing a compound |
AR072707A1 (en) | 2008-07-09 | 2010-09-15 | Sanofi Aventis | HETEROCICLIC COMPOUNDS, PROCESSES FOR THEIR PREPARATION, DRUGS THAT UNDERSTAND THESE COMPOUNDS AND THE USE OF THEM |
JP2011529920A (en) * | 2008-07-31 | 2011-12-15 | ジェネンテック, インコーポレイテッド | Pyrimidine compounds, compositions and methods of use |
MX2011002484A (en) * | 2008-09-05 | 2011-09-26 | Avila Therapeutics Inc | Algorithm for designing irreversible inhibitors. |
CN102264728B (en) * | 2008-09-15 | 2015-02-04 | 加利福尼亚大学董事会 | Methods and compositions for modulating IRE1, SRC, and ABL activity |
CA2737217A1 (en) * | 2008-09-30 | 2010-04-08 | Astrazeneca Ab | Heterocyclic jak kinase inhibitors |
US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
WO2010056758A1 (en) * | 2008-11-12 | 2010-05-20 | Yangbo Feng | Quinazoline derivatives as kinase inhibitors |
US9023834B2 (en) | 2008-11-13 | 2015-05-05 | Taigen Biotechnology Co., Ltd. | Lyophilization formulation |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
PA8851101A1 (en) | 2008-12-16 | 2010-07-27 | Lilly Co Eli | AMINO PIRAZOL COMPOUND |
JP5490137B2 (en) * | 2008-12-19 | 2014-05-14 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Bicyclic pyrazoles as protein kinase inhibitors |
ES2468391T3 (en) | 2008-12-22 | 2014-06-16 | Millennium Pharmaceuticals, Inc. | Combination of Aurora kinase inhibitors and anti-CD20 antibodies |
US8809343B2 (en) | 2008-12-26 | 2014-08-19 | Fudan University | Pyrimidine derivative, preparation method and use thereof |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
PT2401267E (en) | 2009-02-27 | 2014-04-10 | Ambit Biosciences Corp | Jak kinase modulating quinazoline derivatives and their use in methods |
CA2660962A1 (en) | 2009-03-31 | 2010-09-30 | Astellas Pharma Inc. | Novel pharmaceutical composition for treatment of schizophrenia |
US8399663B2 (en) | 2009-04-03 | 2013-03-19 | Astellas Pharma Inc. | Salt of 1,3,5-triazine-2,4,6-triamine derivative |
JO3635B1 (en) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | Solid pharmaceutical compositions and processes for their production |
EP2440052A4 (en) * | 2009-06-08 | 2013-01-23 | Abraxis Bioscience Llc | Triazine derivatives and their therapeutical applications |
KR101460095B1 (en) * | 2009-06-08 | 2014-11-10 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | Triazine derivatives and their therapeutical applications |
BRPI1011527A2 (en) * | 2009-06-09 | 2016-07-26 | California Capital Equity Llc | ureidophenyl substituted triazine derivatives and their therapeutic applications. |
EP2440057A4 (en) * | 2009-06-09 | 2012-12-05 | California Capital Equity Llc | Triazine derivatives and their therapeutical applications |
KR20120026612A (en) | 2009-06-09 | 2012-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | Benzyl substituted triazine derivatives and their therapeutical applications |
EP2440055B1 (en) * | 2009-06-09 | 2015-03-11 | California Capital Equity, LLC | Styryl-triazine derivatives and their therapeutical applications |
EP2443106A1 (en) * | 2009-06-18 | 2012-04-25 | Cellzome Limited | Heterocyclylaminopyrimidines as kinase inhibitors |
US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
TWI468402B (en) * | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | Compounds for the reduction of β-amyloid production |
ES2443016T3 (en) | 2009-08-26 | 2014-02-17 | Sanofi | New crystalline hydrates of heteroaromatic fluoroglycosides, pharmaceutical products comprising these compounds, and their use |
AU2010295690B2 (en) | 2009-09-16 | 2016-07-28 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
CN105193469B (en) * | 2009-11-13 | 2018-12-04 | 直观外科手术操作公司 | End effector with redundant closing mechanisms |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
SG181965A1 (en) | 2009-12-30 | 2012-08-30 | Avila Therapeutics Inc | Ligand-directed covalent modification of protein |
SA111320200B1 (en) * | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors |
CN104031049A (en) | 2010-02-19 | 2014-09-10 | 米伦纽姆医药公司 | Crystalline Forms Of Aurora Kinase Inhibitor |
WO2011107494A1 (en) | 2010-03-03 | 2011-09-09 | Sanofi | Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof |
US20130059830A1 (en) * | 2010-05-20 | 2013-03-07 | Fa-Xiang Ding | Novel prolylcarboxypeptidase inhibitors |
CA2798578C (en) | 2010-05-21 | 2015-12-29 | Chemilia Ab | Novel pyrimidine derivatives |
CA2797947C (en) | 2010-06-04 | 2019-07-09 | Charles Baker-Glenn | Aminopyrimidine derivatives as lrrk2 modulators |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
NO2598482T3 (en) | 2010-07-29 | 2018-09-01 | ||
US20130296363A1 (en) * | 2010-09-01 | 2013-11-07 | Ambit Biosciences Corporation | Quinoline and isoquinoline derivatives for use as jak modulators |
US20130225614A1 (en) * | 2010-09-01 | 2013-08-29 | Ambit Biosciences Corporation | 4-azolylaminoquinazoline derivatives and methods of use thereof |
WO2012030918A1 (en) * | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Adenosine a3 receptor modulating compounds and methods of use thereof |
EP2611793A1 (en) * | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | 2-cycloquinazoline derivatives and methods of use thereof |
ES2619850T3 (en) * | 2010-09-01 | 2017-06-27 | Ambit Biosciences Corporation | Hydrobromide salts of a pyrazolilaminoquinazoline |
WO2012030917A1 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
WO2012059932A1 (en) | 2010-11-01 | 2012-05-10 | Aurigene Discovery Technologies Limited | 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors |
US8815882B2 (en) | 2010-11-10 | 2014-08-26 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
EP2683701B1 (en) | 2011-03-08 | 2014-12-24 | Sanofi | Oxathiazine derivatives substituted with benzyl or heteromethylene groups, method for their preparation, their usage as medicament, medicament containing same and its use |
WO2012120051A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683702B1 (en) | 2011-03-08 | 2014-12-24 | Sanofi | New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application |
EP2683699B1 (en) | 2011-03-08 | 2015-06-24 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
BR112013024378A2 (en) | 2011-03-24 | 2016-12-13 | Chemilia Ab | new pyrimidine derivatives |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
PE20141228A1 (en) * | 2011-09-22 | 2014-10-01 | Pfizer | DERIVATIVES OF PYRROLOPYRIMIDINE AND PURINE |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2771337B1 (en) | 2011-09-27 | 2017-08-02 | Novartis AG | 3-(pyrimidin-4-yl)-oxazolidin-2-ones as inhibitors of mutant idh |
JP6106685B2 (en) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | Inhibitors of C-JUN-N-terminal kinase (JNK) |
WO2013123401A1 (en) * | 2012-02-17 | 2013-08-22 | Abbvie Inc. | Diaminopyrimidines useful as inhibitors of the human respiratory syncytial virus (rsv) |
UY34632A (en) | 2012-02-24 | 2013-05-31 | Novartis Ag | OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME |
TWI485146B (en) * | 2012-02-29 | 2015-05-21 | Taiho Pharmaceutical Co Ltd | Novel piperidine compounds or salts thereof |
US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
CN106986863B (en) | 2012-04-24 | 2019-12-31 | 沃泰克斯药物股份有限公司 | DNA-PK inhibitors |
CN104507929B (en) * | 2012-05-24 | 2018-02-16 | 赛尔佐姆有限公司 | Heterocyclyl pyrimidines analog as TYK2 inhibitor |
KR20150034209A (en) | 2012-06-26 | 2015-04-02 | 델 마 파마슈티컬스 인코포레이티드 | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
HUE029559T2 (en) * | 2012-07-10 | 2017-03-28 | Ares Trading Sa | Pyrimidine pyrazolyl derivatives |
TWI536992B (en) * | 2012-09-19 | 2016-06-11 | Taiho Pharmaceutical Co Ltd | And a medicinal composition for oral administration of improved elution and / or absorption |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
CN103191120B (en) * | 2012-12-31 | 2015-11-25 | 刘强 | A kind of pyrimidine derivatives preparation prevent and/or treat and/or adjuvant therapy of tumors medicine in purposes |
CN103059002B (en) * | 2012-12-31 | 2015-04-22 | 中山大学 | Pyrimidine derivative with Aurora kinase inhibitory activity and preparation method and application thereof |
CN103202843B (en) * | 2012-12-31 | 2015-04-29 | 刘强 | Application of pyrimidine derivative in preparation of drugs capable of prevention and/or treatment and/or adjuvant therapy of cancers |
CN103910716A (en) * | 2013-01-07 | 2014-07-09 | 华东理工大学 | 2,4-disubstituted-cycloalkyl[d]pyrimidine compound and its use |
CN105246883B (en) | 2013-03-12 | 2017-07-21 | 沃泰克斯药物股份有限公司 | DNA PK inhibitor |
JP6387360B2 (en) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 3-pyrimidin-4-yl-oxazolidine-2-one as an inhibitor of mutant IDH |
EP3842424A1 (en) | 2013-03-15 | 2021-06-30 | The Trustees of Columbia University in the City of New York | Map kinase modulators and uses thereof in the tretament of tauopathies |
JP6360881B2 (en) | 2013-03-22 | 2018-07-18 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Combination of catalytic MTORC1 / 2 inhibitor and selective inhibitor of Aurora A kinase |
WO2015003355A2 (en) * | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
AU2014293011A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene |
WO2015028848A1 (en) * | 2013-09-02 | 2015-03-05 | Piramal Enterprises Limited | Bicyclic heterocyclic compounds as multi-kinase inhibitors |
PL3424920T3 (en) | 2013-10-17 | 2020-11-16 | Vertex Pharmaceuticals Incorporated | Co-crystals of (s)-n-methyl-8-(1-((2'-methyl-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide and deuterated derivatives thereof as dna-pk inhibitors |
WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
WO2015058140A1 (en) | 2013-10-18 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
PT3089971T (en) | 2014-01-01 | 2020-09-03 | Medivation Tech Llc | Compounds and methods of use |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
EP4299128A3 (en) | 2014-03-13 | 2024-04-17 | Neuroderm Ltd. | Dopa decarboxylase inhibitor compositions |
JP6538148B2 (en) * | 2014-03-28 | 2019-07-03 | キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
UA121386C2 (en) | 2014-04-04 | 2020-05-25 | Айомет Фарма Лтд | Indole derivatives for use in medicine |
US20170165230A1 (en) | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
CN105367555B (en) * | 2014-08-07 | 2019-06-25 | 广东东阳光药业有限公司 | Substituted heteroaryl compound and combinations thereof and purposes |
EP3236959A4 (en) | 2014-12-23 | 2018-04-25 | Dana Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2016123627A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
EP3283482B1 (en) | 2015-04-17 | 2022-04-06 | Ludwig Institute for Cancer Research Ltd | Plk4 inhibitors |
SG10201910742VA (en) | 2015-05-28 | 2020-01-30 | Theravance Biopharma R&D Ip Llc | Naphthyridine compounds as jak kinase inhibitors |
JP2018135268A (en) * | 2015-06-05 | 2018-08-30 | 大日本住友製薬株式会社 | Novel heteroaryl amino-3-pyrazole derivative and pharmacologically acceptable salt thereof |
JP7028766B2 (en) | 2015-09-09 | 2022-03-02 | ダナ-ファーバー キャンサー インスティテュート, インコーポレイテッド | Inhibitor of cyclin-dependent kinase |
US9938257B2 (en) | 2015-09-11 | 2018-04-10 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
EA201800367A1 (en) * | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | METHODS OF TREATMENT OF HUNTINGTON'S DISEASE |
CN105503754B (en) * | 2015-12-11 | 2017-11-17 | 浙江大学 | The triazine of 2 amino, 4 benzyl, 6 morpholine 1,3,5 and its preparation and application |
CN105384702B (en) * | 2015-12-11 | 2018-04-10 | 浙江大学 | Three substitution s-triazine compounds and preparation method thereof |
CN105399695B (en) * | 2015-12-11 | 2019-04-19 | 浙江大学 | Compound in triazine class and its preparation method and application |
WO2017102091A1 (en) | 2015-12-18 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
JP6881879B2 (en) | 2016-04-28 | 2021-06-02 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Pyrimidine compounds as JAK kinase inhibitors |
WO2017207534A1 (en) | 2016-06-03 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituted heteroarylbenzimidazole compounds |
US11110108B2 (en) | 2016-09-27 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors |
US10858319B2 (en) | 2016-10-03 | 2020-12-08 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
US10968227B2 (en) * | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
CN108239071B (en) * | 2016-12-27 | 2020-12-04 | 沈阳药科大学 | Amide and thioamide derivatives, and preparation method and application thereof |
FR3064275B1 (en) | 2017-03-21 | 2019-06-07 | Arkema France | METHOD FOR HEATING AND / OR AIR CONDITIONING A VEHICLE |
CA3066224A1 (en) | 2017-06-05 | 2018-12-13 | Ptc Therapeutics Inc. | Compounds for treating huntington's disease |
MX2019015578A (en) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Methods for treating huntington's disease. |
CN111163838B (en) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | Methods for treating huntington's disease |
US10329282B2 (en) | 2017-06-30 | 2019-06-25 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
JP7311228B2 (en) | 2017-06-30 | 2023-07-19 | ベイジン タイド ファーマシューティカル カンパニー リミテッド | RHO-related protein kinase inhibitors, pharmaceutical compositions containing same and methods for preparation and use thereof |
US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
CN111683662B (en) * | 2017-08-28 | 2024-04-02 | 陈志宏 | Substituted pyrimidine compounds, pharmaceutical compositions and methods of treatment |
US20200199136A1 (en) * | 2017-08-28 | 2020-06-25 | Acurastem Inc. | Pikfyve kinase inhibitors |
SI3672965T1 (en) | 2017-10-27 | 2022-11-30 | Theravance Biopharma R&D Ip, Llc | Pyrimidine compound as jak kinase inhibitor |
EP3672957A1 (en) * | 2017-11-23 | 2020-07-01 | BioMed X GmbH | Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors |
US11612604B2 (en) | 2017-12-06 | 2023-03-28 | Ludwig Institute For Cancer Research Ltd | Methods of treating cancer with PLK4 inhibitors |
WO2019191092A1 (en) | 2018-03-27 | 2019-10-03 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
US20220169631A9 (en) * | 2018-06-25 | 2022-06-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
SG11202012674PA (en) | 2018-06-27 | 2021-01-28 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for treating huntington's disease |
US11155549B2 (en) | 2019-04-24 | 2021-10-26 | Theravance Biopharma R&D Ip, Llc | Ester and carbonate pyrimidine compounds as JAK kinase inhibitors |
AR118767A1 (en) | 2019-04-24 | 2021-10-27 | Theravance Biopharma R&D Ip Llc | PYRIMIDINES SUBSTITUTED AS JAK INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE SKIN DISEASES |
JP2022542704A (en) * | 2019-08-01 | 2022-10-06 | インテグラル バイオサイエンシーズ プライベート リミテッド | Heterocyclic compounds and their use as kinase inhibitors |
CN114728962A (en) | 2019-09-18 | 2022-07-08 | 武田药品工业有限公司 | Plasma kallikrein inhibitors and uses thereof |
CN110483493A (en) * | 2019-09-19 | 2019-11-22 | 广东工业大学 | A kind of diazole analog derivative and its preparation method and application |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
TW202237119A (en) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk-5 inhibitors and uses thereof |
CN117355523A (en) * | 2021-03-17 | 2024-01-05 | 武田药品工业株式会社 | Polycyclic inhibitors of plasma kallikrein |
JP2024511466A (en) * | 2021-03-26 | 2024-03-13 | スミトモ ファーマ オンコロジー, インコーポレイテッド | ALK-5 inhibitors and their uses |
AU2022272184A1 (en) | 2021-05-11 | 2023-11-30 | Oric Pharmaceuticals, Inc. | Polo like kinase 4 inhibitors |
UY39832A (en) | 2021-06-28 | 2023-01-31 | Blueprint Medicines Corp | CDK2 INHIBITORS |
CN116354938B (en) * | 2021-12-28 | 2024-02-20 | 沈阳药科大学 | Preparation method and application of quinazoline derivatives and analogues thereof |
CN114276302B (en) * | 2022-01-11 | 2023-07-25 | 山东百启生物医药有限公司 | Method for preparing 2, 4-diaminoquinazoline derivative |
WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
CN115403568B (en) * | 2022-09-21 | 2023-09-29 | 中山大学 | Quinazoline Aurora A covalent inhibitor and preparation method and application thereof |
CN117736198A (en) * | 2022-09-21 | 2024-03-22 | 科辉智药生物科技(深圳)有限公司 | Macrocyclic nitrogen crown ether compounds and their use as protein kinase inhibitors |
Citations (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
US3755322A (en) * | 1970-07-15 | 1973-08-28 | Ciba Geigy Corp | Diamino-s-triazines |
US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
US4051252A (en) * | 1974-12-13 | 1977-09-27 | Bayer Aktiengesellschaft | 3-aminoindazole-1 and 2-carboxylic acid derivatives |
US4493726A (en) * | 1980-12-23 | 1985-01-15 | Ciba Geigy Corporation | Phenylpyrimidines as antidotes for protecting cultivated plants against phytotoxic damage caused by herbicides |
US4540698A (en) * | 1982-01-20 | 1985-09-10 | Mitsui Toatsu Chemicals, Incorporated | 5-Methylthiopyrimidine derivatives, their preparation process and fungicides containing same as active ingredients |
US4711951A (en) * | 1981-04-06 | 1987-12-08 | Pharmacia Aktiebolag | Therapeutically active compound and pharmaceutical composition containing the same |
US5124441A (en) * | 1981-04-06 | 1992-06-23 | Pharmacia Aktiebolag | Therapeutically active compound and its use |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5916908A (en) * | 1994-11-10 | 1999-06-29 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
US5972946A (en) * | 1995-04-13 | 1999-10-26 | Dainippon Pharmaceutical Co., Ltd. | Acetamide derivative, process for preparing the same, and a pharmaceutical composition containing the same |
US6093716A (en) * | 1996-09-16 | 2000-07-25 | Celltech Therapeutics, Limited | Substituted 2-pyrimidineamines and processes for their preparation |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6200977B1 (en) * | 1998-02-17 | 2001-03-13 | Tularik Inc. | Pyrimidine derivatives |
US20020052386A1 (en) * | 2000-02-17 | 2002-05-02 | Armistead David M. | Kinase inhibitors |
US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
US6495582B1 (en) * | 2000-09-15 | 2002-12-17 | Vertex Pharmaceuticals Incorporated | Isoxazole compositions useful as inhibitors of ERK |
US20030004164A1 (en) * | 2000-12-21 | 2003-01-02 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US6528509B1 (en) * | 2000-02-05 | 2003-03-04 | Vertex Pharmacuticals, Incorporated | Pyrazole compositions useful as inhibitors of ERK |
US20030055044A1 (en) * | 2000-09-15 | 2003-03-20 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US20030064981A1 (en) * | 2000-09-15 | 2003-04-03 | Ronald Knegtel | Pyrazole compounds useful as protein kinase inhibitors |
US20030064982A1 (en) * | 2000-09-15 | 2003-04-03 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US20030069239A1 (en) * | 2000-12-12 | 2003-04-10 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
US20030073687A1 (en) * | 2000-09-15 | 2003-04-17 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20030083327A1 (en) * | 2000-09-15 | 2003-05-01 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US6558657B1 (en) * | 1998-01-09 | 2003-05-06 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
US20030087922A1 (en) * | 2001-03-29 | 2003-05-08 | Bethiel Randy S. | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
US6562971B2 (en) * | 2000-12-12 | 2003-05-13 | Basf Aktiengesellschaft | Process for the preparation of triethylenediamine (TEDA) |
US20030092714A1 (en) * | 2001-02-09 | 2003-05-15 | Jingrong Cao | Heterocyclic inhibitors of ERK2 and uses thereof |
US20030096816A1 (en) * | 2001-04-13 | 2003-05-22 | Jingrong Cao | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
US20030096813A1 (en) * | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
US6579983B1 (en) * | 1999-06-18 | 2003-06-17 | Celltech R&D Limited | 5-cyano-2-aminopyrimidine derivatives |
US6589958B1 (en) * | 1998-08-21 | 2003-07-08 | Bristol-Myers Squibb Pharma Company | Isoxazolo [4,5-d] pyrimidines as CRF antagonists |
US6593326B1 (en) * | 1998-12-24 | 2003-07-15 | Astrazeneca Ab | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity |
US20030144309A1 (en) * | 2001-05-16 | 2003-07-31 | Young Choon-Moon | Inhibitors of Src and other protein kinases |
US20030171389A1 (en) * | 2001-07-03 | 2003-09-11 | Guy Bemis | Inhibitors of Src and Lck protein kinases |
US20030187002A1 (en) * | 2000-06-28 | 2003-10-02 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
US20030199526A1 (en) * | 2001-12-07 | 2003-10-23 | Deborah Choquette | Pyrimidine-based compounds useful as GSK-3 inhibitors |
US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
US20030225073A1 (en) * | 2002-03-15 | 2003-12-04 | David Bebbington | Compositions useful as inhibitors of protein kinases |
US20040002496A1 (en) * | 2002-03-15 | 2004-01-01 | David Bebbington | Compositions useful as inhibitors of protein kinases |
US20040009981A1 (en) * | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
US20040009996A1 (en) * | 2001-06-15 | 2004-01-15 | Young-Choon Moon | Protein kinase inhibitors and uses thereof |
US20040009974A1 (en) * | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
US20040029857A1 (en) * | 2002-04-26 | 2004-02-12 | Hale Michael Robin | Heterocyclic inhibitors of ERK2 and uses thereof |
US20040097531A1 (en) * | 2002-07-09 | 2004-05-20 | Mark Ledeboer | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
US6838464B2 (en) * | 2000-03-01 | 2005-01-04 | Astrazeneca Ab | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
US6841579B1 (en) * | 1995-12-18 | 2005-01-11 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
US20060270660A1 (en) * | 2002-06-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Processes for preparing substituted pyrimidines |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2585906A (en) | 1952-02-12 | Quaternary salts of pyrimdjines | ||
US18436A (en) * | 1857-10-20 | And saml | ||
US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
MA18829A1 (en) | 1979-05-18 | 1980-12-31 | Ciba Geigy Ag | PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR THERAPEUTIC USE |
EP0136976A3 (en) | 1983-08-23 | 1985-05-15 | Ciba-Geigy Ag | Use of phenyl pyrimidines as plant regulators |
DE3725638A1 (en) | 1987-08-03 | 1989-02-16 | Bayer Ag | NEW ARYLOXY (OR THIO) AMINOPYRIMIDINE |
JPH0532662A (en) | 1990-11-09 | 1993-02-09 | Nissan Chem Ind Ltd | Substituted pyrazole derivative and agricultural and horticultural fungicide |
US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5597920A (en) | 1992-04-30 | 1997-01-28 | Neurogen Corporation | Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes |
JPH0665237A (en) * | 1992-05-07 | 1994-03-08 | Nissan Chem Ind Ltd | Substituted pyrazole derivative and germicide for agriculture and horticulture |
EP0672042B1 (en) | 1993-10-01 | 2006-05-03 | Novartis AG | Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof |
CA2230896A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
US5935966A (en) | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
JPH10130150A (en) | 1996-09-05 | 1998-05-19 | Dainippon Pharmaceut Co Ltd | Medicine comprising acetic acid amide derivative |
ES2239779T3 (en) | 1996-10-02 | 2005-10-01 | Novartis Ag | PIRIMIDINE DERIVATIVES AND PROCEDURES FOR THE PREPARATION OF THE SAME. |
AU738341B2 (en) | 1996-10-11 | 2001-09-13 | Abbott Gmbh & Co. Kg | Asparate ester inhibitors of interleukin-1beta converting enzyme |
AU741203B2 (en) | 1997-10-10 | 2001-11-22 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
JP2000026421A (en) | 1998-01-29 | 2000-01-25 | Kumiai Chem Ind Co Ltd | Diaryl sulfide derivative and pest controlling agent |
DE69925268T2 (en) | 1998-03-16 | 2006-03-23 | Cytovia, Inc., San Diego | Dipeptide caspase inhibitors and their use |
OA12147A (en) | 1998-06-02 | 2006-05-05 | Osi Pharm Inc | PyrroloÄ2,3dÜpyrimidine compositions and their use. |
CN1312807A (en) | 1998-06-19 | 2001-09-12 | 希龙公司 | Inhibitors of glycogen synthase kinase 3 |
WO2000003901A1 (en) * | 1998-07-16 | 2000-01-27 | Continental Teves Ag & Co. Ohg | Method and device for detecting the critical driving states in vehicles which are being driven |
ATE294796T1 (en) * | 1998-10-08 | 2005-05-15 | Astrazeneca Ab | QUINAZOLINE DERIVATIVES |
GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
JP2002534515A (en) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | 1-heterocyclic-substituted diarylamines |
ES2265929T3 (en) | 1999-03-30 | 2007-03-01 | Novartis Ag | FTALAZINE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES. |
JP2003502424A (en) * | 1999-06-17 | 2003-01-21 | シオノギ バイオリサーチ コーポレイション | Inhibitor of IL-12 production |
CN1222520C (en) | 1999-08-12 | 2005-10-12 | 沃泰克斯药物股份有限公司 | Inhibitors of c-JUN N-terminal kinase (JNK) and other protein kinases |
DE60039059D1 (en) * | 1999-10-07 | 2008-07-10 | Amgen Inc | TRIAZINE KINASE INHIBITORS |
EE200200275A (en) | 1999-11-30 | 2003-10-15 | Pfizer Products Inc. | 2,4-Diaminopyrimidine compounds used as immunosuppressants |
CA2393179A1 (en) | 1999-12-02 | 2001-06-07 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof |
US6376489B1 (en) | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
MY125768A (en) | 1999-12-15 | 2006-08-30 | Bristol Myers Squibb Co | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
AU2001251165A1 (en) | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
JP2004501083A (en) | 2000-04-18 | 2004-01-15 | アゴーロン・ファーマシューティカルズ・インコーポレイテッド | Pyrazole for inhibiting protein kinases |
JP3890184B2 (en) * | 2000-05-15 | 2007-03-07 | Necパーソナルプロダクツ株式会社 | Power supply device, power control method thereof, and information processing apparatus |
DZ3398A1 (en) | 2000-08-31 | 2002-03-07 | Pfizer Prod Inc | PYRAZOLE DERIVATIVES AND THEIR USE AS KINASE PROTEIN INHIBITORS |
HUP0302221A3 (en) | 2000-09-20 | 2004-01-28 | Merck Patent Gmbh | 4-amino-quinazolines |
US6641579B1 (en) | 2000-09-29 | 2003-11-04 | Spectrasonics Imaging, Inc. | Apparatus and method for ablating cardiac tissue |
EP1351691A4 (en) | 2000-12-12 | 2005-06-22 | Cytovia Inc | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2003026664A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Corporation | 2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors |
US6569499B2 (en) | 2001-10-02 | 2003-05-27 | Xerox Corporation | Apparatus and method for coating photoreceptor substrates |
CN1319968C (en) | 2002-08-02 | 2007-06-06 | 沃泰克斯药物股份有限公司 | Compositions useful as inhibitors of GSK-3 |
WO2008077086A1 (en) | 2006-12-19 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
-
2001
- 2001-12-19 US US10/027,001 patent/US6653301B2/en not_active Expired - Fee Related
- 2001-12-19 DK DK01994323T patent/DK1353916T3/en active
- 2001-12-19 KR KR1020037008427A patent/KR100875091B1/en not_active IP Right Cessation
- 2001-12-19 DE DE60119774T patent/DE60119774T2/en not_active Expired - Lifetime
- 2001-12-19 JP JP2002567928A patent/JP4234435B2/en not_active Expired - Fee Related
- 2001-12-19 AU AU2002234047A patent/AU2002234047A1/en not_active Abandoned
- 2001-12-19 HU HU0400639A patent/HUP0400639A3/en unknown
- 2001-12-19 IL IL15636801A patent/IL156368A0/en not_active IP Right Cessation
- 2001-12-19 AT AT01994323T patent/ATE340172T1/en active
- 2001-12-19 AT AT01993360T patent/ATE326461T1/en active
- 2001-12-19 JP JP2002557938A patent/JP4210520B2/en not_active Expired - Fee Related
- 2001-12-19 JP JP2002559413A patent/JP4160392B2/en not_active Expired - Fee Related
- 2001-12-19 ES ES01273861T patent/ES2280313T3/en not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/049139 patent/WO2002066461A1/en active IP Right Grant
- 2001-12-19 MX MXPA03005609A patent/MXPA03005609A/en active IP Right Grant
- 2001-12-19 DE DE60119776T patent/DE60119776T2/en not_active Expired - Lifetime
- 2001-12-19 NZ NZ526473A patent/NZ526473A/en not_active IP Right Cessation
- 2001-12-19 MX MXPA03005607A patent/MXPA03005607A/en active IP Right Grant
- 2001-12-19 KR KR1020037008387A patent/KR100843114B1/en not_active IP Right Cessation
- 2001-12-19 DK DK01273861T patent/DK1355905T3/en active
- 2001-12-19 CN CNB018221025A patent/CN100436452C/en not_active Expired - Fee Related
- 2001-12-19 HU HU0400908A patent/HUP0400908A3/en unknown
- 2001-12-19 CA CA002432799A patent/CA2432799C/en not_active Expired - Fee Related
- 2001-12-19 KR KR1020037008385A patent/KR100889246B1/en not_active IP Right Cessation
- 2001-12-19 BR BR0116411-2A patent/BR0116411A/en not_active IP Right Cessation
- 2001-12-19 WO PCT/US2001/049401 patent/WO2002057259A2/en active Application Filing
- 2001-12-19 EP EP01994510A patent/EP1345927B1/en not_active Expired - Lifetime
- 2001-12-19 RU RU2003122209/04A patent/RU2355688C2/en not_active IP Right Cessation
- 2001-12-19 KR KR1020037008409A patent/KR100909665B1/en not_active IP Right Cessation
- 2001-12-19 IL IL15640701A patent/IL156407A0/en not_active IP Right Cessation
- 2001-12-19 JP JP2002551561A patent/JP4160389B2/en not_active Expired - Fee Related
- 2001-12-19 WO PCT/US2001/049140 patent/WO2002050065A2/en active IP Right Grant
- 2001-12-19 ES ES01994323T patent/ES2272567T3/en not_active Expired - Lifetime
- 2001-12-19 AT AT01273861T patent/ATE354573T1/en active
- 2001-12-19 ES ES01271061T patent/ES2266095T3/en not_active Expired - Lifetime
- 2001-12-19 US US10/025,164 patent/US6664247B2/en not_active Expired - Fee Related
- 2001-12-19 IL IL15640801A patent/IL156408A0/en unknown
- 2001-12-19 NZ NZ526471A patent/NZ526471A/en not_active IP Right Cessation
- 2001-12-19 AU AU2002255452A patent/AU2002255452B2/en not_active Ceased
- 2001-12-19 WO PCT/US2001/051031 patent/WO2002062789A1/en active IP Right Grant
- 2001-12-19 CA CA002432223A patent/CA2432223C/en not_active Expired - Fee Related
- 2001-12-19 ES ES01994510T patent/ES2265452T3/en not_active Expired - Lifetime
- 2001-12-19 MX MXPA03005606A patent/MXPA03005606A/en active IP Right Grant
- 2001-12-19 EP EP10184271A patent/EP2264028A1/en not_active Withdrawn
- 2001-12-19 EP EP01273861A patent/EP1355905B1/en not_active Expired - Lifetime
- 2001-12-19 AT AT01994510T patent/ATE326462T1/en active
- 2001-12-19 US US10/026,975 patent/US6653300B2/en not_active Expired - Fee Related
- 2001-12-19 CN CNB01822136XA patent/CN100340555C/en not_active Expired - Fee Related
- 2001-12-19 HU HU0400638A patent/HUP0400638A2/en unknown
- 2001-12-19 PL PL363244A patent/PL210414B1/en not_active IP Right Cessation
- 2001-12-19 NZ NZ526469A patent/NZ526469A/en not_active IP Right Cessation
- 2001-12-19 ES ES06011799T patent/ES2375491T3/en not_active Expired - Lifetime
- 2001-12-19 AT AT01271061T patent/ATE327989T1/en active
- 2001-12-19 MX MXPA03005610A patent/MXPA03005610A/en active IP Right Grant
- 2001-12-19 DE DE60126828T patent/DE60126828T2/en not_active Expired - Lifetime
- 2001-12-19 AP APAP/P/2003/002816A patent/AP1588A/en active
- 2001-12-19 SI SI200130656T patent/SI1353916T1/en unknown
- 2001-12-19 DK DK01271061T patent/DK1345922T3/en active
- 2001-12-19 HU HU0400842A patent/HUP0400842A2/en unknown
- 2001-12-19 CN CNB01822105XA patent/CN100406454C/en not_active Expired - Fee Related
- 2001-12-19 CN CNB018221351A patent/CN100408573C/en not_active Expired - Fee Related
- 2001-12-19 CA CA2432303A patent/CA2432303C/en not_active Expired - Fee Related
- 2001-12-19 DE DE60120219T patent/DE60120219T2/en not_active Expired - Lifetime
- 2001-12-19 SI SI200130722T patent/SI1355905T1/en unknown
- 2001-12-19 JP JP2002563142A patent/JP4160395B2/en not_active Expired - Fee Related
- 2001-12-19 NZ NZ526468A patent/NZ526468A/en not_active IP Right Cessation
- 2001-12-19 EP EP01994323A patent/EP1353916B1/en not_active Expired - Lifetime
- 2001-12-19 PT PT01994323T patent/PT1353916E/en unknown
- 2001-12-19 NZ NZ526472A patent/NZ526472A/en not_active IP Right Cessation
- 2001-12-19 MX MXPA03005608A patent/MXPA03005608A/en not_active Application Discontinuation
- 2001-12-19 WO PCT/US2001/050312 patent/WO2002068415A1/en active IP Right Grant
- 2001-12-19 KR KR1020037008397A patent/KR100947185B1/en not_active IP Right Cessation
- 2001-12-19 CA CA002432131A patent/CA2432131C/en not_active Expired - Fee Related
- 2001-12-19 PT PT01273861T patent/PT1355905E/en unknown
- 2001-12-19 US US10/026,992 patent/US7625913B2/en not_active Expired - Fee Related
- 2001-12-19 CA CA002432129A patent/CA2432129C/en not_active Expired - Fee Related
- 2001-12-19 US US10/026,966 patent/US20030105090A1/en not_active Abandoned
- 2001-12-19 CN CNA018221033A patent/CN1486310A/en active Pending
- 2001-12-19 NZ NZ526470A patent/NZ526470A/en not_active IP Right Cessation
- 2001-12-19 AP APAP/P/2003/002825A patent/AP2003002825A0/en unknown
- 2001-12-19 ES ES01993360T patent/ES2265450T3/en not_active Expired - Lifetime
- 2001-12-19 AU AU2001297619A patent/AU2001297619B2/en not_active Ceased
- 2001-12-19 EP EP01985059A patent/EP1345925B1/en not_active Expired - Lifetime
- 2001-12-19 US US10/026,967 patent/US6989385B2/en not_active Expired - Fee Related
- 2001-12-19 PT PT01271061T patent/PT1345922E/en unknown
- 2001-12-19 CN CN2011101042845A patent/CN102250071A/en active Pending
- 2001-12-19 BR BR0116493-7A patent/BR0116493A/en not_active IP Right Cessation
- 2001-12-19 EP EP01271061A patent/EP1345922B1/en not_active Expired - Lifetime
- 2001-12-19 AT AT06011799T patent/ATE528303T1/en not_active IP Right Cessation
- 2001-12-19 EP EP06011799A patent/EP1702920B1/en not_active Expired - Lifetime
- 2001-12-19 CA CA002432222A patent/CA2432222C/en not_active Expired - Fee Related
- 2001-12-19 EP EP01993360A patent/EP1345926B1/en not_active Expired - Lifetime
- 2001-12-19 IL IL15638901A patent/IL156389A0/en active IP Right Grant
- 2001-12-19 MX MXPA03005605A patent/MXPA03005605A/en active IP Right Grant
- 2001-12-19 AT AT01985059T patent/ATE326460T1/en active
- 2001-12-19 JP JP2002565976A patent/JP2004518743A/en active Pending
- 2001-12-19 WO PCT/US2001/051120 patent/WO2002059111A2/en active IP Right Grant
- 2001-12-19 ES ES01985059T patent/ES2265446T3/en not_active Expired - Lifetime
- 2001-12-19 IL IL15636901A patent/IL156369A0/en active IP Right Grant
- 2001-12-19 DE DE60119775T patent/DE60119775T2/en not_active Expired - Lifetime
- 2001-12-19 KR KR10-2003-7008415A patent/KR20030061858A/en active IP Right Grant
- 2001-12-19 HU HU0400641A patent/HUP0400641A3/en unknown
- 2001-12-19 DE DE60123283T patent/DE60123283T2/en not_active Expired - Lifetime
- 2001-12-19 PL PL363246A patent/PL210066B1/en unknown
- 2001-12-20 WO PCT/US2001/049594 patent/WO2002059112A2/en active IP Right Grant
- 2001-12-20 NZ NZ526475A patent/NZ526475A/en unknown
- 2001-12-20 EP EP01994347A patent/EP1345929B1/en not_active Expired - Lifetime
- 2001-12-20 KR KR10-2003-7008364A patent/KR20030061463A/en active IP Right Grant
- 2001-12-20 US US10/034,019 patent/US6727251B2/en not_active Expired - Fee Related
- 2001-12-20 AR ARP010105960A patent/AR042397A1/en active IP Right Grant
- 2001-12-20 MX MXPA03005612A patent/MXPA03005612A/en not_active Application Discontinuation
- 2001-12-20 AR ARP010105961A patent/AR042398A1/en unknown
- 2001-12-20 AR ARP010105963A patent/AR040925A1/en active IP Right Grant
- 2001-12-20 AT AT01994347T patent/ATE326463T1/en not_active IP Right Cessation
- 2001-12-20 JP JP2002559414A patent/JP2004517927A/en active Pending
- 2001-12-20 AT AT01991439T patent/ATE353890T1/en not_active IP Right Cessation
- 2001-12-20 JP JP2002551562A patent/JP2004516292A/en active Pending
- 2001-12-20 AR ARP010105962A patent/AR042169A1/en active IP Right Grant
- 2001-12-20 CA CA002432132A patent/CA2432132C/en not_active Expired - Fee Related
- 2001-12-20 CA CA002432872A patent/CA2432872C/en not_active Expired - Fee Related
- 2001-12-20 US US10/034,683 patent/US6656939B2/en not_active Expired - Fee Related
- 2001-12-20 AU AU2002246754A patent/AU2002246754B2/en not_active Ceased
- 2001-12-20 NZ NZ526474A patent/NZ526474A/en unknown
- 2001-12-20 DE DE60126658T patent/DE60126658T2/en not_active Expired - Lifetime
- 2001-12-20 KR KR10-2003-7008366A patent/KR20030061464A/en not_active Application Discontinuation
- 2001-12-20 AU AU3116602A patent/AU3116602A/en active Pending
- 2001-12-20 WO PCT/US2001/049585 patent/WO2002050066A2/en active IP Right Grant
- 2001-12-20 DE DE60119777T patent/DE60119777T2/en not_active Expired - Lifetime
- 2001-12-20 AU AU2002231166A patent/AU2002231166B2/en not_active Ceased
- 2001-12-20 EP EP01991439A patent/EP1345928B1/en not_active Expired - Lifetime
- 2001-12-20 MX MXPA03005611A patent/MXPA03005611A/en unknown
- 2001-12-21 MY MYPI20015823A patent/MY140377A/en unknown
- 2001-12-25 TW TW095139649A patent/TWI313269B/en not_active IP Right Cessation
- 2001-12-25 TW TW090131846A patent/TWI290551B/en not_active IP Right Cessation
-
2003
- 2003-06-10 IL IL156369A patent/IL156369A/en not_active IP Right Cessation
- 2003-06-11 IL IL156389A patent/IL156389A/en not_active IP Right Cessation
- 2003-06-12 NO NO20032670A patent/NO328537B1/en not_active IP Right Cessation
- 2003-06-12 NO NO20032671A patent/NO20032671L/en not_active Application Discontinuation
- 2003-06-13 NO NO20032703A patent/NO328501B1/en not_active IP Right Cessation
- 2003-06-13 NO NO20032704A patent/NO330527B1/en not_active IP Right Cessation
- 2003-06-16 NO NO20032736A patent/NO20032736L/en unknown
- 2003-08-01 US US10/632,428 patent/US7531536B2/en not_active Expired - Fee Related
- 2003-11-25 US US10/722,374 patent/US20040157893A1/en not_active Abandoned
- 2003-12-15 US US10/736,426 patent/US7087603B2/en not_active Expired - Fee Related
-
2004
- 2004-02-10 US US10/775,699 patent/US7427681B2/en not_active Expired - Fee Related
- 2004-02-12 HK HK04100960A patent/HK1059776A1/en not_active IP Right Cessation
- 2004-03-15 HK HK04101882A patent/HK1060346A1/en not_active IP Right Cessation
- 2004-03-15 HK HK04101883A patent/HK1060347A1/en not_active IP Right Cessation
- 2004-03-16 HK HK04101941A patent/HK1062433A1/en not_active IP Right Cessation
- 2004-03-16 HK HK04101940A patent/HK1060557A1/en not_active IP Right Cessation
- 2004-03-17 HK HK04101996A patent/HK1060349A1/en not_active IP Right Cessation
- 2004-03-22 HK HK04102099A patent/HK1061389A1/en not_active IP Right Cessation
- 2004-07-27 HK HK04105510.6A patent/HK1062565A1/en not_active IP Right Cessation
- 2004-12-17 JP JP2004366925A patent/JP2005097322A/en not_active Withdrawn
-
2006
- 2006-03-21 AU AU2006201267A patent/AU2006201267B2/en not_active Ceased
- 2006-12-20 CY CY20061101823T patent/CY1106297T1/en unknown
-
2008
- 2008-04-01 JP JP2008095581A patent/JP2008189682A/en not_active Withdrawn
- 2008-04-01 JP JP2008095584A patent/JP2008260767A/en not_active Withdrawn
- 2008-04-03 JP JP2008097620A patent/JP2008222719A/en active Pending
- 2008-04-04 JP JP2008098506A patent/JP2008189687A/en active Pending
- 2008-04-25 US US12/109,598 patent/US8304414B2/en not_active Expired - Fee Related
- 2008-05-07 JP JP2008121724A patent/JP2008247920A/en active Pending
- 2008-05-07 JP JP2008121727A patent/JP2008247921A/en active Pending
- 2008-05-07 JP JP2008121723A patent/JP2008201808A/en active Pending
-
2009
- 2009-04-17 JP JP2009101481A patent/JP5249842B2/en not_active Expired - Fee Related
- 2009-08-21 US US12/545,347 patent/US7982037B2/en not_active Expired - Fee Related
- 2009-09-14 JP JP2009212566A patent/JP2009286805A/en not_active Withdrawn
-
2010
- 2010-12-07 IL IL209827A patent/IL209827A0/en unknown
-
2012
- 2012-09-28 US US13/631,488 patent/US8697698B2/en not_active Expired - Fee Related
-
2013
- 2013-07-19 JP JP2013150948A patent/JP2013213068A/en active Pending
- 2013-12-24 US US14/139,889 patent/US20140187772A1/en not_active Abandoned
Patent Citations (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
US3755322A (en) * | 1970-07-15 | 1973-08-28 | Ciba Geigy Corp | Diamino-s-triazines |
US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
US4051252A (en) * | 1974-12-13 | 1977-09-27 | Bayer Aktiengesellschaft | 3-aminoindazole-1 and 2-carboxylic acid derivatives |
US4493726A (en) * | 1980-12-23 | 1985-01-15 | Ciba Geigy Corporation | Phenylpyrimidines as antidotes for protecting cultivated plants against phytotoxic damage caused by herbicides |
US5124441A (en) * | 1981-04-06 | 1992-06-23 | Pharmacia Aktiebolag | Therapeutically active compound and its use |
US4711951A (en) * | 1981-04-06 | 1987-12-08 | Pharmacia Aktiebolag | Therapeutically active compound and pharmaceutical composition containing the same |
US4540698A (en) * | 1982-01-20 | 1985-09-10 | Mitsui Toatsu Chemicals, Incorporated | 5-Methylthiopyrimidine derivatives, their preparation process and fungicides containing same as active ingredients |
US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5916908A (en) * | 1994-11-10 | 1999-06-29 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
US5972946A (en) * | 1995-04-13 | 1999-10-26 | Dainippon Pharmaceutical Co., Ltd. | Acetamide derivative, process for preparing the same, and a pharmaceutical composition containing the same |
US6841579B1 (en) * | 1995-12-18 | 2005-01-11 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
US6093716A (en) * | 1996-09-16 | 2000-07-25 | Celltech Therapeutics, Limited | Substituted 2-pyrimidineamines and processes for their preparation |
US6558657B1 (en) * | 1998-01-09 | 2003-05-06 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
US6528513B2 (en) * | 1998-02-17 | 2003-03-04 | Tularik Inc | Pyrimidine derivatives |
US20010018436A1 (en) * | 1998-02-17 | 2001-08-30 | Tularik Inc. | Pyrimidine derivatives |
US6200977B1 (en) * | 1998-02-17 | 2001-03-13 | Tularik Inc. | Pyrimidine derivatives |
US6589958B1 (en) * | 1998-08-21 | 2003-07-08 | Bristol-Myers Squibb Pharma Company | Isoxazolo [4,5-d] pyrimidines as CRF antagonists |
US6277989B1 (en) * | 1998-08-28 | 2001-08-21 | Scios, Inc. | Quinazoline derivatives as medicaments |
US20030069248A1 (en) * | 1998-08-28 | 2003-04-10 | Sarvajit Chakravarty | Quinazoline derivatives as medicaments |
US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6593326B1 (en) * | 1998-12-24 | 2003-07-15 | Astrazeneca Ab | 2,4-diamino pyrimidine compounds having anti-cell proliferative activity |
US6579983B1 (en) * | 1999-06-18 | 2003-06-17 | Celltech R&D Limited | 5-cyano-2-aminopyrimidine derivatives |
US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
US6528509B1 (en) * | 2000-02-05 | 2003-03-04 | Vertex Pharmacuticals, Incorporated | Pyrazole compositions useful as inhibitors of ERK |
US20020052386A1 (en) * | 2000-02-17 | 2002-05-02 | Armistead David M. | Kinase inhibitors |
US6838464B2 (en) * | 2000-03-01 | 2005-01-04 | Astrazeneca Ab | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
US20030187002A1 (en) * | 2000-06-28 | 2003-10-02 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
US20040097501A1 (en) * | 2000-09-15 | 2004-05-20 | David Bebbington | Triazole compounds useful as protein kinase inhibitors |
US6638926B2 (en) * | 2000-09-15 | 2003-10-28 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US20030073687A1 (en) * | 2000-09-15 | 2003-04-17 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20050004110A1 (en) * | 2000-09-15 | 2005-01-06 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20030078166A1 (en) * | 2000-09-15 | 2003-04-24 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US20030083327A1 (en) * | 2000-09-15 | 2003-05-01 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US20030064981A1 (en) * | 2000-09-15 | 2003-04-03 | Ronald Knegtel | Pyrazole compounds useful as protein kinase inhibitors |
US6495582B1 (en) * | 2000-09-15 | 2002-12-17 | Vertex Pharmaceuticals Incorporated | Isoxazole compositions useful as inhibitors of ERK |
US20030055044A1 (en) * | 2000-09-15 | 2003-03-20 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US6696452B2 (en) * | 2000-09-15 | 2004-02-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US20030064982A1 (en) * | 2000-09-15 | 2003-04-03 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US7008948B2 (en) * | 2000-09-15 | 2006-03-07 | Vertex Pharmaceuticals, Incorporated | Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors |
US7098330B2 (en) * | 2000-09-15 | 2006-08-29 | Vertex Pharmaceuticals Incorporated | Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors |
US7115739B2 (en) * | 2000-09-15 | 2006-10-03 | Vertex Pharmaceuticals Incorporated | Triazole compounds useful as protein kinase inhibitors |
US6562971B2 (en) * | 2000-12-12 | 2003-05-13 | Basf Aktiengesellschaft | Process for the preparation of triethylenediamine (TEDA) |
US20030069239A1 (en) * | 2000-12-12 | 2003-04-10 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
US20030022885A1 (en) * | 2000-12-21 | 2003-01-30 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US6656939B2 (en) * | 2000-12-21 | 2003-12-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US20040214814A1 (en) * | 2000-12-21 | 2004-10-28 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20030004164A1 (en) * | 2000-12-21 | 2003-01-02 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20030105090A1 (en) * | 2000-12-21 | 2003-06-05 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20030004161A1 (en) * | 2000-12-21 | 2003-01-02 | David Bebbington | Pyrazole compounds useful as protein kinase inhititors |
US7087603B2 (en) * | 2000-12-21 | 2006-08-08 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6653300B2 (en) * | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6653301B2 (en) * | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6727251B2 (en) * | 2000-12-21 | 2004-04-27 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US20030036543A1 (en) * | 2000-12-21 | 2003-02-20 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US6989385B2 (en) * | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6664247B2 (en) * | 2000-12-21 | 2003-12-16 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US20050038023A1 (en) * | 2000-12-21 | 2005-02-17 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20030055068A1 (en) * | 2000-12-21 | 2003-03-20 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20030078275A1 (en) * | 2000-12-21 | 2003-04-24 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20040229875A1 (en) * | 2001-02-09 | 2004-11-18 | Jingrong Cao | Heterocyclic inhibitors of ERK2 and uses thereof |
US7253187B2 (en) * | 2001-02-09 | 2007-08-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
US6743791B2 (en) * | 2001-02-09 | 2004-06-01 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
US20030092714A1 (en) * | 2001-02-09 | 2003-05-15 | Jingrong Cao | Heterocyclic inhibitors of ERK2 and uses thereof |
US6949544B2 (en) * | 2001-03-29 | 2005-09-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
US20030087922A1 (en) * | 2001-03-29 | 2003-05-08 | Bethiel Randy S. | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
US20030096816A1 (en) * | 2001-04-13 | 2003-05-22 | Jingrong Cao | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
US6642227B2 (en) * | 2001-04-13 | 2003-11-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
US20040023963A1 (en) * | 2001-04-13 | 2004-02-05 | Jingrong Cao | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
US7084159B2 (en) * | 2001-04-13 | 2006-08-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
US20030096813A1 (en) * | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
US20030144309A1 (en) * | 2001-05-16 | 2003-07-31 | Young Choon-Moon | Inhibitors of Src and other protein kinases |
US20040009996A1 (en) * | 2001-06-15 | 2004-01-15 | Young-Choon Moon | Protein kinase inhibitors and uses thereof |
US20030171389A1 (en) * | 2001-07-03 | 2003-09-11 | Guy Bemis | Inhibitors of Src and Lck protein kinases |
US20030199526A1 (en) * | 2001-12-07 | 2003-10-23 | Deborah Choquette | Pyrimidine-based compounds useful as GSK-3 inhibitors |
US20040009981A1 (en) * | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
US20040002496A1 (en) * | 2002-03-15 | 2004-01-01 | David Bebbington | Compositions useful as inhibitors of protein kinases |
US20030225073A1 (en) * | 2002-03-15 | 2003-12-04 | David Bebbington | Compositions useful as inhibitors of protein kinases |
US20040009974A1 (en) * | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
US7091343B2 (en) * | 2002-03-15 | 2006-08-15 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US6846928B2 (en) * | 2002-03-15 | 2005-01-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US7179826B2 (en) * | 2002-03-15 | 2007-02-20 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
US20050234059A1 (en) * | 2002-04-26 | 2005-10-20 | Michael Robin Hale | Heterocyclic inhibitors of ERK2 and uses thereof |
US20040029857A1 (en) * | 2002-04-26 | 2004-02-12 | Hale Michael Robin | Heterocyclic inhibitors of ERK2 and uses thereof |
US20060270660A1 (en) * | 2002-06-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Processes for preparing substituted pyrimidines |
US20040097531A1 (en) * | 2002-07-09 | 2004-05-20 | Mark Ledeboer | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
Cited By (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070270444A1 (en) * | 2000-09-15 | 2007-11-22 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20040116454A1 (en) * | 2000-09-15 | 2004-06-17 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US7951820B2 (en) | 2000-09-15 | 2011-05-31 | Vertex Pharmaceuticals Incorporated | Triazole compounds useful as protein kinase inhibitors |
US20100256170A1 (en) * | 2000-09-15 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7691853B2 (en) | 2000-09-15 | 2010-04-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US20060258658A1 (en) * | 2000-09-15 | 2006-11-16 | David Bebbington | Triazole compounds useful as protein kinase inhibitors |
US8524720B2 (en) | 2000-09-15 | 2013-09-03 | Vertex Pharmaceuticals Incorporated | Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors |
US20030064982A1 (en) * | 2000-09-15 | 2003-04-03 | Robert Davies | Pyrazole compounds useful as protein kinase inhibitors |
US8633210B2 (en) | 2000-09-15 | 2014-01-21 | Vertex Pharmaceuticals Incorporated | Triazole compounds useful as protein kinase inhibitors |
US7473691B2 (en) | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7390815B2 (en) | 2000-09-15 | 2008-06-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7531536B2 (en) | 2000-12-21 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US8304414B2 (en) | 2000-12-21 | 2012-11-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7625913B2 (en) | 2000-12-21 | 2009-12-01 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US20050038023A1 (en) * | 2000-12-21 | 2005-02-17 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20040167141A1 (en) * | 2000-12-21 | 2004-08-26 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US8697698B2 (en) | 2000-12-21 | 2014-04-15 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US7427681B2 (en) | 2000-12-21 | 2008-09-23 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US20080287444A1 (en) * | 2000-12-21 | 2008-11-20 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20040214814A1 (en) * | 2000-12-21 | 2004-10-28 | David Bebbington | Pyrazole compounds useful as protein kinase inhibitors |
US20070270420A1 (en) * | 2002-02-06 | 2007-11-22 | Harbeson Scott L | Heteroaryl compounds useful as inhibitors of gsk-3 |
US20070190634A1 (en) * | 2002-03-15 | 2007-08-16 | David Bebbington | Compositions useful as inhibitors of protein kinases |
US8669081B2 (en) | 2002-03-15 | 2014-03-11 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US8779127B2 (en) | 2002-06-20 | 2014-07-15 | Vertex Pharmaceuticals Incorporated | Processes for preparing substituted pyrimidines |
US8268829B2 (en) | 2002-06-20 | 2012-09-18 | Vertex Pharmaceuticals Inc. | Substituted pyrimidines useful as protein kinase inhibitors |
US20090221602A1 (en) * | 2002-06-20 | 2009-09-03 | Vertex Pharmaceuticals Incorporated | Processes for preparing substituted pyrimidines |
US7557106B2 (en) | 2002-06-20 | 2009-07-07 | Vertex Pharmaceuticals Incorporated | Substituted pyrimidines useful as protein kinase inhibitors |
US20060270660A1 (en) * | 2002-06-20 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Processes for preparing substituted pyrimidines |
US7491730B2 (en) | 2002-08-02 | 2009-02-17 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of GSK-3 |
US7872129B2 (en) | 2002-08-02 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of GSK-3 |
US20090118278A1 (en) * | 2002-08-02 | 2009-05-07 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of gsk-3 |
US20090325968A1 (en) * | 2003-02-06 | 2009-12-31 | Vertex Pharmaceuticals Incorporated | Compositions Useful as Inhibitors of Protein Kinases |
US8653088B2 (en) | 2003-02-06 | 2014-02-18 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
US20100081657A1 (en) * | 2003-12-04 | 2010-04-01 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7550598B2 (en) | 2004-08-18 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8288536B2 (en) | 2004-10-15 | 2012-10-16 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8153630B2 (en) | 2004-11-17 | 2012-04-10 | Miikana Therapeutics, Inc. | Kinase inhibitors |
US20100222367A1 (en) * | 2005-08-18 | 2010-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
US7737151B2 (en) | 2005-08-18 | 2010-06-15 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
US20070173516A1 (en) * | 2005-08-18 | 2007-07-26 | Michael Mortimore | Pyrazine kinase inhibitors |
US7989456B2 (en) * | 2005-08-18 | 2011-08-02 | Vertex Pharmaceuticals Incorporated | Pyrazine kinase inhibitors |
US20070142368A1 (en) * | 2005-09-30 | 2007-06-21 | Xiao-Yi Xiao | Substituted pyrazole compounds |
US8114870B2 (en) | 2005-09-30 | 2012-02-14 | Miikana Therapeutics, Inc. | Method of treating disease states using substituted pyrazole compounds |
US7563787B2 (en) | 2005-09-30 | 2009-07-21 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
US20090264422A1 (en) * | 2005-09-30 | 2009-10-22 | Xiao-Yi Xiao | Method of treating disease states using substituted pyrazole compounds |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US8557833B2 (en) | 2005-11-03 | 2013-10-15 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US20090181938A1 (en) * | 2005-11-03 | 2009-07-16 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US20070249031A1 (en) * | 2005-11-03 | 2007-10-25 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US20070259869A1 (en) * | 2005-11-03 | 2007-11-08 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US20110020469A1 (en) * | 2005-11-03 | 2011-01-27 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US7767672B2 (en) | 2005-11-03 | 2010-08-03 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US20080032963A1 (en) * | 2005-11-03 | 2008-02-07 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US8637511B2 (en) | 2005-11-03 | 2014-01-28 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US20100310675A1 (en) * | 2005-11-03 | 2010-12-09 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US7820685B2 (en) | 2005-11-03 | 2010-10-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US8129399B2 (en) | 2005-11-03 | 2012-03-06 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US7528142B2 (en) | 2005-11-03 | 2009-05-05 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US8088821B2 (en) | 2006-06-27 | 2012-01-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
US20100197761A1 (en) * | 2006-06-27 | 2010-08-05 | Tsuneo Yasuma | Fused cyclic compounds |
US8598226B2 (en) | 2006-06-27 | 2013-12-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
US8492430B2 (en) | 2006-06-27 | 2013-07-23 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
US20080004302A1 (en) * | 2006-06-30 | 2008-01-03 | Astrazeneca Ab | Novel Compounds |
US20100022502A1 (en) * | 2006-11-02 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
US8372850B2 (en) | 2006-11-02 | 2013-02-12 | Vertex Pharmaceuticals Incorporated | Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
US8426425B2 (en) | 2006-12-19 | 2013-04-23 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
US20100022507A1 (en) * | 2006-12-19 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
US8518953B2 (en) | 2007-03-09 | 2013-08-27 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
US20110020376A1 (en) * | 2007-03-09 | 2011-01-27 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
US8410133B2 (en) | 2007-03-09 | 2013-04-02 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
US8735593B2 (en) | 2007-03-09 | 2014-05-27 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
US20110021559A1 (en) * | 2007-03-09 | 2011-01-27 | Vertex Pharmaceuticals Incorporated | Aminopyridines useful as inhibitors of protein kinases |
US20110020377A1 (en) * | 2007-03-09 | 2011-01-27 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
US8664219B2 (en) | 2007-03-09 | 2014-03-04 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as inhibitors of protein kinases |
US8455507B2 (en) | 2007-04-13 | 2013-06-04 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US8278450B2 (en) | 2007-04-18 | 2012-10-02 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100215772A1 (en) * | 2007-05-02 | 2010-08-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US20110046104A1 (en) * | 2007-05-02 | 2011-02-24 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US8785444B2 (en) | 2007-05-02 | 2014-07-22 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
US8383633B2 (en) | 2007-05-02 | 2013-02-26 | Vertex Pharmaceuticals Incorporated | Aminopyrimidines useful as kinase inhibitors |
US8268811B2 (en) | 2007-05-02 | 2012-09-18 | Vertex Pharmaceuticals Inc. | Thiazoles and pyrazoles useful as kinase inhibitors |
US20100317641A1 (en) * | 2007-05-02 | 2010-12-16 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
US20110060013A1 (en) * | 2007-05-24 | 2011-03-10 | Vertex Pharmaceuticals Incorporated | Thiazoles and pyrazoles useful as kinase inhibitors |
US20090029992A1 (en) * | 2007-06-11 | 2009-01-29 | Agoston Gregory E | Substituted pyrazole compounds |
US8242272B2 (en) | 2007-07-31 | 2012-08-14 | Vertex Pharmaceuticals Inc. | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives thereof |
US20100184980A1 (en) * | 2007-07-31 | 2010-07-22 | Juan-Miguel Jimenez | Process for Preparing 5-Fluoro-1H-Pyrazolo [3,4-b] Pyridin-3-amine and Derivatives Thereof |
US8598361B2 (en) | 2007-07-31 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1H-pyrazolo [3,4-B] pyridin-3-amine and derivatives therof |
US10819726B2 (en) | 2008-05-27 | 2020-10-27 | The Trustees Of Columbia University In The City Of New York | Detecting network anomalies by probabilistic modeling of argument strings with markov chains |
US20110236478A1 (en) * | 2008-09-03 | 2011-09-29 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
US8541025B2 (en) | 2008-09-03 | 2013-09-24 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
US8633207B2 (en) | 2010-09-01 | 2014-01-21 | Ambit Biosciences Corporation | Quinazoline compounds and methods of use thereof |
US8637537B2 (en) | 2011-08-25 | 2014-01-28 | Genentech, Inc. | Serine/threonine kinase inhibitors |
US8815877B2 (en) | 2011-12-22 | 2014-08-26 | Genentech, Inc. | Serine/threonine kinase inhibitors |
US9346792B2 (en) | 2012-03-16 | 2016-05-24 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
US9365556B2 (en) | 2012-03-16 | 2016-06-14 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
US9382237B2 (en) | 2012-03-16 | 2016-07-05 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
US8916555B2 (en) | 2012-03-16 | 2014-12-23 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
US9540351B2 (en) | 2013-09-18 | 2017-01-10 | Axikin Pharmaceuticals, Inc. | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
US9546163B2 (en) | 2014-12-23 | 2017-01-17 | Axikin Pharmaceuticals, Inc. | 3,5-diaminopyrazole kinase inhibitors |
US9730914B2 (en) | 2014-12-23 | 2017-08-15 | Axikin Pharmaceuticals | 3,5-diaminopyrazole kinase inhibitors |
US10822311B2 (en) | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
WO2017165255A1 (en) * | 2016-03-25 | 2017-09-28 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
US10662162B2 (en) | 2016-03-25 | 2020-05-26 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
US11230532B2 (en) | 2016-03-25 | 2022-01-25 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
US11737463B2 (en) | 2017-05-30 | 2023-08-29 | Basf Se | Pyridine and pyrazine compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1345929B1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
EP1317452B1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
AU2002246754A1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
ZA200301703B (en) | Pyrazole compounds useful as protein kinase inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |